monoamine molecular messenger - Ontology Report - Rat Genome Database

Submit Data | Help | Video Tutorials | News | Publications | Download | REST API | Citing RGD | Contact

Advanced Search (OLGA)

CHEBI ONTOLOGY - ANNOTATIONS

{{ watchLinkText }}

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:	monoamine molecular messenger	go back to main search page
Accession:	CHEBI:25375	browse the term
Definition:	A group of neurotransmitters and neuromodulators that contain one amino group that is connected to an aromatic ring by ethylene group (-CH2-CH2-). Monoamines are derived from the aromatic amino acids phenylalanine, tyrosine, histidine and tryptophan.
Synonyms:	related_synonym:	monamines; monoamines

show annotations for term's descendants Sort by:
Rat (639) Mouse (633) Human (647) Chinchilla (0) Bonobo (0) Dog (9) Squirrel (0) Pig (7) Green Monkey (0) Naked Mole-rat (0) All
Genes (639)

(R)-adrenaline

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily C member 1

multiple interactions
increases export

[Epinephrine co-treated with [verlukast results in decreased activity of ABCC1 protein]] results in increased abundance of Glutathione Disulfide; [verlukast results in decreased activity of ABCC1 protein] which promotes the reaction and affects the abundance of Epinephrine metabolite
ABCC1 protein results in increased export of Epinephrine metabolite

NCBI chr10:528,961...655,179
Ensembl chr10:531,812...655,114

G

aconitase 2

increases expression

Epinephrine results in increased expression of ACO2 protein

NCBI chr 7:113,385,677...113,428,794
Ensembl chr 7:113,385,646...113,428,261

G

actinin, alpha 1

increases expression

Epinephrine results in increased expression of ACTN1 protein

NCBI chr 6:98,998,553...99,093,334
Ensembl chr 6:98,998,556...99,093,251

G

adiponectin, C1Q and collagen domain containing

multiple interactions
decreases expression

Sildenafil Citrate inhibits the reaction [Epinephrine results in decreased expression of ADIPOQ protein]; Tadalafil inhibits the reaction [Epinephrine results in decreased expression of ADIPOQ protein]

NCBI chr11:77,721,912...77,735,644
Ensembl chr11:77,721,912...77,735,564

G

adrenoceptor alpha 1A

multiple interactions
increases activity
affects binding

[Epinephrine binds to and results in increased activity of ADRA1A protein] which results in increased transport of Calcium; Epinephrine binds to and results in increased activity of ADRA1A protein
Epinephrine results in increased activity of ADRA1A protein
[Epinephrine binds to and results in increased activity of ADRA1A protein] which results in increased abundance of Calcium; [Epinephrine results in increased activity of ADRA1A protein] which results in increased abundance of Calcium; carvedilol inhibits the reaction [[Epinephrine results in increased activity of ADRA1A protein] which results in increased abundance of Calcium]; Epinephrine binds to and results in increased activity of ADRA1A protein; Epinephrine inhibits the reaction [ADRA1A protein binds to Prazosin]; Phentolamine inhibits the reaction [[Epinephrine results in increased activity of ADRA1A protein] which results in increased abundance of Calcium]
Epinephrine binds to ADRA1A protein

PMID:8183249 PMID:15306222 PMID:15672411 PMID:20030735

NCBI chr15:40,830,125...40,935,902
Ensembl chr15:40,832,534...40,927,500

G

adrenoceptor alpha 1B

multiple interactions
increases activity

[Epinephrine binds to and results in increased activity of ADRA1B protein] which results in increased abundance of Calcium; [Epinephrine results in increased activity of ADRA1B protein] which results in increased abundance of Calcium; carvedilol inhibits the reaction [[Epinephrine results in increased activity of ADRA1B protein] which results in increased abundance of Calcium]; Epinephrine binds to and results in increased activity of ADRA1B protein; Epinephrine inhibits the reaction [ADRA1B protein binds to Prazosin]; Phentolamine inhibits the reaction [[Epinephrine results in increased activity of ADRA1B protein] which results in increased abundance of Calcium]

PMID:15306222 PMID:20030735

NCBI chr10:28,255,025...28,373,418
Ensembl chr10:28,255,025...28,312,919

G

adrenoceptor alpha 1D

affects binding
increases activity
multiple interactions

Epinephrine binds to ADRA1D protein
Epinephrine results in increased activity of ADRA1D protein
[Epinephrine binds to and results in increased activity of ADRA1D protein] which results in increased abundance of Calcium; [Epinephrine results in increased activity of ADRA1D protein] which results in increased abundance of Calcium; Carvedilol inhibits the reaction [[Epinephrine results in increased activity of ADRA1D protein] which results in increased abundance of Calcium]; Epinephrine binds to and results in increased activity of ADRA1D protein; Epinephrine inhibits the reaction [ADRA1D protein binds to Prazosin]; Phentolamine inhibits the reaction [[Epinephrine results in increased activity of ADRA1D protein] which results in increased abundance of Calcium]

PMID:8183249 PMID:15306222 PMID:20030735

NCBI chr 3:118,793,356...118,809,354
Ensembl chr 3:118,793,346...118,809,354

G

adrenoceptor alpha 2A

increases activity
multiple interactions

Epinephrine results in increased activity of ADRA2A protein
Epinephrine promotes the reaction [GNB2 protein binds to ADRA2A protein]; Epinephrine promotes the reaction [GNB4 protein binds to ADRA2A protein]; Epinephrine promotes the reaction [GNG12 protein binds to ADRA2A protein]; Epinephrine promotes the reaction [GNG2 protein binds to ADRA2A protein]; Epinephrine promotes the reaction [GNG3 protein binds to ADRA2A protein]; Epinephrine promotes the reaction [GNG4 protein binds to ADRA2A protein]
[Epinephrine binds to and results in increased activity of ADRA2A protein] which results in increased abundance of Calcium; ADRA2A promotes the reaction [Epinephrine results in increased expression of CCND1 protein]; ADRA2A promotes the reaction [Epinephrine results in increased phosphorylation of CREB1 protein]; ADRA2A promotes the reaction [Epinephrine results in increased phosphorylation of MAPK1 protein]; ADRA2A promotes the reaction [Epinephrine results in increased phosphorylation of MAPK3 protein]; Epinephrine binds to and results in increased activity of ADRA2A protein; Epinephrine inhibits the reaction [ADRA2A protein binds to 2-methoxyidazoxan]

PMID:17341653 PMID:17680988 PMID:20030735 PMID:30737458

NCBI chr 1:253,061,480...253,064,280
Ensembl chr 1:253,060,218...253,064,365

G

adrenoceptor alpha 2B

multiple interactions

[Epinephrine binds to and results in increased activity of ADRA2B protein] which results in increased abundance of Calcium; ADRA2B promotes the reaction [Epinephrine results in increased expression of CCND1 protein]; ADRA2B promotes the reaction [Epinephrine results in increased phosphorylation of CREB1 protein]; ADRA2B promotes the reaction [Epinephrine results in increased phosphorylation of MAPK1 protein]; ADRA2B promotes the reaction [Epinephrine results in increased phosphorylation of MAPK3 protein]; Epinephrine binds to and results in increased activity of ADRA2B protein; Epinephrine inhibits the reaction [ADRA2B protein binds to 2-methoxyidazoxan]

PMID:17680988 PMID:20030735

NCBI chr 3:114,585,174...114,589,220
Ensembl chr 3:114,585,169...114,589,355

G

adrenoceptor alpha 2C

multiple interactions

[Epinephrine binds to and results in increased activity of ADRA2C protein] which results in increased abundance of Calcium; ADRA2C promotes the reaction [Epinephrine results in increased expression of CCND1 protein]; ADRA2C promotes the reaction [Epinephrine results in increased phosphorylation of CREB1 protein]; ADRA2C promotes the reaction [Epinephrine results in increased phosphorylation of MAPK1 protein]; ADRA2C promotes the reaction [Epinephrine results in increased phosphorylation of MAPK3 protein]; Epinephrine binds to and results in increased activity of ADRA2C protein; Epinephrine inhibits the reaction [ADRA2C protein binds to 2-methoxyidazoxan]

PMID:17680988 PMID:20030735

NCBI chr14:75,470,884...75,472,846
Ensembl chr14:75,471,143...75,472,846

G

adrenoceptor beta 1

multiple interactions

[CGP 20712A binds to and results in decreased activity of ADRB1 protein] which results in decreased activity of Epinephrine
Epinephrine inhibits the reaction [Iodocyanopindolol binds to ADRB1 protein]
[Epinephrine binds to and results in increased activity of ADRB1 protein] which results in increased abundance of Cyclic AMP; Epinephrine binds to and results in increased activity of ADRB1 protein; Epinephrine inhibits the reaction [cyanopindolol binds to ADRB1 protein]; Epinephrine inhibits the reaction [Iodocyanopindolol binds to ADRB1 protein]

PMID:8096834 PMID:12010770 PMID:14730417

NCBI chr 1:255,771,962...255,774,973
Ensembl chr 1:255,771,597...255,807,259

G

adrenoceptor beta 2

multiple interactions
affects response to substance
increases activity

[Epinephrine binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP; Atenolol inhibits the reaction [[Epinephrine binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP]; Atenolol inhibits the reaction [Epinephrine binds to and results in increased activity of ADRB2 protein]; carvedilol inhibits the reaction [Epinephrine binds to and results in increased activity of ADRB2 protein]; Epinephrine binds to and results in increased activity of ADRB2 protein; Epinephrine inhibits the reaction [cyanopindolol binds to ADRB2 protein]; Epinephrine promotes the reaction [GRK2 protein results in increased phosphorylation of ADRB2 protein]; Epinephrine promotes the reaction [GRK5 protein results in increased phosphorylation of ADRB2 protein]; Epinephrine results in increased phosphorylation of and results in increased localization of ADRB2 protein; ICI 118551 inhibits the reaction [[Epinephrine binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP]; ICI 118551 inhibits the reaction [Epinephrine binds to and results in increased activity of ADRB2 protein]; Propranolol inhibits the reaction [[Epinephrine binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP]; Propranolol inhibits the reaction [Epinephrine binds to and results in increased activity of ADRB2 protein]
[Epinephrine results in increased activity of ADRB2 protein] which results in increased secretion of Histamine
ADRB2 affects the susceptibility to Epinephrine

PMID:1389726 PMID:11164953 PMID:12920204 PMID:14722251 PMID:14730417 More...

NCBI chr18:55,642,459...55,644,501
Ensembl chr18:55,502,903...55,644,512

G

adrenoceptor beta 3

multiple interactions

Epinephrine binds to and results in increased activity of ADRB3 protein
[Epinephrine binds to and results in increased activity of ADRB3 protein] which results in increased abundance of Cyclic AMP; Epinephrine binds to and results in increased activity of ADRB3 protein; Epinephrine inhibits the reaction [cyanopindolol binds to ADRB3 protein]

PMID:1682311 PMID:7815362 PMID:14730417

NCBI chr16:64,839,820...64,844,552
Ensembl chr16:64,841,788...64,844,552

G

adenylate kinase 2

decreases expression
multiple interactions

Epinephrine results in decreased expression of AK2 protein
[Epinephrine co-treated with Xanthine co-treated with XDH] results in decreased expression of AK2 protein

NCBI chr 5:141,308,650...141,364,633
Ensembl chr 5:141,346,063...141,364,632

G

AKT serine/threonine kinase 1

multiple interactions

[Epinephrine co-treated with INS protein] results in increased phosphorylation of AKT1 protein

NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921

G

amine oxidase, copper containing 1

multiple interactions
increases activity

Cycloheximide inhibits the reaction [Epinephrine results in increased activity of AOC1 protein]; Dactinomycin inhibits the reaction [Epinephrine results in increased activity of AOC1 protein]; Timolol inhibits the reaction [Epinephrine results in increased activity of AOC1 protein]

NCBI chr 4:77,812,260...77,831,846
Ensembl chr 4:77,812,260...77,831,840

G

aquaporin 7

affects localization
multiple interactions
increases expression

Epinephrine affects the localization of AQP7 protein
INS1 inhibits the reaction [Epinephrine results in increased expression of AQP7 mRNA]

NCBI chr 5:56,171,649...56,186,642
Ensembl chr 5:56,172,519...56,186,642

G

ATP synthase F1 subunit alpha

increases expression

Epinephrine results in increased expression of ATP5F1A protein

NCBI chr18:71,292,406...71,300,342
Ensembl chr18:71,292,374...71,300,794

G

BCL2, apoptosis regulator

increases expression

Epinephrine results in increased expression of BCL2 protein

NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

bone morphogenetic protein 2

decreases expression

Epinephrine results in decreased expression of BMP2 mRNA; Epinephrine results in decreased expression of BMP2 protein

NCBI chr 3:120,812,660...120,822,579
Ensembl chr 3:120,812,882...120,821,397

G

complement C1q binding protein

multiple interactions
increases expression

[Epinephrine co-treated with Xanthine co-treated with XDH] results in increased expression of C1QBP protein
Epinephrine results in increased expression of C1QBP protein

NCBI chr10:55,699,954...55,704,605
Ensembl chr10:55,699,954...55,704,649

G

calcitonin-related polypeptide alpha

increases abundance

CALCA protein results in increased abundance of Epinephrine

NCBI chr 1:168,878,212...168,883,176
Ensembl chr 1:168,878,214...168,883,105

G

calcyon neuron-specific vesicular protein

decreases secretion

CALY protein results in decreased secretion of Epinephrine

NCBI chr 1:194,862,671...194,873,861
Ensembl chr 1:194,862,672...194,873,551

G

carbonic anhydrase 2

increases expression

Epinephrine results in increased expression of CA2 mRNA

NCBI chr 2:86,741,625...86,756,766
Ensembl chr 2:86,741,626...86,756,818

G

caspase 3

multiple interactions
increases expression
increases activity

Atenolol inhibits the reaction [Epinephrine results in increased activity of CASP3 protein]; carvedilol inhibits the reaction [Epinephrine results in increased activity of CASP3 protein]
Epinephrine results in increased expression of CASP3 protein
Epinephrine promotes the reaction [[Xanthine co-treated with XDH protein] results in increased activity of CASP3 protein]; Sildenafil Citrate inhibits the reaction [Epinephrine results in increased expression of CASP3 protein]; Tadalafil inhibits the reaction [Epinephrine results in increased expression of CASP3 protein]; Vardenafil Dihydrochloride inhibits the reaction [Epinephrine results in increased expression of CASP3 protein]

PMID:10728402 PMID:19135123 PMID:29233027

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

catalase

decreases response to substance

CAT results in decreased susceptibility to Epinephrine

NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478

G

C-C motif chemokine ligand 3

multiple interactions

Epinephrine inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of CCL3 mRNA]; Epinephrine inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of CCL3 protein]; Propranolol inhibits the reaction [Epinephrine inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of CCL3 protein]]
Epinephrine inhibits the reaction [Lipopolysaccharides results in increased expression of CCL3 mRNA]; Epinephrine inhibits the reaction [Lipopolysaccharides results in increased secretion of CCL3 protein]; Epinephrine inhibits the reaction [Thioglycolates results in increased secretion of CCL3 protein]

PMID:9863660 PMID:12538206

NCBI chr10:68,451,388...68,452,938
Ensembl chr10:68,451,388...68,452,938

G

cyclin D1

multiple interactions
increases expression

2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one promotes the reaction [Epinephrine results in increased expression of CCND1 protein]; 2-methoxyidazoxan inhibits the reaction [Epinephrine results in increased expression of CCND1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Epinephrine results in increased expression of CCND1 mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Epinephrine results in increased expression of CCND1 protein]; Niclosamide inhibits the reaction [Epinephrine results in increased expression of CCND1 mRNA]
Epinephrine results in increased expression of CCND1 mRNA; Epinephrine results in increased expression of CCND1 protein
ADRA2A promotes the reaction [Epinephrine results in increased expression of CCND1 protein]; ADRA2B promotes the reaction [Epinephrine results in increased expression of CCND1 protein]; ADRA2C promotes the reaction [Epinephrine results in increased expression of CCND1 protein]

PMID:17680988 PMID:26964897

NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602

G

CCAAT/enhancer binding protein beta

decreases expression

Epinephrine results in decreased expression of CEBPB protein

NCBI chr 3:156,398,035...156,399,466
Ensembl chr 3:156,397,052...156,399,473

G

cholinergic receptor nicotinic alpha 7 subunit

multiple interactions

[methyllycaconitine binds to and results in decreased activity of CHRNA7 protein] inhibits the reaction [Nicotine results in increased abundance of Epinephrine]

NCBI chr 1:116,711,559...116,837,269
Ensembl chr 1:116,714,711...116,837,240

G

catechol-O-methyltransferase

increases methylation
multiple interactions

COMT protein results in increased methylation of Epinephrine
[COMT protein results in increased methylation of Epinephrine] which results in increased abundance of Metanephrine; tolcapone inhibits the reaction [[COMT protein results in increased methylation of Epinephrine] which results in increased abundance of Metanephrine]
[tolcapone results in decreased activity of COMT protein] which results in increased abundance of Epinephrine

PMID:8821542 PMID:10064789 PMID:11160877 PMID:11248589

NCBI chr11:82,568,052...82,587,642
Ensembl chr11:82,568,025...82,587,642

G

cAMP responsive element binding protein 1

multiple interactions
increases phosphorylation

ADRA2A promotes the reaction [Epinephrine results in increased phosphorylation of CREB1 protein]; ADRA2B promotes the reaction [Epinephrine results in increased phosphorylation of CREB1 protein]; ADRA2C promotes the reaction [Epinephrine results in increased phosphorylation of CREB1 protein]
1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione inhibits the reaction [Epinephrine results in increased phosphorylation of CREB1 protein]; Dietary Fats promotes the reaction [Epinephrine results in increased phosphorylation of CREB1 protein]; Epinephrine promotes the reaction [Dietary Fats results in increased phosphorylation of CREB1 protein]; Ketoconazole inhibits the reaction [Epinephrine results in increased phosphorylation of CREB1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Epinephrine results in increased phosphorylation of CREB1 protein]

PMID:17680988 PMID:22496244

NCBI chr 9:65,903,511...65,972,562
Ensembl chr 9:65,903,547...65,970,816

G

corticotropin releasing hormone

multiple interactions
increases abundance

corticotropin releasing hormone (9-41) inhibits the reaction [CRH protein affects the abundance of Epinephrine]
CRH results in increased abundance of Epinephrine

NCBI chr 2:102,143,055...102,144,919
Ensembl chr 2:102,143,055...102,144,919

G

C-terminal Src kinase

multiple interactions

CSK protein promotes the reaction [Epinephrine results in increased abundance of Cyclic AMP]; Isoproterenol inhibits the reaction [CSK protein promotes the reaction [Epinephrine results in increased abundance of Cyclic AMP]]

NCBI chr 8:58,029,748...58,048,742
Ensembl chr 8:58,029,749...58,048,292

G

catenin beta 1

increases phosphorylation
multiple interactions

Epinephrine results in increased phosphorylation of CTNNB1 protein
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Epinephrine results in increased phosphorylation of CTNNB1 protein]; Niclosamide inhibits the reaction [Epinephrine results in increased phosphorylation of CTNNB1 protein]

NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111

G

cathepsin K

increases expression

Epinephrine results in increased expression of CTSK mRNA

NCBI chr 2:183,058,586...183,069,551
Ensembl chr 2:183,058,569...183,069,550

G

cytochrome c, somatic

multiple interactions
increases expression

[Epinephrine co-treated with Xanthine co-treated with XDH] results in increased expression of CYCS protein
Epinephrine results in increased expression of CYCS protein

NCBI chr 4:79,651,894...79,653,994
Ensembl chr 4:79,651,378...79,654,054
Ensembl chr18:79,651,378...79,654,054

G

dopamine beta-hydroxylase

affects abundance

DBH gene polymorphism affects the abundance of Epinephrine

NCBI chr 3:10,488,260...10,505,245
Ensembl chr 3:10,488,260...10,505,248

G

desmin

multiple interactions
decreases expression

[Epinephrine co-treated with Xanthine co-treated with XDH] results in decreased expression of DES protein
Epinephrine results in decreased expression of DES protein

NCBI chr 9:76,850,979...76,858,695
Ensembl chr 9:76,850,982...76,858,699

G

dihydrolipoamide S-acetyltransferase

multiple interactions

[Epinephrine co-treated with Xanthine co-treated with XDH] results in decreased expression of DLAT protein

NCBI chr 8:50,979,151...51,004,435
Ensembl chr 8:50,978,051...51,004,479
Ensembl chr 1:50,978,051...51,004,479

G

enoyl-CoA hydratase, short chain 1

multiple interactions

[Epinephrine co-treated with Xanthine co-treated with XDH] results in decreased expression of ECHS1 protein

NCBI chr 1:194,895,036...194,903,863
Ensembl chr 1:194,895,036...194,903,884

G

Eph receptor A4

increases phosphorylation

Epinephrine results in increased phosphorylation of EPHA4 protein

NCBI chr 9:78,815,460...78,958,139
Ensembl chr 9:78,815,460...78,958,139

G

electron transfer flavoprotein subunit beta

multiple interactions

[Epinephrine co-treated with Xanthine co-treated with XDH] results in decreased expression of ETFB protein

NCBI chr 1:93,851,908...93,866,072
Ensembl chr 1:93,851,858...93,866,068

G

fatty acid binding protein 3

affects expression
multiple interactions

Epinephrine affects the expression of FABP3 protein
[Epinephrine co-treated with Xanthine co-treated with XDH] results in decreased expression of FABP3 protein

NCBI chr 5:142,651,962...142,658,707
Ensembl chr 5:142,651,956...142,658,718

G

Fas cell surface death receptor

multiple interactions
increases expression

Atenolol inhibits the reaction [Epinephrine results in increased expression of FAS protein]; carvedilol inhibits the reaction [Epinephrine results in increased expression of FAS protein]

NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591

G

Fas ligand

multiple interactions
increases expression

Atenolol inhibits the reaction [Epinephrine results in increased expression of FASLG protein]; carvedilol inhibits the reaction [Epinephrine results in increased expression of FASLG protein]

NCBI chr13:74,151,519...74,172,760
Ensembl chr13:74,154,954...74,162,215

G

fumarate hydratase

increases expression

Epinephrine results in increased expression of FH protein

NCBI chr13:87,524,331...87,550,215
Ensembl chr13:87,524,337...87,550,266

G

forkhead box O1

decreases expression

Epinephrine results in decreased expression of FOXO1 protein

NCBI chr 2:136,312,168...136,390,603
Ensembl chr 2:136,312,168...136,387,790

G

G protein subunit beta 2

multiple interactions

Epinephrine promotes the reaction [GNB2 protein binds to ADRA2A protein]

NCBI chr12:19,159,002...19,164,021
Ensembl chr12:19,158,973...19,164,019

G

G protein subunit beta 4

multiple interactions

Epinephrine promotes the reaction [GNB4 protein binds to ADRA2A protein]

NCBI chr 2:115,360,746...115,400,680
Ensembl chr 2:115,364,918...115,400,579

G

G protein subunit gamma 12

multiple interactions

Epinephrine promotes the reaction [GNG12 protein binds to ADRA2A protein]

NCBI chr 4:96,011,118...96,134,767
Ensembl chr 4:96,010,952...96,134,712

G

G protein subunit gamma 2

multiple interactions

Epinephrine promotes the reaction [GNG2 protein binds to ADRA2A protein]

NCBI chr15:4,316,038...4,416,918
Ensembl chr15:4,316,059...4,417,183

G

G protein subunit gamma 3

multiple interactions

Epinephrine promotes the reaction [GNG3 protein binds to ADRA2A protein]

NCBI chr 1:205,731,837...205,733,603
Ensembl chr 1:205,731,837...205,733,603

G

G protein subunit gamma 4

multiple interactions

Epinephrine promotes the reaction [GNG4 protein binds to ADRA2A protein]

NCBI chr17:86,448,708...86,497,560
Ensembl chr17:86,449,022...86,495,254

G

G protein-coupled receptor kinase 2

multiple interactions

Epinephrine promotes the reaction [GRK2 protein results in increased phosphorylation of ADRB2 protein]

NCBI chr 1:201,580,823...201,601,580
Ensembl chr 1:201,581,480...201,601,582

G

G protein-coupled receptor kinase 5

multiple interactions

Epinephrine promotes the reaction [GRK5 protein results in increased phosphorylation of ADRB2 protein]

NCBI chr 1:260,028,269...260,223,699
Ensembl chr 1:260,028,242...260,218,701

G

hydroxyacyl-CoA dehydrogenase

multiple interactions

[Epinephrine co-treated with Xanthine co-treated with XDH] results in decreased expression of HADH protein

NCBI chr 2:219,787,935...219,830,335
Ensembl chr 2:219,787,927...219,830,353

G

hypoxia inducible factor 1 subunit alpha

increases expression

Epinephrine results in increased expression of HIF1A protein

NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261

G

hexokinase 2

increases expression

Epinephrine results in increased expression of HK2 protein

NCBI chr 4:115,234,509...115,283,530
Ensembl chr 4:115,234,509...115,283,530

G

heat shock transcription factor 1

multiple interactions
affects localization

Epinephrine promotes the reaction [[Xanthine co-treated with XDH protein] affects the localization of HSF1 protein]
Epinephrine affects the localization of HSF1 protein

NCBI chr 7:108,196,040...108,223,011
Ensembl chr 7:108,196,056...108,223,011

G

heat shock protein 90 alpha family class B member 1

multiple interactions

[Epinephrine co-treated with Xanthine co-treated with XDH] results in decreased expression of HSP90AB1 protein

NCBI chr 9:15,432,986...15,438,358
Ensembl chr 9:15,433,691...15,438,488

G

heat shock protein family A (Hsp70) member 5

multiple interactions

[Epinephrine co-treated with Xanthine co-treated with XDH] results in increased expression of HSPA5 protein

NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891

G

heat shock protein family A (Hsp70) member 8

increases expression

Epinephrine results in increased expression of HSPA8 protein

NCBI chr 8:41,183,397...41,187,260
Ensembl chr 8:41,183,264...41,187,259

G

heat shock protein family A (Hsp70) member 9

multiple interactions

[Epinephrine co-treated with Xanthine co-treated with XDH] results in decreased expression of HSPA9 protein

NCBI chr18:26,536,131...26,554,294
Ensembl chr18:26,535,798...26,554,292

G

heat shock protein family B (small) member 6

decreases expression
multiple interactions

Epinephrine results in decreased expression of HSPB6 protein
[Epinephrine co-treated with Xanthine co-treated with XDH] results in decreased expression of HSPB6 protein

NCBI chr 1:85,806,898...85,809,072
Ensembl chr 1:85,806,146...85,809,071

G

isocitrate dehydrogenase (NADP(+)) 2

decreases expression
multiple interactions

Epinephrine results in decreased expression of IDH2 protein
[Epinephrine co-treated with Xanthine co-treated with XDH] results in decreased expression of IDH2 protein

NCBI chr 1:134,038,644...134,057,969
Ensembl chr 1:134,029,772...134,058,025

G

interleukin 10

multiple interactions

Epinephrine promotes the reaction [Lipopolysaccharides results in increased expression of IL10 protein]

NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313

G

interleukin 1 beta

multiple interactions

Epinephrine inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B protein]

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 6

decreases expression
multiple interactions

Epinephrine results in decreased expression of IL6 mRNA
Epinephrine inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 protein]

PMID:10588509 PMID:12423672

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

insulin 1

multiple interactions

INS1 inhibits the reaction [Epinephrine results in increased expression of AQP7 mRNA]
cilostamide inhibits the reaction [INS1 protein inhibits the reaction [Epinephrine results in increased transport of Fatty Acids, Nonesterified]]; Cytochalasin B inhibits the reaction [INS1 protein inhibits the reaction [Epinephrine results in increased transport of Fatty Acids, Nonesterified]]; hydroxy-2-naphthalenyl-methyl phosphonic acid trisacetoxymethylester inhibits the reaction [INS1 protein inhibits the reaction [Epinephrine results in increased transport of Fatty Acids, Nonesterified]]; INS1 protein inhibits the reaction [Epinephrine results in increased transport of Fatty Acids, Nonesterified]; Wortmannin inhibits the reaction [INS1 protein inhibits the reaction [Epinephrine results in increased transport of Fatty Acids, Nonesterified]]

PMID:10777495 PMID:15172182

NCBI chr 1:251,244,973...251,245,540
Ensembl chr 1:251,244,973...251,245,536

G

insulin 2

multiple interactions
decreases expression

[Epinephrine co-treated with INS protein] results in increased phosphorylation of AKT1 protein; Butoxamine inhibits the reaction [Epinephrine results in decreased expression of INS protein]; Pentolinium Tartrate inhibits the reaction [Epinephrine results in decreased secretion of INS protein]; Propranolol inhibits the reaction [Epinephrine results in decreased expression of INS protein]

PMID:1218171 PMID:6018752 PMID:6314140 PMID:32305330

NCBI chr 1:197,843,277...197,992,522
Ensembl chr 1:197,843,281...197,864,775

G

integrin subunit alpha 2

multiple interactions

ITGA2 gene SNP affects the susceptibility to [Aspirin co-treated with clopidogrel co-treated with Epinephrine]

NCBI chr 2:46,520,345...46,621,487
Ensembl chr 2:46,523,948...46,621,481

G

integrin subunit alpha V

increases expression

Epinephrine results in increased expression of ITGAV mRNA

NCBI chr 3:68,838,514...68,926,653
Ensembl chr 3:68,838,189...68,926,639

G

integrin subunit beta 1

increases response to substance

ITGB1 results in increased susceptibility to Epinephrine

NCBI chr19:56,705,123...56,753,199
Ensembl chr19:56,705,171...56,753,195

G

lipase E, hormone sensitive type

multiple interactions
increases expression
affects localization
increases activity

Theophylline inhibits the reaction [Epinephrine results in increased activity of LIPE protein]
Epinephrine results in increased expression of LIPE mRNA
Epinephrine affects the localization of LIPE protein

PMID:7155675 PMID:10777495 PMID:11160373

NCBI chr 1:80,965,612...80,984,313
Ensembl chr 1:80,965,627...80,984,310

G

mitogen activated protein kinase 1

multiple interactions
increases phosphorylation
increases activity
affects activity

ADRA2A promotes the reaction [Epinephrine results in increased phosphorylation of MAPK1 protein]; ADRA2B promotes the reaction [Epinephrine results in increased phosphorylation of MAPK1 protein]; ADRA2C promotes the reaction [Epinephrine results in increased phosphorylation of MAPK1 protein]; Epinephrine inhibits the reaction [Estradiol results in decreased phosphorylation of MAPK1 protein]
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Epinephrine results in increased phosphorylation of MAPK1 protein]
Epinephrine deficiency results in increased activity of MAPK1 protein
Epinephrine affects the activity of MAPK1 protein

PMID:11093795 PMID:15292328 PMID:17680988 PMID:22496244

NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616

G

mitogen activated protein kinase 3

multiple interactions
increases phosphorylation
increases activity
affects activity

ADRA2A promotes the reaction [Epinephrine results in increased phosphorylation of MAPK3 protein]; ADRA2B promotes the reaction [Epinephrine results in increased phosphorylation of MAPK3 protein]; ADRA2C promotes the reaction [Epinephrine results in increased phosphorylation of MAPK3 protein]; Epinephrine inhibits the reaction [Estradiol results in decreased phosphorylation of MAPK3 protein]
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Epinephrine results in increased phosphorylation of MAPK3 protein]
Epinephrine deficiency results in increased activity of MAPK3 protein
Epinephrine affects the activity of MAPK3 protein

PMID:11093795 PMID:15292328 PMID:17680988 PMID:22496244

NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863

G

Meis homeobox 1

decreases expression

Epinephrine results in decreased expression of MEIS1 protein

NCBI chr14:93,155,426...93,294,373
Ensembl chr14:93,155,419...93,294,265

G

myosin light chain 2

multiple interactions
affects expression

[Epinephrine co-treated with Xanthine co-treated with XDH] affects the expression of MYL2 protein
Epinephrine affects the expression of MYL2 protein

NCBI chr12:34,454,223...34,468,554
Ensembl chr12:34,454,218...34,468,983

G

neurofilament heavy chain

affects expression

Epinephrine affects the expression of NEFH mRNA

NCBI chr14:79,830,362...79,840,347
Ensembl chr14:79,830,362...79,840,351

G

nuclear factor kappa B subunit 1

multiple interactions

Epinephrine promotes the reaction [[Xanthine co-treated with XDH protein] results in increased activity of [RELA protein binds to NFKB1 protein]]; Epinephrine results in increased activity of [RELA protein binds to NFKB1 protein]

NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404

G

nitric oxide synthase 2

multiple interactions
increases expression

Atenolol inhibits the reaction [Epinephrine inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased abundance of Nitrites]]; Atenolol inhibits the reaction [Epinephrine inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]]; Epinephrine inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased abundance of Nitrites]; Epinephrine inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]; Prazosin inhibits the reaction [Epinephrine inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased abundance of Nitrites]]; Prazosin inhibits the reaction [Epinephrine inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]]
Epinephrine results in increased expression of NOS2 mRNA

PMID:16925470 PMID:19439816

NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210

G

neurotrophin 3

increases expression

Epinephrine results in increased expression of NTF3 mRNA; Epinephrine results in increased expression of NTF3 protein

NCBI chr 4:158,914,984...158,984,453
Ensembl chr 4:158,914,957...158,984,596

G

purinergic receptor P2X 7

decreases activity

Epinephrine results in decreased activity of P2RX7 protein

NCBI chr12:33,889,709...33,934,168
Ensembl chr12:33,879,745...33,934,619

G

purinergic receptor P2Y12

multiple interactions

Epinephrine inhibits the reaction [P2RY12 gene mutant form results in decreased susceptibility to Adenosine Diphosphate]

NCBI chr 2:143,481,468...143,523,340
Ensembl chr 2:143,481,430...143,523,361

G

poly (ADP-ribose) polymerase 1

decreases cleavage

Epinephrine results in decreased cleavage of PARP1 protein

NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404

G

proliferating cell nuclear antigen

increases expression

Epinephrine results in increased expression of PCNA protein

NCBI chr 3:119,499,039...119,502,911
Ensembl chr 3:119,498,810...119,502,995

G

prohibitin 1

multiple interactions
increases expression

[Epinephrine co-treated with Xanthine co-treated with XDH] results in increased expression of PHB1 protein
Epinephrine results in increased expression of PHB1 protein

NCBI chr10:80,605,268...80,618,043
Ensembl chr10:80,605,251...80,618,042

G

phosphoglycerate dehydrogenase

increases expression

Epinephrine results in increased expression of PHGDH mRNA

NCBI chr 2:185,906,962...185,936,054
Ensembl chr 2:185,906,966...185,935,944

G

pyruvate kinase M1/2

multiple interactions
increases expression

[Epinephrine co-treated with Xanthine co-treated with XDH] results in decreased expression of PKM protein
Epinephrine results in increased expression of PKM protein

PMID:19464573 PMID:36423730

NCBI chr 8:60,057,629...60,079,600
Ensembl chr 8:60,057,402...60,079,599

G

PPARG coactivator 1 alpha

increases expression

Epinephrine results in increased expression of PPARGC1A mRNA

NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656

G

protein phosphatase 2 scaffold subunit A alpha

decreases expression
multiple interactions

Epinephrine results in decreased expression of PPP2R1A protein
[Epinephrine co-treated with Xanthine co-treated with XDH] results in decreased expression of PPP2R1A protein

NCBI chr 1:60,540,223...60,559,467
Ensembl chr 1:60,540,194...60,560,129

G

peroxiredoxin 6

multiple interactions
decreases expression

[Epinephrine co-treated with Xanthine co-treated with XDH] results in decreased expression of PRDX6 protein
Epinephrine results in decreased expression of PRDX6 protein

NCBI chr13:73,528,746...73,539,295
Ensembl chr13:73,528,210...73,539,355

G

protein kinase C, epsilon

affects response to substance

PRKCE protein affects the susceptibility to Epinephrine

NCBI chr 6:7,965,048...8,451,966
Ensembl chr 6:7,965,048...8,451,719

G

prostaglandin-endoperoxide synthase 2

decreases expression

Epinephrine results in decreased expression of PTGS2 mRNA; Epinephrine results in decreased expression of PTGS2 protein

NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188

G

RELA proto-oncogene, NF-kB subunit

multiple interactions

Epinephrine promotes the reaction [[Xanthine co-treated with XDH protein] results in increased activity of [RELA protein binds to NFKB1 protein]]; Epinephrine results in increased activity of [RELA protein binds to NFKB1 protein]

NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484

G

renin

multiple interactions
increases activity

ICI 118551 inhibits the reaction [Epinephrine results in increased activity of REN protein]

PMID:6314140 PMID:8592096

NCBI chr13:44,796,260...44,807,491
Ensembl chr13:44,796,091...44,807,489

G

secretin

multiple interactions

Epinephrine inhibits the reaction [SCT protein results in increased abundance of Cyclic AMP]

NCBI chr 1:196,382,857...196,383,668
Ensembl chr 1:196,382,856...196,383,658

G

serpin family E member 1

increases expression

Epinephrine results in increased expression of SERPINE1 mRNA

NCBI chr12:19,601,272...19,611,657
Ensembl chr12:19,601,272...19,611,657

G

solute carrier family 22 member 3

multiple interactions
increases uptake

[Corticosterone results in decreased activity of SLC22A3 protein] inhibits the reaction [Epinephrine results in increased abundance of Epinephrine metabolite]; [Corticosterone results in decreased activity of SLC22A3 protein] which results in decreased abundance of Epinephrine
SLC22A3 protein results in increased uptake of Epinephrine

PMID:19053318 PMID:20858707

NCBI chr 1:48,235,476...48,324,617
Ensembl chr 1:48,235,476...48,324,612

G

solute carrier family 29 member 4

increases uptake

SLC29A4 protein results in increased uptake of Epinephrine

NCBI chr12:11,853,540...11,884,660
Ensembl chr12:11,853,540...11,874,834

G

superoxide dismutase 1

multiple interactions
affects binding
increases expression
increases activity

6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid inhibits the reaction [Epinephrine results in increased activity of SOD1 protein]; Atenolol inhibits the reaction [Epinephrine results in increased activity of SOD1 protein]; Vitamin E inhibits the reaction [Epinephrine results in increased activity of SOD1 protein]
Epinephrine binds to SOD1 protein mutant form
[Epinephrine co-treated with Xanthine co-treated with XDH] results in increased expression of SOD1 protein
Epinephrine results in increased expression of SOD1 protein
Epinephrine results in increased expression of SOD1 mRNA; Epinephrine results in increased expression of SOD1 protein

PMID:11163531 PMID:19464573 PMID:23612299

NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249

G

superoxide dismutase 2

multiple interactions
increases expression
increases activity

6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid inhibits the reaction [Epinephrine results in increased activity of SOD2 protein]; Atenolol inhibits the reaction [Epinephrine results in increased activity of SOD2 protein]; Vitamin E inhibits the reaction [Epinephrine results in increased activity of SOD2 protein]
[Epinephrine co-treated with Xanthine co-treated with XDH] results in decreased expression of SOD2 protein
Epinephrine results in increased expression of SOD2 protein
Epinephrine results in increased expression of SOD2 mRNA; Epinephrine results in increased expression of SOD2 protein

PMID:11163531 PMID:19464573

NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189

G

succinate-CoA ligase GDP-forming subunit beta

increases expression

Epinephrine results in increased expression of SUCLG2 protein

NCBI chr 4:128,067,031...128,337,146
Ensembl chr 4:128,067,033...128,337,170

G

tyrosine hydroxylase

increases chemical synthesis
multiple interactions

TH protein results in increased chemical synthesis of Epinephrine
[Clonidine results in increased expression of TH protein] which results in increased abundance of Epinephrine

PMID:9822156 PMID:19067675

NCBI chr 1:198,071,500...198,078,832
Ensembl chr 1:198,071,503...198,109,767

G

Thy-1 cell surface antigen

multiple interactions
decreases expression

Propranolol inhibits the reaction [Epinephrine results in decreased expression of THY1]

NCBI chr 8:44,389,495...44,394,688
Ensembl chr 8:44,389,513...44,394,659

G

tumor necrosis factor

multiple interactions
decreases expression
decreases secretion

Epinephrine inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]
Epinephrine results in decreased expression of TNF mRNA
Epinephrine results in decreased secretion of TNF protein

PMID:10588509 PMID:12423672

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

tumor protein p53

decreases expression

Epinephrine results in decreased expression of TP53 protein

NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524

G

voltage-dependent anion channel 1

increases expression
multiple interactions

Epinephrine results in increased expression of VDAC1 protein
[Epinephrine co-treated with Xanthine co-treated with XDH] results in increased expression of VDAC1 protein

NCBI chr10:36,532,306...36,559,642
Ensembl chr10:36,532,244...36,559,640

G

Wnt family member 4

decreases expression

Epinephrine results in decreased expression of WNT4 mRNA; Epinephrine results in decreased expression of WNT4 protein

NCBI chr 5:149,513,573...149,535,415
Ensembl chr 5:149,514,018...149,532,859

G

xanthine dehydrogenase

multiple interactions

[Epinephrine co-treated with Xanthine co-treated with XDH] affects the expression of MYL2 protein; [Epinephrine co-treated with Xanthine co-treated with XDH] results in decreased expression of AK2 protein; [Epinephrine co-treated with Xanthine co-treated with XDH] results in decreased expression of DES protein; [Epinephrine co-treated with Xanthine co-treated with XDH] results in decreased expression of DLAT protein; [Epinephrine co-treated with Xanthine co-treated with XDH] results in decreased expression of ECHS1 protein; [Epinephrine co-treated with Xanthine co-treated with XDH] results in decreased expression of ETFB protein; [Epinephrine co-treated with Xanthine co-treated with XDH] results in decreased expression of FABP3 protein; [Epinephrine co-treated with Xanthine co-treated with XDH] results in decreased expression of HADH protein; [Epinephrine co-treated with Xanthine co-treated with XDH] results in decreased expression of HSP90AB1 protein; [Epinephrine co-treated with Xanthine co-treated with XDH] results in decreased expression of HSPA9 protein; [Epinephrine co-treated with Xanthine co-treated with XDH] results in decreased expression of HSPB6 protein; [Epinephrine co-treated with Xanthine co-treated with XDH] results in decreased expression of IDH2 protein; [Epinephrine co-treated with Xanthine co-treated with XDH] results in decreased expression of PKM protein; [Epinephrine co-treated with Xanthine co-treated with XDH] results in decreased expression of PPP2R1A protein; [Epinephrine co-treated with Xanthine co-treated with XDH] results in decreased expression of PRDX6 protein; [Epinephrine co-treated with Xanthine co-treated with XDH] results in decreased expression of SOD2 protein; [Epinephrine co-treated with Xanthine co-treated with XDH] results in increased expression of C1QBP protein; [Epinephrine co-treated with Xanthine co-treated with XDH] results in increased expression of CYCS protein; [Epinephrine co-treated with Xanthine co-treated with XDH] results in increased expression of HSPA5 protein; [Epinephrine co-treated with Xanthine co-treated with XDH] results in increased expression of PHB1 protein; [Epinephrine co-treated with Xanthine co-treated with XDH] results in increased expression of SOD1 protein; [Epinephrine co-treated with Xanthine co-treated with XDH] results in increased expression of VDAC1 protein; Epinephrine promotes the reaction [[Xanthine co-treated with XDH protein] affects the localization of HSF1 protein]; Epinephrine promotes the reaction [[Xanthine co-treated with XDH protein] results in increased activity of [RELA protein binds to NFKB1 protein]]; Epinephrine promotes the reaction [[Xanthine co-treated with XDH protein] results in increased activity of CASP3 protein]

PMID:19135123 PMID:19464573

NCBI chr 6:21,530,463...21,592,172
Ensembl chr 6:21,530,113...21,592,268

(R)-noradrenaline

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

aralkylamine N-acetyltransferase

multiple interactions
increases activity

11-nor-delta(9)-tetrahydrocannabinol-9-carboxylic acid inhibits the reaction [Norepinephrine results in increased activity of AANAT protein]; Cannabidiol inhibits the reaction [Norepinephrine results in increased activity of AANAT protein]; Cannabinol inhibits the reaction [Norepinephrine results in increased activity of AANAT protein]

NCBI chr10:101,827,072...101,831,805
Ensembl chr10:101,827,301...101,831,801

G

actin, alpha 1, skeletal muscle

increases expression

Norepinephrine results in increased expression of ACTA1 mRNA

NCBI chr19:51,883,709...51,886,735
Ensembl chr19:51,883,715...51,886,742

G

actin alpha 2, smooth muscle

increases expression
multiple interactions

Norepinephrine results in increased expression of ACTA2 mRNA
[Clorgyline co-treated with Selegiline] inhibits the reaction [Norepinephrine results in increased expression of ACTA2 mRNA]; Carnosine inhibits the reaction [Norepinephrine results in increased expression of ACTA2 mRNA]; FPS-ZM1 inhibits the reaction [Norepinephrine results in increased expression of ACTA2 mRNA]

NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554

G

adenosine deaminase

multiple interactions
decreases response to substance

[ADA protein co-treated with Norepinephrine] results in increased secretion of Glycerol
Propranolol promotes the reaction [ADA protein results in decreased susceptibility to Norepinephrine]

PMID:7949234 PMID:17428236

NCBI chr 3:152,398,745...152,422,854
Ensembl chr 3:152,398,747...152,447,088

G

adrenoceptor alpha 1A

affects binding
multiple interactions
increases activity
affects expression
affects response to substance

Norepinephrine binds to ADRA1A protein
[Norepinephrine binds to and results in increased activity of ADRA1A protein] which results in increased abundance of Calcium; Norepinephrine binds to and results in increased activity of ADRA1A protein; Norepinephrine inhibits the reaction [ADRA1A protein binds to Prazosin]
Norepinephrine results in increased activity of ADRA1A protein
5-methylurapidil inhibits the reaction [Norepinephrine results in increased activity of ADRA1A protein]; [chlorethylclonidine co-treated with Phenoxybenzamine] inhibits the reaction [Norepinephrine results in increased activity of ADRA1A protein]; BMY 7378 inhibits the reaction [Norepinephrine results in increased activity of ADRA1A protein]; chlorethylclonidine inhibits the reaction [Norepinephrine results in increased activity of ADRA1A protein]; Phenoxybenzamine inhibits the reaction [Norepinephrine results in increased activity of ADRA1A protein]; Prazosin inhibits the reaction [Norepinephrine results in increased activity of ADRA1A protein]; Spiperone inhibits the reaction [Norepinephrine results in increased activity of ADRA1A protein]
Norepinephrine affects the expression of ADRA1A protein
ADRA1A protein affects the susceptibility to Norepinephrine

PMID:8183249 PMID:10416824 PMID:12417256 PMID:20030735

NCBI chr15:40,830,125...40,935,902
Ensembl chr15:40,832,534...40,927,500

G

adrenoceptor alpha 1B

multiple interactions

[Norepinephrine binds to and results in increased activity of ADRA1B protein] which results in increased abundance of Calcium; Norepinephrine binds to and results in increased activity of ADRA1B protein; Norepinephrine inhibits the reaction [ADRA1B protein binds to Prazosin]

NCBI chr10:28,255,025...28,373,418
Ensembl chr10:28,255,025...28,312,919

G

adrenoceptor alpha 1D

affects binding
multiple interactions
affects response to substance

Norepinephrine binds to ADRA1D protein
[Norepinephrine binds to and results in increased activity of ADRA1D protein] which results in increased abundance of Calcium; Norepinephrine binds to and results in increased activity of ADRA1D protein; Norepinephrine inhibits the reaction [ADRA1D protein binds to Prazosin]
ADRA1D affects the susceptibility to Norepinephrine
Norepinephrine binds to and affects the activity of ADRA1D protein

PMID:8183249 PMID:9639061 PMID:11901185 PMID:15493479 PMID:20030735

NCBI chr 3:118,793,356...118,809,354
Ensembl chr 3:118,793,346...118,809,354

G

adrenoceptor alpha 2A

affects secretion
multiple interactions
affects abundance
affects binding

ADRA2A protein affects the secretion of Norepinephrine
[ADRA2A protein mutant form co-treated with ADRA2C protein mutant form] results in increased abundance of Norepinephrine
ADRA2A protein affects the abundance of Norepinephrine
1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione inhibits the reaction [Norepinephrine binds to and results in increased activity of ADRA2A protein]; [Norepinephrine binds to and results in increased activity of ADRA2A protein] which results in increased abundance of Calcium; Brimonidine Tartrate inhibits the reaction [Norepinephrine binds to and results in increased activity of ADRA2A protein]; Dexmedetomidine inhibits the reaction [Norepinephrine binds to and results in increased activity of ADRA2A protein]; Doxazosin inhibits the reaction [Norepinephrine binds to and results in increased activity of ADRA2A protein]; Norepinephrine binds to and results in increased activity of ADRA2A protein; Norepinephrine inhibits the reaction [ADRA2A protein binds to 2-methoxyidazoxan]; Prazosin inhibits the reaction [Norepinephrine binds to and results in increased activity of ADRA2A protein]; talipexole inhibits the reaction [Norepinephrine binds to and results in increased activity of ADRA2A protein]; Thapsigargin inhibits the reaction [Norepinephrine binds to and results in increased activity of ADRA2A protein]; Yohimbine inhibits the reaction [Norepinephrine binds to and results in increased activity of ADRA2A protein]
Norepinephrine binds to ADRA2A protein
[BRL 44408 binds to and results in decreased activity of ADRA2A protein] inhibits the reaction [Xylazine inhibits the reaction [Potassium results in increased secretion of Norepinephrine]]

PMID:10336518 PMID:10742289 PMID:11312645 PMID:20030735 PMID:20083574

NCBI chr 1:253,061,480...253,064,280
Ensembl chr 1:253,060,218...253,064,365

G

adrenoceptor alpha 2B

multiple interactions

[Norepinephrine binds to and results in increased activity of ADRA2B protein] which results in increased abundance of Calcium; Norepinephrine binds to and results in increased activity of ADRA2B protein; Norepinephrine inhibits the reaction [ADRA2B protein binds to 2-methoxyidazoxan]

NCBI chr 3:114,585,174...114,589,220
Ensembl chr 3:114,585,169...114,589,355

G

adrenoceptor alpha 2C

affects binding
multiple interactions

Norepinephrine binds to ADRA2C protein
[ADRA2A protein mutant form co-treated with ADRA2C protein mutant form] results in increased abundance of Norepinephrine
[Norepinephrine binds to and results in increased activity of ADRA2C protein] which results in increased abundance of Calcium; Norepinephrine binds to and results in increased activity of ADRA2C protein; Norepinephrine inhibits the reaction [ADRA2C protein binds to 2-methoxyidazoxan]

PMID:10336518 PMID:20030735 PMID:20083574

NCBI chr14:75,470,884...75,472,846
Ensembl chr14:75,471,143...75,472,846

G

adrenoceptor beta 1

multiple interactions

[Norepinephrine binds to and results in increased activity of ADRB1 protein] which results in increased abundance of Cyclic AMP; Norepinephrine binds to and results in increased activity of ADRB1 protein; Norepinephrine inhibits the reaction [cyanopindolol binds to ADRB1 protein]; Norepinephrine inhibits the reaction [Iodocyanopindolol binds to ADRB1 protein]; Norepinephrine promotes the reaction [ADRB1 protein results in increased activity of GNAS protein]; Octopamine inhibits the reaction [Norepinephrine binds to ADRB1 protein]; Propranolol inhibits the reaction [Norepinephrine binds to and results in increased activity of ADRB1 protein]
[CGP 20712A binds to and results in decreased activity of ADRB1 protein] which results in decreased activity of Norepinephrine

PMID:8096834 PMID:10344530 PMID:12010770 PMID:14730417 PMID:17200720

NCBI chr 1:255,771,962...255,774,973
Ensembl chr 1:255,771,597...255,807,259

G

adrenoceptor beta 2

multiple interactions
affects binding

[ICI 118551 binds to and results in decreased activity of ADRB2 protein] inhibits the reaction [Fenoterol affects the abundance of Norepinephrine]
[Norepinephrine binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP; Norepinephrine binds to and results in increased activity of ADRB2 protein; Norepinephrine inhibits the reaction [cyanopindolol binds to ADRB2 protein]; Octopamine inhibits the reaction [Norepinephrine binds to ADRB2 protein]; Propranolol inhibits the reaction [Norepinephrine binds to ADRB2 protein]; quercetin 3-O-glucuronide inhibits the reaction [Norepinephrine binds to ADRB2 protein]

PMID:7969507 PMID:10344530 PMID:14730417 PMID:24929186

NCBI chr18:55,642,459...55,644,501
Ensembl chr18:55,502,903...55,644,512

G

adrenoceptor beta 3

multiple interactions
increases activity

[Norepinephrine binds to and results in increased activity of ADRB3 protein] which results in increased abundance of Cyclic AMP; Norepinephrine binds to and results in increased activity of ADRB3 protein; Norepinephrine inhibits the reaction [cyanopindolol binds to ADRB3 protein]; Octopamine inhibits the reaction [Norepinephrine binds to ADRB3 protein]
Norepinephrine results in increased activity of ADRB3 protein
3-(2-ethylphenoxy)-1-(1,2,3,4-tetrahydronaphth-1-ylamino)-2-propanol oxalate inhibits the reaction [Norepinephrine results in increased activity of ADRB3 protein]; Norepinephrine binds to and results in increased activity of ADRB3 protein

PMID:1682311 PMID:7815362 PMID:8569714 PMID:10344530 PMID:14730417 More...

NCBI chr16:64,839,820...64,844,552
Ensembl chr16:64,841,788...64,844,552

G

angiotensinogen

increases abundance
affects abundance
multiple interactions

AGT protein results in increased abundance of Norepinephrine
Norepinephrine affects the abundance of AGT protein
carvedilol inhibits the reaction [AGT protein results in increased abundance of Norepinephrine]; Losartan inhibits the reaction [AGT protein results in increased abundance of Norepinephrine]

PMID:614752 PMID:15741261

NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977

G

angiotensin II receptor, type 2

affects response to substance

AGTR2 protein affects the susceptibility to Norepinephrine

NCBI chr X:112,119,876...112,124,060
Ensembl chr X:112,120,228...112,124,057

G

AKT serine/threonine kinase 1

decreases expression

Norepinephrine results in decreased expression of AKT1 protein modified form

NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921

G

arachidonate 5-lipoxygenase activating protein

increases expression

Norepinephrine results in increased expression of ALOX5AP mRNA

NCBI chr12:5,748,941...5,772,986
Ensembl chr12:5,748,944...5,772,986

G

annexin A1

multiple interactions

ANXA1 affects the reaction [Norepinephrine results in decreased secretion of IL6 protein]

NCBI chr 1:217,861,175...217,877,205
Ensembl chr 1:217,861,175...217,877,343

G

aquaporin 2

decreases expression

Norepinephrine results in decreased expression of AQP2 protein

NCBI chr 7:130,711,433...130,716,468
Ensembl chr 7:130,711,413...130,716,468

G

ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 2

affects abundance
decreases expression

ATP2A2 protein affects the abundance of Norepinephrine
Norepinephrine results in decreased expression of ATP2A2 mRNA

PMID:17592507 PMID:19328205

NCBI chr12:34,072,710...34,122,142
Ensembl chr12:34,072,683...34,122,101

G

arginine vasopressin

multiple interactions

[AVP protein co-treated with Norepinephrine] inhibits the reaction [Triiodothyronine inhibits the reaction [EGF protein results in decreased expression of UCP1 mRNA]]; [AVP protein co-treated with Norepinephrine] inhibits the reaction [Triiodothyronine promotes the reaction [FGF1 protein results in increased expression of UCP1 mRNA]]; [AVP protein co-treated with Norepinephrine] inhibits the reaction [Triiodothyronine promotes the reaction [FGF2 protein results in increased expression of UCP1 mRNA]]; [AVP protein co-treated with Norepinephrine] inhibits the reaction [Triiodothyronine results in increased expression of UCP1 mRNA]; [EGF protein co-treated with AVP protein co-treated with Norepinephrine co-treated with Triiodothyronine] results in decreased expression of UCP1 mRNA; [FGF1 protein co-treated with AVP protein co-treated with Norepinephrine co-treated with Triiodothyronine] results in decreased expression of UCP1 mRNA

NCBI chr 3:117,793,447...117,805,091
Ensembl chr 3:117,793,457...117,795,425

G

BCL2 associated X, apoptosis regulator

multiple interactions
increases expression

N-(1-methyl-5-indolyl)-N'-(3-methyl-5-isothiazolyl)urea inhibits the reaction [Norepinephrine results in increased expression of BAX protein]
Norepinephrine results in increased expression of BAX mRNA; Norepinephrine results in increased expression of BAX protein

PMID:18675472 PMID:20374255

NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368

G

BCL2, apoptosis regulator

multiple interactions
decreases expression

Acetylcysteine inhibits the reaction [Norepinephrine results in decreased expression of BCL2 protein]; N-(1-methyl-5-indolyl)-N'-(3-methyl-5-isothiazolyl)urea inhibits the reaction [Norepinephrine results in decreased expression of BCL2 protein]

PMID:14732211 PMID:17041759 PMID:20374255

NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

Bcl2-like 1

decreases expression

Norepinephrine results in decreased expression of BCL2L1 mRNA

NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479
Ensembl chr 1:141,253,523...141,303,479

G

bradykinin receptor B2

affects response to substance

BDKRB2 affects the susceptibility to Norepinephrine

NCBI chr 6:124,472,317...124,502,497
Ensembl chr 6:124,472,566...124,502,497

G

complement C5a receptor 2

increases expression

Norepinephrine results in increased expression of C5AR2 mRNA; Norepinephrine results in increased expression of C5AR2 protein

NCBI chr 1:76,930,381...76,945,432
Ensembl chr 1:76,930,383...76,959,517

G

calcitonin-related polypeptide alpha

affects response to substance
increases abundance
multiple interactions

CALCA protein affects the susceptibility to Norepinephrine
CALCA protein results in increased abundance of Norepinephrine
Propranolol promotes the reaction [CALCA protein affects the susceptibility to Norepinephrine]

PMID:8058111 PMID:18055875

NCBI chr 1:168,878,212...168,883,176
Ensembl chr 1:168,878,214...168,883,105

G

calcyon neuron-specific vesicular protein

increases secretion

CALY protein results in increased secretion of Norepinephrine

NCBI chr 1:194,862,671...194,873,861
Ensembl chr 1:194,862,672...194,873,551

G

calcium/calmodulin-dependent protein kinase II beta

increases expression

Norepinephrine results in increased expression of CAMK2B mRNA

NCBI chr14:80,845,206...80,934,172
Ensembl chr14:80,845,238...80,933,994

G

caspase 12

multiple interactions
increases cleavage

CAT protein inhibits the reaction [Norepinephrine results in increased cleavage of CASP12 protein alternative form]

NCBI chr 8:2,642,296...2,669,549
Ensembl chr 8:2,642,434...2,674,037

G

caspase 2

multiple interactions
increases activity

Acetylcysteine inhibits the reaction [Norepinephrine results in increased activity of CASP2 protein]; Ascorbic Acid inhibits the reaction [Norepinephrine results in increased activity of CASP2 protein]

PMID:14732211 PMID:15158148 PMID:17041759

NCBI chr 4:71,149,632...71,167,388
Ensembl chr 4:71,149,669...71,167,379

G

caspase 3

multiple interactions
increases activity
increases cleavage
increases expression

Acetylcysteine inhibits the reaction [Norepinephrine results in increased activity of and results in increased cleavage of CASP3 protein]; Norepinephrine results in increased activity of and results in increased cleavage of CASP3 protein
Norepinephrine results in increased activity of CASP3 protein
Norepinephrine results in increased cleavage of CASP3 protein
Norepinephrine results in increased expression of CASP3 protein
Acetylcysteine inhibits the reaction [Norepinephrine results in increased activity of CASP3 protein]; Ascorbic Acid inhibits the reaction [Norepinephrine results in increased activity of CASP3 protein]; N-(1-methyl-5-indolyl)-N'-(3-methyl-5-isothiazolyl)urea inhibits the reaction [Norepinephrine results in increased expression of CASP3 protein]; Norepinephrine inhibits the reaction [Okadaic Acid results in increased activity of CASP3 protein]

PMID:11099166 PMID:14732211 PMID:15158148 PMID:16338971 PMID:17041759 More...

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

caspase 6

multiple interactions
increases activity

Acetylcysteine inhibits the reaction [Norepinephrine results in increased activity of CASP6 protein]; Ascorbic Acid inhibits the reaction [Norepinephrine results in increased activity of CASP6 protein]

PMID:14732211 PMID:15158148

NCBI chr 2:218,466,063...218,478,503
Ensembl chr 2:218,466,076...218,478,502

G

caspase 7

multiple interactions

Acetylcysteine inhibits the reaction [Norepinephrine results in increased activity of and results in increased cleavage of CASP7 protein]; Norepinephrine results in increased activity of and results in increased cleavage of CASP7 protein

NCBI chr 1:255,437,438...255,476,737
Ensembl chr 1:255,437,172...255,476,729

G

caspase 8

affects activity

Norepinephrine affects the activity of CASP8 protein

NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542

G

caspase 9

multiple interactions
affects activity
increases cleavage
increases activity

Acetylcysteine inhibits the reaction [Norepinephrine results in increased activity of CASP9 protein]; Ascorbic Acid inhibits the reaction [Norepinephrine results in increased activity of CASP9 protein]
Norepinephrine affects the activity of CASP9 protein
Norepinephrine results in increased cleavage of CASP9 protein

PMID:14732211 PMID:15158148 PMID:16338971 PMID:25437044

NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626

G

catalase

multiple interactions

CAT protein inhibits the reaction [Norepinephrine results in increased cleavage of CASP12 protein alternative form]

NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478

G

C-C motif chemokine ligand 3

multiple interactions

Norepinephrine inhibits the reaction [Lipopolysaccharides results in increased expression of CCL3 mRNA]; Norepinephrine inhibits the reaction [Lipopolysaccharides results in increased secretion of CCL3 protein]; Norepinephrine inhibits the reaction [Thioglycolates results in increased secretion of CCL3 protein]; Propranolol inhibits the reaction [Norepinephrine inhibits the reaction [Lipopolysaccharides results in increased secretion of CCL3 protein]]

NCBI chr10:68,451,388...68,452,938
Ensembl chr10:68,451,388...68,452,938

G

C-C motif chemokine ligand 5

increases secretion
multiple interactions

Norepinephrine results in increased secretion of CCL5 protein
Prazosin inhibits the reaction [Norepinephrine results in increased secretion of CCL5 protein]

NCBI chr10:68,322,826...68,327,380
Ensembl chr10:68,322,829...68,327,377

G

cellular communication network factor 1

increases expression

Norepinephrine results in increased expression of CCN1 mRNA

NCBI chr 2:234,562,410...234,565,370
Ensembl chr 2:234,562,408...234,565,484

G

Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal domain, 4

decreases expression

Norepinephrine results in decreased expression of CITED4 mRNA

NCBI chr 5:134,246,936...134,247,827
Ensembl chr 5:134,246,682...134,248,135

G

cannabinoid receptor 1

affects expression

Norepinephrine affects the expression of CNR1 mRNA

NCBI chr 5:48,408,543...48,436,099
Ensembl chr 5:48,408,574...48,435,099

G

collagen type I alpha 1 chain

multiple interactions
increases expression

carvedilol inhibits the reaction [Norepinephrine results in increased expression of COL1A1 mRNA]; Doxazosin inhibits the reaction [Norepinephrine results in increased expression of COL1A1 mRNA]
[Clorgyline co-treated with Selegiline] inhibits the reaction [Norepinephrine results in increased expression of COL1A1 mRNA]; FPS-ZM1 inhibits the reaction [Norepinephrine results in increased expression of COL1A1 mRNA]

PMID:10722803 PMID:14577597 PMID:19575289 PMID:34609854

NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624

G

collagen type III alpha 1 chain

increases expression
multiple interactions

Norepinephrine results in increased expression of COL3A1 mRNA
[Clorgyline co-treated with Selegiline] inhibits the reaction [Norepinephrine results in increased expression of COL3A1 mRNA]; Carnosine inhibits the reaction [Norepinephrine results in increased expression of COL3A1 mRNA]; FPS-ZM1 inhibits the reaction [Norepinephrine results in increased expression of COL3A1 mRNA]
carvedilol inhibits the reaction [Norepinephrine results in increased expression of COL3A1 mRNA]

PMID:10722803 PMID:14577597 PMID:34609854

NCBI chr 9:47,374,611...47,410,547
Ensembl chr 9:47,374,593...47,410,547

G

catechol-O-methyltransferase

multiple interactions
increases methylation

[tolcapone results in decreased activity of COMT protein] which results in increased abundance of Norepinephrine
COMT protein results in increased methylation of Norepinephrine

PMID:11160877 PMID:11248589

NCBI chr11:82,568,052...82,587,642
Ensembl chr11:82,568,025...82,587,642

G

carnitine palmitoyltransferase 1A

decreases expression

Norepinephrine results in decreased expression of CPT1A mRNA

NCBI chr 1:200,564,634...200,627,059
Ensembl chr 1:200,565,613...200,627,055

G

cAMP responsive element modulator

increases expression

Norepinephrine results in increased expression of CREM mRNA

NCBI chr17:54,238,889...54,305,989
Ensembl chr17:54,239,030...54,305,989

G

corticotropin releasing hormone

multiple interactions
increases abundance

corticotropin releasing hormone (9-41) inhibits the reaction [CRH protein affects the abundance of Norepinephrine]; Norepinephrine affects the expression of and affects the secretion of CRH protein; Propranolol affects the reaction [Norepinephrine affects the expression of and affects the secretion of CRH protein]; Yohimbine affects the reaction [Norepinephrine affects the expression of and affects the secretion of CRH protein]
CRH results in increased abundance of Norepinephrine

PMID:1320258 PMID:3497798

NCBI chr 2:102,143,055...102,144,919
Ensembl chr 2:102,143,055...102,144,919

G

corticotropin releasing hormone receptor 1

multiple interactions

[CP 154526 binds to and results in decreased activity of CRHR1 protein] inhibits the reaction [Morphine deficiency affects the abundance of Norepinephrine]; [CP 154526 binds to and results in decreased activity of CRHR1 protein] inhibits the reaction [Naloxone affects the abundance of Norepinephrine]

NCBI chr10:89,040,186...89,083,481
Ensembl chr10:89,040,203...89,083,481

G

carnitine O-octanoyltransferase

increases expression

Norepinephrine results in increased expression of CROT mRNA

NCBI chr 4:25,068,270...25,133,111
Ensembl chr 4:25,080,587...25,133,109

G

cytochrome c, somatic

affects localization
increases localization

Norepinephrine affects the localization of CYCS protein
Norepinephrine results in increased localization of CYCS protein

NCBI chr 4:79,651,894...79,653,994
Ensembl chr 4:79,651,378...79,654,054
Ensembl chr18:79,651,378...79,654,054

G

dopamine beta-hydroxylase

affects abundance
increases abundance
decreases abundance

DBH gene polymorphism affects the abundance of Norepinephrine
DBH protein results in increased abundance of Norepinephrine
DBH mutant form results in decreased abundance of Norepinephrine

PMID:15148402 PMID:16163519 PMID:18329701

NCBI chr 3:10,488,260...10,505,245
Ensembl chr 3:10,488,260...10,505,248

G

DNA-damage inducible transcript 3

increases expression

Norepinephrine results in increased expression of DDIT3 mRNA; Norepinephrine results in increased expression of DDIT3 protein

NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201

G

dynamin 2

decreases expression

Norepinephrine results in decreased expression of DNM2 mRNA

NCBI chr 8:19,978,313...20,060,162
Ensembl chr 8:19,978,400...20,060,157

G

dopamine receptor D1

multiple interactions

Norepinephrine inhibits the reaction [Rotenone results in decreased expression of DRD1 mRNA]; Norepinephrine inhibits the reaction [Rotenone results in decreased expression of DRD1 protein]

NCBI chr17:10,540,440...10,544,971
Ensembl chr17:10,540,558...10,545,002

G

dopamine receptor D2

multiple interactions

[Norepinephrine binds to and results in increased activity of DRD2 protein alternative form] which results in decreased transport of Calcium; Sulpiride inhibits the reaction [[Norepinephrine binds to and results in increased activity of DRD2 protein alternative form] which results in decreased transport of Calcium]
Norepinephrine inhibits the reaction [Rotenone results in increased expression of DRD2 mRNA]; Norepinephrine inhibits the reaction [Rotenone results in increased expression of DRD2 protein]

PMID:8032591 PMID:20887679

NCBI chr 8:49,708,927...49,772,876
Ensembl chr 8:49,708,927...49,772,875

G

endothelin 1

multiple interactions
increases expression
increases activity
decreases secretion
increases secretion

1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione inhibits the reaction [EDN1 protein results in increased secretion of Norepinephrine]; [EDN1 protein binds to and results in increased activity of EDNRB protein] which results in decreased secretion of Norepinephrine; BQ 610 inhibits the reaction [EDN1 protein results in increased secretion of Norepinephrine]; BQ 788 inhibits the reaction [EDN1 protein results in decreased secretion of Norepinephrine]; BQ 788 inhibits the reaction [EDN1 protein results in increased secretion of Norepinephrine]; KT 5823 inhibits the reaction [EDN1 protein results in decreased secretion of Norepinephrine]; Metoprolol inhibits the reaction [Norepinephrine results in increased expression of EDN1 mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [EDN1 protein results in increased secretion of Norepinephrine]; Picrotoxin inhibits the reaction [EDN1 protein results in decreased secretion of Norepinephrine]
Norepinephrine results in increased activity of EDN1 promoter

PMID:11435416 PMID:12184995 PMID:14759557 PMID:16023617

NCBI chr17:22,454,924...22,460,812
Ensembl chr17:22,454,420...22,460,885

G

endothelin 3

multiple interactions
decreases secretion
increases secretion

1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione inhibits the reaction [EDN3 protein results in increased secretion of Norepinephrine]; 2-aminoethoxydiphenyl borate inhibits the reaction [EDN3 protein results in increased secretion of Norepinephrine]; [EDN3 protein binds to and results in increased activity of EDNRB protein] which results in decreased secretion of Norepinephrine; bisindolylmaleimide I inhibits the reaction [EDN3 protein results in increased secretion of Norepinephrine]; BQ 788 inhibits the reaction [EDN3 protein results in decreased secretion of Norepinephrine]; KT 5823 inhibits the reaction [EDN3 protein results in decreased secretion of Norepinephrine]; Picrotoxin inhibits the reaction [EDN3 protein results in decreased secretion of Norepinephrine]

PMID:12184995 PMID:14759557 PMID:16023617

NCBI chr 3:163,562,307...163,586,636
Ensembl chr 3:163,562,520...163,585,093

G

endothelin receptor type A

multiple interactions

[cyclo(Trp-Asp-Pro-Val-Leu) binds to and results in decreased activity of EDNRA protein] which results in decreased susceptibility to Norepinephrine

NCBI chr19:30,233,540...30,303,727
Ensembl chr19:30,233,571...30,297,049

G

endothelin receptor type B

multiple interactions

[EDN1 protein binds to and results in increased activity of EDNRB protein] which results in decreased secretion of Norepinephrine; [EDN3 protein binds to and results in increased activity of EDNRB protein] which results in decreased secretion of Norepinephrine

NCBI chr15:80,640,839...80,672,115
Ensembl chr15:80,643,043...80,672,115

G

EF-hand domain family, member D2

increases secretion

EFHD2 gene mutant form results in increased secretion of Norepinephrine

NCBI chr 5:154,160,945...154,176,980
Ensembl chr 5:154,160,946...154,176,980

G

epidermal growth factor

multiple interactions

[AVP protein co-treated with Norepinephrine] inhibits the reaction [Triiodothyronine inhibits the reaction [EGF protein results in decreased expression of UCP1 mRNA]]; [EGF protein co-treated with AVP protein co-treated with Norepinephrine co-treated with Triiodothyronine] results in decreased expression of UCP1 mRNA; [EGF protein co-treated with Norepinephrine] results in increased expression of MYC mRNA

PMID:11742803 PMID:12632255

NCBI chr 2:218,219,408...218,302,359
Ensembl chr 2:218,219,415...218,302,064

G

epidermal growth factor receptor

multiple interactions

EGFR protein inhibits the reaction [Norepinephrine results in increased phosphorylation of SHC1 protein alternative form]

NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382

G

early growth response 1

increases expression

Norepinephrine results in increased expression of EGR1

NCBI chr18:26,462,967...26,466,766
Ensembl chr18:26,462,981...26,466,766

G

ETS transcription factor ELK1

multiple interactions

[Norepinephrine co-treated with Propranolol] results in increased phosphorylation of ELK1 protein; Mn(III) 5,10,15,20-tetrakis(N-methylpyridinium-2-yl)porphyrin inhibits the reaction [[Norepinephrine co-treated with Propranolol] results in increased phosphorylation of ELK1 protein]

NCBI chr X:1,138,826...1,155,713
Ensembl chr X:1,139,756...1,155,713

G

ELOVL fatty acid elongase 3

multiple interactions
increases expression

[Dexamethasone co-treated with Norepinephrine] results in increased expression of ELOVL3 mRNA; Dactinomycin inhibits the reaction [Norepinephrine results in increased expression of ELOVL3 mRNA]; Norepinephrine results in increased expression of and results in decreased degradation of ELOVL3 mRNA; rosiglitazone promotes the reaction [[Dexamethasone co-treated with Norepinephrine] results in increased expression of ELOVL3 mRNA]

NCBI chr 1:244,997,287...245,001,115
Ensembl chr 1:244,997,287...245,001,115

G

erythropoietin

decreases response to substance

EPO protein results in decreased susceptibility to Norepinephrine

NCBI chr12:19,204,258...19,207,948
Ensembl chr12:19,204,508...19,207,946

G

coagulation factor III, tissue factor

multiple interactions
increases expression

Acetylcysteine inhibits the reaction [Norepinephrine results in increased expression of F3 mRNA]; Ascorbic Acid inhibits the reaction [Norepinephrine results in increased expression of F3 mRNA]; Norepinephrine promotes the reaction [REL protein binds to F3 promoter]; Norepinephrine promotes the reaction [RELA protein binds to F3 promoter]; prolinedithiocarbamate inhibits the reaction [Norepinephrine results in increased expression of F3 mRNA]; REL mutant form inhibits the reaction [Norepinephrine results in increased expression of F3 mRNA]; RELA mutant form inhibits the reaction [Norepinephrine results in increased expression of F3 mRNA]; Vitamin E inhibits the reaction [Norepinephrine results in increased expression of F3 mRNA]

NCBI chr 2:209,827,061...209,838,666
Ensembl chr 2:209,826,959...209,838,668

G

fibroblast growth factor 1

multiple interactions

[AVP protein co-treated with Norepinephrine] inhibits the reaction [Triiodothyronine promotes the reaction [FGF1 protein results in increased expression of UCP1 mRNA]]; [FGF1 protein co-treated with AVP protein co-treated with Norepinephrine co-treated with Triiodothyronine] results in decreased expression of UCP1 mRNA; KT 5720 inhibits the reaction [Norepinephrine inhibits the reaction [Carbachol results in increased expression of FGF1 protein]]; Norepinephrine inhibits the reaction [Carbachol results in increased expression of FGF1 protein]

PMID:11742803 PMID:15264218

NCBI chr18:30,686,555...30,772,667
Ensembl chr18:30,686,581...30,772,357

G

fibroblast growth factor 2

multiple interactions

[AVP protein co-treated with Norepinephrine] inhibits the reaction [Triiodothyronine promotes the reaction [FGF2 protein results in increased expression of UCP1 mRNA]]

NCBI chr 2:120,236,328...120,290,673
Ensembl chr 2:120,236,328...120,291,221

G

FGR proto-oncogene, Src family tyrosine kinase

increases expression

Norepinephrine results in increased expression of FGR mRNA

NCBI chr 5:145,189,814...145,219,571
Ensembl chr 5:145,189,841...145,217,326

G

fibronectin 1

multiple interactions

[Norepinephrine co-treated with Prazosin] results in decreased expression of FN1 protein; [Norepinephrine co-treated with Propranolol] results in increased expression of FN1 protein

NCBI chr 9:73,196,044...73,264,695
Ensembl chr 9:73,196,044...73,264,678

G

fibronectin type III domain containing 5

decreases abundance

FNDC5 protein results in decreased abundance of Norepinephrine

NCBI chr 5:141,481,593...141,491,257
Ensembl chr 5:141,481,590...141,490,731

G

Fos proto-oncogene, AP-1 transcription factor subunit

increases expression
multiple interactions

Norepinephrine results in increased expression of FOS mRNA
Norepinephrine results in increased expression of FOS; Norepinephrine results in increased expression of FOS mRNA
1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione inhibits the reaction [Norepinephrine results in increased expression of FOS mRNA]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Norepinephrine results in increased expression of FOS mRNA]; bisindolylmaleimide inhibits the reaction [Norepinephrine results in increased expression of FOS mRNA]; Prazosin inhibits the reaction [Norepinephrine results in increased expression of FOS mRNA]; Tetradecanoylphorbol Acetate promotes the reaction [Norepinephrine results in increased expression of FOS mRNA]

PMID:7605896 PMID:7905536 PMID:12729908 PMID:19225867

NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036

G

FosB proto-oncogene, AP-1 transcription factor subunit

increases expression

Norepinephrine results in increased expression of FOSB

NCBI chr 1:78,954,312...78,961,492
Ensembl chr 1:78,954,115...78,961,465

G

forkhead box O3

multiple interactions
increases phosphorylation

2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Norepinephrine results in increased phosphorylation of FOXO3 protein]; SHC1 protein affects the reaction [Norepinephrine results in increased phosphorylation of FOXO3 protein]

NCBI chr20:45,669,708...45,764,606
Ensembl chr20:45,672,995...45,764,561

G

glucose-6-phosphate dehydrogenase

increases activity
multiple interactions
increases expression

Norepinephrine results in increased activity of G6PD mRNA; Norepinephrine results in increased activity of G6PD protein
Metoprolol inhibits the reaction [Norepinephrine results in increased activity of G6PD protein]; Prazosin inhibits the reaction [Norepinephrine results in increased activity of G6PD protein]
Norepinephrine results in increased expression of G6PD mRNA

PMID:1378361 PMID:7605896

NCBI chr X:152,201,081...152,220,863
Ensembl chr X:152,201,098...152,220,801

G

GA binding protein transcription factor subunit alpha

multiple interactions

[Progesterone co-treated with Norepinephrine] results in increased expression of GABPA mRNA

NCBI chr11:23,888,586...23,917,612
Ensembl chr11:23,888,815...23,917,605

G

gap junction protein, alpha 1

increases expression

Norepinephrine results in increased expression of GJA1 mRNA

NCBI chr20:35,756,007...35,768,481
Ensembl chr20:35,755,991...35,768,582

G

glycerol kinase

increases activity
increases expression

Norepinephrine results in increased activity of GK protein
Norepinephrine results in increased expression of GK mRNA

NCBI chr X:50,162,089...50,238,707
Ensembl chr X:50,163,123...50,238,631

G

GNAS complex locus

multiple interactions

Norepinephrine promotes the reaction [ADRB1 protein results in increased activity of GNAS protein]

NCBI chr 3:163,071,003...163,136,350
Ensembl chr 3:163,071,417...163,127,262
Ensembl chr 3:163,071,417...163,127,262

G

glypican 3

increases expression

Norepinephrine results in increased expression of GPC3 mRNA

NCBI chr X:131,868,986...132,236,824
Ensembl chr X:131,868,990...132,236,798

G

hemoglobin subunit beta

increases expression

Norepinephrine results in increased expression of HBB mRNA

NCBI chr 1:158,250,421...158,251,832
Ensembl chr 1:158,120,200...158,252,012

G

histidine decarboxylase

affects abundance

HDC protein affects the abundance of Norepinephrine

NCBI chr 3:113,847,256...113,865,334
Ensembl chr 3:113,847,260...113,865,341

G

heme oxygenase 1

multiple interactions
increases expression

Propranolol inhibits the reaction [Norepinephrine results in increased expression of HMOX1 mRNA]; quercetin 3-O-glucuronide inhibits the reaction [Norepinephrine results in increased expression of HMOX1 mRNA]

NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079

G

heat shock protein family A (Hsp70) member 5

increases expression

Norepinephrine results in increased expression of HSPA5 mRNA; Norepinephrine results in increased expression of HSPA5 protein

NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891

G

5-hydroxytryptamine receptor 2B

multiple interactions
increases expression

N-(1-methyl-5-indolyl)-N'-(3-methyl-5-isothiazolyl)urea inhibits the reaction [Norepinephrine results in increased expression of HTR2B protein]

NCBI chr 9:86,735,793...86,756,638
Ensembl chr 9:86,742,102...86,755,108

G

intercellular adhesion molecule 1

multiple interactions
increases expression

4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [Norepinephrine promotes the reaction [RELA protein binds to ICAM1 promoter]]; Acetylcysteine inhibits the reaction [Norepinephrine results in increased expression of ICAM1 mRNA]; Ascorbic Acid inhibits the reaction [Norepinephrine results in increased expression of ICAM1 mRNA]; bisindolylmaleimide I inhibits the reaction [Norepinephrine promotes the reaction [NFKB1 protein binds to ICAM1 promoter]]; bisindolylmaleimide I inhibits the reaction [Norepinephrine promotes the reaction [REL protein binds to ICAM1 promoter]]; NFKB1 mutant form inhibits the reaction [Norepinephrine results in increased expression of ICAM1 mRNA]; Norepinephrine promotes the reaction [NFKB1 protein binds to ICAM1 promoter]; Norepinephrine promotes the reaction [REL protein binds to ICAM1 promoter]; Norepinephrine promotes the reaction [RELA protein binds to ICAM1 promoter]; prolinedithiocarbamate inhibits the reaction [Norepinephrine results in increased expression of ICAM1 mRNA]; REL mutant form inhibits the reaction [Norepinephrine results in increased expression of ICAM1 mRNA]; RELA mutant form inhibits the reaction [Norepinephrine results in increased expression of ICAM1 mRNA]; Vitamin E inhibits the reaction [Norepinephrine results in increased expression of ICAM1 mRNA]; wortmannin inhibits the reaction [Norepinephrine promotes the reaction [REL protein binds to ICAM1 promoter]]

NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438

G

insulin-like growth factor 1

multiple interactions
decreases response to substance

Prazosin inhibits the reaction [IGF1 protein results in decreased susceptibility to Norepinephrine]

NCBI chr 7:22,282,895...22,361,972
Ensembl chr 7:22,282,930...22,359,296

G

interleukin 1 beta

affects secretion
increases expression
multiple interactions

Norepinephrine affects the secretion of IL1B protein
Norepinephrine results in increased expression of IL1B mRNA
carvedilol inhibits the reaction [Norepinephrine results in increased expression of IL1B mRNA]; Norepinephrine promotes the reaction [IL1B protein results in increased expression of IL6 protein]

PMID:8392517 PMID:10722803 PMID:16386803

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 6

multiple interactions
increases expression
increases activity
decreases secretion

Norepinephrine results in increased expression of and results in increased secretion of IL6 protein; sulforaphane inhibits the reaction [Norepinephrine results in increased expression of and results in increased secretion of IL6 protein]
Norepinephrine results in increased expression of IL6 mRNA; Norepinephrine results in increased expression of IL6 protein
Norepinephrine results in increased activity of IL6 protein
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Norepinephrine results in increased expression of IL6 mRNA]; Carvedilol inhibits the reaction [Norepinephrine results in increased expression of IL6 mRNA]; ICI 118551 inhibits the reaction [Norepinephrine results in increased expression of IL6 mRNA]; Metoprolol inhibits the reaction [Norepinephrine results in increased expression of IL6 mRNA]; Norepinephrine promotes the reaction [IL1B protein results in increased expression of IL6 protein]; Norepinephrine promotes the reaction [TNF protein results in increased expression of IL6 protein]; Propranolol inhibits the reaction [Norepinephrine results in increased expression of IL6 mRNA]
Norepinephrine results in decreased secretion of IL6 protein
ANXA1 affects the reaction [Norepinephrine results in decreased secretion of IL6 protein]

PMID:8392517 PMID:10722803 PMID:11406463 PMID:12619890 PMID:14577597 More...

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

insulin 1

multiple interactions

INS1 protein inhibits the reaction [[Theophylline co-treated with Norepinephrine] results in increased abundance of Cyclic AMP]

NCBI chr 1:251,244,973...251,245,540
Ensembl chr 1:251,244,973...251,245,536

G

Jun proto-oncogene, AP-1 transcription factor subunit

multiple interactions
increases phosphorylation
increases expression

1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione inhibits the reaction [Norepinephrine results in increased expression of JUN mRNA]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Norepinephrine results in increased expression of JUN mRNA]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Norepinephrine results in increased phosphorylation of JUN protein]; bisindolylmaleimide inhibits the reaction [Norepinephrine results in increased expression of JUN mRNA]; bisindolylmaleimide inhibits the reaction [Norepinephrine results in increased phosphorylation of JUN protein]; Prazosin inhibits the reaction [Norepinephrine results in increased expression of JUN mRNA]; pyrazolanthrone inhibits the reaction [Norepinephrine results in increased phosphorylation of JUN protein]; Tetradecanoylphorbol Acetate promotes the reaction [Norepinephrine results in increased expression of JUN mRNA]
Norepinephrine results in increased expression of JUN; Norepinephrine results in increased expression of JUN mRNA

PMID:7905536 PMID:19225867

NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656

G

JunB proto-oncogene, AP-1 transcription factor subunit

increases expression

Norepinephrine results in increased expression of JUNB

NCBI chr19:23,176,265...23,178,049
Ensembl chr19:23,176,294...23,178,035

G

potassium calcium-activated channel subfamily M alpha 1

affects response to substance

KCNMA1 protein affects the susceptibility to Norepinephrine

NCBI chr15:302,480...1,007,675
Ensembl chr15:302,214...1,001,198

G

luteinizing hormone subunit beta

multiple interactions

Norepinephrine results in decreased secretion of and results in decreased expression of LHB protein; Phenoxybenzamine inhibits the reaction [Norepinephrine results in decreased secretion of and results in decreased expression of LHB protein]; Piperoxan inhibits the reaction [Norepinephrine results in decreased secretion of and results in decreased expression of LHB protein]; Prazosin inhibits the reaction [Norepinephrine results in decreased secretion of and results in decreased expression of LHB protein]

NCBI chr 1:95,898,269...95,901,973
Ensembl chr 1:95,900,984...95,901,972
Ensembl chr 1:95,900,984...95,901,972

G

lipoprotein lipase

multiple interactions
increases expression

Prazosin inhibits the reaction [Norepinephrine results in increased expression of LPL mRNA]; Propranolol inhibits the reaction [Norepinephrine results in increased expression of LPL mRNA]

NCBI chr16:20,830,055...20,853,855
Ensembl chr16:20,829,465...20,855,249

G

monoamine oxidase A

increases metabolic processing
increases abundance

MAOA protein results in increased metabolism of Norepinephrine
MAOA mutant form results in increased abundance of Norepinephrine

PMID:10647887 PMID:11834493

NCBI chr X:6,032,172...6,098,308
Ensembl chr X:6,030,795...6,099,593

G

monoamine oxidase B

increases abundance

MAOB mutant form results in increased abundance of Norepinephrine

NCBI chr X:5,907,327...6,010,996
Ensembl chr X:5,907,266...6,011,003

G

mitogen activated protein kinase 1

multiple interactions
increases phosphorylation

Norepinephrine inhibits the reaction [Estradiol results in decreased phosphorylation of MAPK1 protein]
Norepinephrine results in increased phosphorylation of MAPK1 protein
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Norepinephrine results in increased phosphorylation of MAPK1 protein]; AG 1879 inhibits the reaction [Norepinephrine results in increased phosphorylation of MAPK1 protein]
1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [[Norepinephrine co-treated with Timolol] results in increased activity of and results in increased phosphorylation of MAPK1 protein]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Norepinephrine results in increased activity of and results in increased phosphorylation of MAPK1 protein]; 4-(2-aminoethyl)benzenesulfonylfluoride inhibits the reaction [[Norepinephrine co-treated with Propranolol] results in increased phosphorylation of MAPK1 protein]; 4-amino-5-(4-methylphenyl)-7-(tert-butyl)pyrazolo(3,4-d)pyrimidine inhibits the reaction [[Norepinephrine co-treated with Timolol] results in increased activity of and results in increased phosphorylation of MAPK1 protein]; [Norepinephrine co-treated with Propranolol] results in increased phosphorylation of MAPK1 protein; [Norepinephrine co-treated with Timolol] results in increased activity of and results in increased phosphorylation of MAPK1 protein; AG 1879 inhibits the reaction [[Norepinephrine co-treated with Timolol] results in increased phosphorylation of MAPK1 protein]; Cadmium Chloride inhibits the reaction [[Norepinephrine co-treated with Propranolol] results in increased phosphorylation of MAPK1 protein]; cadmium sulfate inhibits the reaction [[Norepinephrine co-treated with Propranolol] results in increased phosphorylation of MAPK1 protein]; Carvedilol inhibits the reaction [Norepinephrine results in increased phosphorylation of MAPK1 protein]; diphenyleneiodonium inhibits the reaction [[Norepinephrine co-treated with Propranolol] results in increased phosphorylation of MAPK1 protein]; Egtazic Acid inhibits the reaction [[Norepinephrine co-treated with Timolol] results in increased activity of and results in increased phosphorylation of MAPK1 protein]; Gadolinium inhibits the reaction [[Norepinephrine co-treated with Timolol] results in increased activity of MAPK1 protein]; Mn(III) 5,10,15,20-tetrakis(N-methylpyridinium-2-yl)porphyrin inhibits the reaction [[Norepinephrine co-treated with Propranolol] results in increased phosphorylation of MAPK1 protein]; N,N'-bis(salicylideneamino)ethane-manganese(II) inhibits the reaction [[Norepinephrine co-treated with Propranolol] results in increased phosphorylation of MAPK1 protein]; N-(8-aminooctyl)-5-iodonaphthalene-1-sulfonamide inhibits the reaction [[Norepinephrine co-treated with Timolol] results in increased activity of and results in increased phosphorylation of MAPK1 protein]; Norepinephrine results in increased activity of and results in increased phosphorylation of MAPK1 protein; oxophenylarsine inhibits the reaction [[Norepinephrine co-treated with Propranolol] results in increased phosphorylation of MAPK1 protein]; Prazosin affects the reaction [Norepinephrine results in increased activity of and results in increased phosphorylation of MAPK1 protein]; Prazosin inhibits the reaction [[Norepinephrine co-treated with Propranolol] results in increased phosphorylation of MAPK1 protein]; Trifluoperazine inhibits the reaction [[Norepinephrine co-treated with Timolol] results in increased activity of MAPK1 protein]; W 7 inhibits the reaction [[Norepinephrine co-treated with Timolol] results in increased activity of and results in increased phosphorylation of MAPK1 protein]

PMID:10788502 PMID:11054474 PMID:11880281 PMID:11914123 PMID:15292328 More...

NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616

G

mitogen activated protein kinase 10

multiple interactions

MAPK10 protein affects the reaction [MAPK9 protein affects the susceptibility to Norepinephrine]

NCBI chr14:6,497,662...6,790,109
Ensembl chr14:6,497,707...6,786,201

G

mitogen activated protein kinase 3

multiple interactions
increases phosphorylation

Norepinephrine inhibits the reaction [Estradiol results in decreased phosphorylation of MAPK3 protein]
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Norepinephrine results in increased phosphorylation of MAPK3 protein]
1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [[Norepinephrine co-treated with Timolol] results in increased activity of and results in increased phosphorylation of MAPK3 protein]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Norepinephrine results in increased activity of and results in increased phosphorylation of MAPK3 protein]; 4-(2-aminoethyl)benzenesulfonylfluoride inhibits the reaction [[Norepinephrine co-treated with Propranolol] results in increased phosphorylation of MAPK3 protein]; 4-amino-5-(4-methylphenyl)-7-(tert-butyl)pyrazolo(3,4-d)pyrimidine inhibits the reaction [[Norepinephrine co-treated with Timolol] results in increased activity of and results in increased phosphorylation of MAPK3 protein]; [Norepinephrine co-treated with Propranolol] results in increased phosphorylation of MAPK3 protein; [Norepinephrine co-treated with Timolol] results in increased activity of and results in increased phosphorylation of MAPK3 protein; AG 1879 inhibits the reaction [[Norepinephrine co-treated with Timolol] results in increased phosphorylation of MAPK3 protein]; Cadmium Chloride inhibits the reaction [[Norepinephrine co-treated with Propranolol] results in increased phosphorylation of MAPK3 protein]; cadmium sulfate inhibits the reaction [[Norepinephrine co-treated with Propranolol] results in increased phosphorylation of MAPK3 protein]; Carvedilol inhibits the reaction [Norepinephrine results in increased phosphorylation of MAPK3 protein]; diphenyleneiodonium inhibits the reaction [[Norepinephrine co-treated with Propranolol] results in increased phosphorylation of MAPK3 protein]; Egtazic Acid inhibits the reaction [[Norepinephrine co-treated with Timolol] results in increased activity of and results in increased phosphorylation of MAPK3 protein]; Gadolinium inhibits the reaction [[Norepinephrine co-treated with Timolol] results in increased activity of MAPK3 protein]; Mn(III) 5,10,15,20-tetrakis(N-methylpyridinium-2-yl)porphyrin inhibits the reaction [[Norepinephrine co-treated with Propranolol] results in increased phosphorylation of MAPK3 protein]; N,N'-bis(salicylideneamino)ethane-manganese(II) inhibits the reaction [[Norepinephrine co-treated with Propranolol] results in increased phosphorylation of MAPK3 protein]; N-(8-aminooctyl)-5-iodonaphthalene-1-sulfonamide inhibits the reaction [[Norepinephrine co-treated with Timolol] results in increased activity of and results in increased phosphorylation of MAPK3 protein]; Norepinephrine results in increased activity of and results in increased phosphorylation of MAPK3 protein; oxophenylarsine inhibits the reaction [[Norepinephrine co-treated with Propranolol] results in increased phosphorylation of MAPK3 protein]; Prazosin inhibits the reaction [[Norepinephrine co-treated with Propranolol] results in increased phosphorylation of MAPK3 protein]; Trifluoperazine inhibits the reaction [[Norepinephrine co-treated with Timolol] results in increased activity of MAPK3 protein]; W 7 inhibits the reaction [[Norepinephrine co-treated with Timolol] results in increased activity of and results in increased phosphorylation of MAPK3 protein]

PMID:10788502 PMID:11054474 PMID:11880281 PMID:11914123 PMID:15292328 More...

NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863

G

mitogen-activated protein kinase 8

multiple interactions
increases phosphorylation

Acetylcysteine inhibits the reaction [Norepinephrine results in increased phosphorylation of MAPK8 protein]

NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981

G

mitogen-activated protein kinase 9

multiple interactions
affects response to substance

MAPK10 protein affects the reaction [MAPK9 protein affects the susceptibility to Norepinephrine]

NCBI chr10:34,169,661...34,211,138
Ensembl chr10:34,169,675...34,210,178

G

matrix metallopeptidase 2

multiple interactions
increases expression
increases activity

Cromolyn Sodium inhibits the reaction [Norepinephrine results in increased expression of MMP2 mRNA]; Metoprolol inhibits the reaction [Norepinephrine results in increased expression of MMP2 mRNA]; Norepinephrine results in increased activity of and results in increased expression of MMP2 protein; Prazosin inhibits the reaction [Norepinephrine results in increased expression of MMP2 mRNA]; trans-sodium crocetinate inhibits the reaction [Norepinephrine results in increased activity of MMP2 protein]; trans-sodium crocetinate inhibits the reaction [Norepinephrine results in increased expression of MMP2 mRNA]
Propranolol inhibits the reaction [Norepinephrine results in increased expression of MMP2 mRNA]; quercetin 3-O-glucuronide inhibits the reaction [Norepinephrine results in increased expression of MMP2 mRNA]; SB 203580 inhibits the reaction [Norepinephrine results in increased expression of MMP2 mRNA]

PMID:14577597 PMID:15326086 PMID:16864425 PMID:24929186

NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870

G

matrix metallopeptidase 9

multiple interactions
increases expression
increases activity

trans-sodium crocetinate inhibits the reaction [Norepinephrine results in increased expression of MMP9 mRNA]
Norepinephrine results in increased activity of MMP9 protein
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Norepinephrine results in increased expression of MMP9 mRNA]; Propranolol inhibits the reaction [Norepinephrine results in increased activity of MMP9 protein]; Propranolol inhibits the reaction [Norepinephrine results in increased expression of MMP9 mRNA]; quercetin 3-O-glucuronide inhibits the reaction [Norepinephrine results in increased activity of MMP9 protein]; quercetin 3-O-glucuronide inhibits the reaction [Norepinephrine results in increased expression of MMP9 mRNA]; SR 11302 inhibits the reaction [Norepinephrine results in increased expression of MMP9 mRNA]; tanshinone inhibits the reaction [Norepinephrine results in increased expression of MMP9 mRNA]

PMID:16864425 PMID:24929186

NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120

G

metallothionein 3

increases expression

Norepinephrine results in increased expression of MT3 mRNA

NCBI chr19:10,848,754...10,850,158
Ensembl chr19:10,848,755...10,850,158

G

MYC proto-oncogene, bHLH transcription factor

multiple interactions
increases expression

[EGF protein co-treated with Norepinephrine] results in increased expression of MYC mRNA
Norepinephrine results in increased expression of MYC

PMID:7605896 PMID:12632255

NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630

G

myosin heavy chain 11

increases expression

Norepinephrine results in increased expression of MYH11 mRNA

NCBI chr10:743,364...838,459
Ensembl chr10:743,685...838,459

G

myosin heavy chain 6

decreases expression

Norepinephrine results in decreased expression of MYH6 mRNA

NCBI chr15:28,418,120...28,442,316
Ensembl chr15:28,417,616...28,441,720

G

myosin heavy chain 7

multiple interactions
affects expression
increases expression

Propranolol promotes the reaction [Norepinephrine results in increased expression of MYH7 mRNA]
Norepinephrine affects the expression of MYH7 mRNA

PMID:17592507 PMID:25437044

NCBI chr15:28,446,550...28,469,888
Ensembl chr15:28,446,550...28,468,217

G

myosin, light chain 1

multiple interactions
increases phosphorylation

PRKD1 protein affects the reaction [Norepinephrine results in increased phosphorylation of MYL1 protein]
chelerythrine inhibits the reaction [Norepinephrine results in increased phosphorylation of MYL1 protein]; CRT 0066101 inhibits the reaction [Norepinephrine results in increased phosphorylation of MYL1 protein]; fasudil inhibits the reaction [Norepinephrine results in increased phosphorylation of MYL1 protein]

NCBI chr 9:68,437,514...68,458,256
Ensembl chr 9:68,437,517...68,458,261

G

myosin light chain 3

decreases expression

Norepinephrine results in decreased expression of MYL3 mRNA

NCBI chr 8:110,738,669...110,744,814
Ensembl chr 8:110,738,661...110,744,816

G

N-acetylated alpha-linked acidic dipeptidase 2

decreases expression

Norepinephrine results in decreased expression of NAALAD2 mRNA

NCBI chr 8:15,406,119...15,479,714
Ensembl chr 8:15,407,043...15,479,714

G

NFE2 like bZIP transcription factor 2

increases expression

Norepinephrine results in increased expression of NFE2L2 mRNA

NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737

G

nuclear factor, interleukin 3 regulated

increases expression

Norepinephrine results in increased expression of NFIL3 mRNA

NCBI chr17:12,280,499...12,295,728
Ensembl chr17:12,280,484...12,295,858

G

nuclear factor kappa B subunit 1

multiple interactions
affects localization

Acetylcysteine inhibits the reaction [Norepinephrine affects the localization of NFKB1 protein]; Ascorbic Acid inhibits the reaction [Norepinephrine affects the localization of NFKB1 protein]; bisindolylmaleimide I inhibits the reaction [Norepinephrine affects the localization of NFKB1 protein]; bisindolylmaleimide I inhibits the reaction [Norepinephrine promotes the reaction [NFKB1 protein binds to ICAM1 promoter]]; NFKB1 mutant form inhibits the reaction [Norepinephrine results in increased expression of ICAM1 mRNA]; NFKB1 mutant form inhibits the reaction [Norepinephrine results in increased expression of SOD2 mRNA]; Norepinephrine affects the localization of [NFKB1 protein binds to RELA protein]; Norepinephrine promotes the reaction [[NFKB1 protein binds to RELA protein] which binds to SOD2 promoter]; Norepinephrine promotes the reaction [NFKB1 protein binds to ICAM1 promoter]; Norepinephrine results in increased activity of [NFKB1 protein binds to RELA protein]; prolinedithiocarbamate inhibits the reaction [Norepinephrine affects the localization of NFKB1 protein]; Vitamin E inhibits the reaction [Norepinephrine affects the localization of NFKB1 protein]

PMID:16782692 PMID:23114885

NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404

G

nerve growth factor

decreases expression

Norepinephrine results in decreased expression of NGF mRNA; Norepinephrine results in decreased expression of NGF protein

NCBI chr 2:189,901,058...189,954,452
Ensembl chr 2:189,901,058...189,954,452

G

nitric oxide synthase 2

multiple interactions
affects response to substance

[GW 274150 results in decreased activity of NOS2 protein] which results in increased susceptibility to Norepinephrine; Atenolol inhibits the reaction [Norepinephrine inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased abundance of Nitrites]]; Atenolol inhibits the reaction [Norepinephrine inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]]; Norepinephrine inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased abundance of Nitrites]; Norepinephrine inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]; Prazosin inhibits the reaction [Norepinephrine inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased abundance of Nitrites]]; Prazosin inhibits the reaction [Norepinephrine inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]]
NOS2 protein affects the susceptibility to Norepinephrine

PMID:16424707 PMID:19439816

NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210

G

natriuretic peptide A

increases expression
multiple interactions

Norepinephrine results in increased expression of NPPA mRNA
1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione inhibits the reaction [Norepinephrine results in increased expression of NPPA mRNA]; Carvedilol inhibits the reaction [Norepinephrine results in increased expression of NPPA mRNA]; Prazosin inhibits the reaction [Norepinephrine results in increased expression of NPPA mRNA]; Propranolol promotes the reaction [Norepinephrine results in increased expression of NPPA mRNA]

PMID:9788975 PMID:10722803 PMID:14577597 PMID:14618266 PMID:15240149 More...

NCBI chr 5:158,429,042...158,430,351
Ensembl chr 5:158,429,042...158,430,351

G

natriuretic peptide B

affects abundance
decreases abundance

NPPB affects the abundance of Norepinephrine
NPPB protein results in decreased abundance of Norepinephrine

PMID:16333235 PMID:20339970

NCBI chr 5:158,416,813...158,418,175
Ensembl chr 5:158,416,866...158,418,168

G

neuropeptide Y

affects response to substance

NPY protein affects the susceptibility to Norepinephrine

NCBI chr 4:78,881,294...78,888,495
Ensembl chr 4:78,881,264...78,888,495

G

nuclear respiratory factor 1

multiple interactions

[Estradiol co-treated with Norepinephrine] results in decreased expression of NRF1 mRNA

NCBI chr 4:58,664,932...58,772,328
Ensembl chr 4:58,664,957...58,825,328

G

neurotrophin 3

increases expression

Norepinephrine results in increased expression of NTF3 mRNA; Norepinephrine results in increased expression of NTF3 protein

NCBI chr 4:158,914,984...158,984,453
Ensembl chr 4:158,914,957...158,984,596

G

ornithine decarboxylase 1

decreases activity

Norepinephrine results in decreased activity of ODC1 protein

NCBI chr 6:40,329,831...40,336,444
Ensembl chr 6:40,329,964...40,336,440

G

opioid receptor, delta 1

multiple interactions

[dextrallorphan binds to OPRD1 protein] which results in decreased uptake of Norepinephrine; [Dextromethorphan binds to OPRD1 protein] which results in decreased uptake of Norepinephrine; [Dextropropoxyphene binds to OPRD1 protein] which results in decreased uptake of Norepinephrine; [Dextrorphan binds to OPRD1 protein] which results in decreased uptake of Norepinephrine; [Levallorphan binds to OPRD1 protein] which results in decreased uptake of Norepinephrine; [Levorphanol binds to OPRD1 protein] which results in decreased uptake of Norepinephrine; [Methadone binds to OPRD1 protein] which results in decreased uptake of Norepinephrine; [Methadyl Acetate binds to OPRD1 protein] which results in decreased uptake of Norepinephrine; [Tramadol binds to OPRD1 protein] which results in decreased uptake of Norepinephrine

NCBI chr 5:144,306,188...144,340,960
Ensembl chr 5:144,306,188...144,340,960

G

opioid receptor, kappa 1

multiple interactions

[dextrallorphan binds to OPRK1 protein] which results in decreased uptake of Norepinephrine; [Dextromethorphan binds to OPRK1 protein] which results in decreased uptake of Norepinephrine; [Dextropropoxyphene binds to OPRK1 protein] which results in decreased uptake of Norepinephrine; [Dextrorphan binds to OPRK1 protein] which results in decreased uptake of Norepinephrine; [Levallorphan binds to OPRK1 protein] which results in decreased uptake of Norepinephrine; [Levorphanol binds to OPRK1 protein] which results in decreased uptake of Norepinephrine; [Methadone binds to OPRK1 protein] which results in decreased uptake of Norepinephrine; [Methadyl Acetate binds to OPRK1 protein] which results in decreased uptake of Norepinephrine; [Tramadol binds to OPRK1 protein] which results in decreased uptake of Norepinephrine

NCBI chr 5:13,860,016...13,877,823
Ensembl chr 5:13,860,021...13,877,823

G

opioid receptor, mu 1

multiple interactions

[dextrallorphan binds to OPRM1 protein] which results in decreased uptake of Norepinephrine; [Dextromethorphan binds to OPRM1 protein] which results in decreased uptake of Norepinephrine; [Dextropropoxyphene binds to OPRM1 protein] which results in decreased uptake of Norepinephrine; [Dextrorphan binds to OPRM1 protein] which results in decreased uptake of Norepinephrine; [Levallorphan binds to OPRM1 protein] which results in decreased uptake of Norepinephrine; [Levorphanol binds to OPRM1 protein] which results in decreased uptake of Norepinephrine; [Methadone binds to OPRM1 protein] which results in decreased uptake of Norepinephrine; [Methadyl Acetate binds to OPRM1 protein] which results in decreased uptake of Norepinephrine; [Tramadol binds to OPRM1 protein] which results in decreased uptake of Norepinephrine

NCBI chr 1:43,160,057...43,413,409
Ensembl chr 1:43,160,057...43,413,409

G

p21 (RAC1) activated kinase 3

decreases expression

Norepinephrine results in decreased expression of PAK3 mRNA

NCBI chr X:107,116,308...107,374,342
Ensembl chr X:107,260,898...107,368,314

G

peptidylglycine alpha-amidating monooxygenase

increases expression

Norepinephrine results in increased expression of PAM mRNA

NCBI chr 9:97,998,581...98,271,966
Ensembl chr 9:98,122,916...98,271,965

G

period circadian regulator 1

increases expression

Norepinephrine results in increased expression of PER1 mRNA

NCBI chr10:53,800,126...53,814,963
Ensembl chr10:53,805,535...53,814,431

G

period circadian regulator 2

increases expression

Norepinephrine results in increased expression of PER2 mRNA

NCBI chr 9:92,007,289...92,049,551
Ensembl chr 9:92,007,296...92,049,459

G

peroxisomal biogenesis factor 2

increases expression

Norepinephrine results in increased expression of PEX2 mRNA

NCBI chr 2:96,050,380...96,072,928
Ensembl chr 2:96,045,958...96,073,404

G

phosphogluconate dehydrogenase

multiple interactions
increases activity

carvedilol inhibits the reaction [Norepinephrine results in increased activity of PGD mRNA]; carvedilol inhibits the reaction [Norepinephrine results in increased activity of PGD protein]

NCBI chr 5:159,582,746...159,598,945
Ensembl chr 5:159,561,271...159,742,778

G

phosphatidylinositol 3-kinase, catalytic subunit type 3

increases expression

Norepinephrine results in increased expression of PIK3C3 mRNA

NCBI chr18:21,845,282...21,934,387
Ensembl chr18:21,845,295...21,929,048

G

phospholipase C beta 1

increases activity
multiple interactions
increases expression

Norepinephrine results in increased activity of PLCB1 protein
1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione inhibits the reaction [Norepinephrine results in increased expression of PLCB1 mRNA]; 1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione inhibits the reaction [Norepinephrine results in increased expression of PLCB1 protein]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Norepinephrine results in increased expression of PLCB1 mRNA]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Norepinephrine results in increased expression of PLCB1 protein]; bisindolylmaleimide I inhibits the reaction [Norepinephrine results in increased expression of PLCB1 mRNA]; bisindolylmaleimide I inhibits the reaction [Norepinephrine results in increased expression of PLCB1 protein]; Norepinephrine results in increased expression of and results in increased activity of PLCB1 protein; Prazosin inhibits the reaction [Norepinephrine results in increased expression of and results in increased activity of PLCB1 protein]; Prazosin inhibits the reaction [Norepinephrine results in increased expression of PLCB1 mRNA]; Prazosin inhibits the reaction [Norepinephrine results in increased expression of PLCB1 protein]; pyrazolanthrone inhibits the reaction [Norepinephrine results in increased expression of PLCB1 mRNA]
Norepinephrine results in increased expression of PLCB1 mRNA; Norepinephrine results in increased expression of PLCB1 protein

PMID:16714034 PMID:19225867

NCBI chr 3:122,059,988...122,772,896
Ensembl chr 3:122,060,031...122,772,869

G

phospholipase C beta 3

increases activity
multiple interactions
increases expression

Norepinephrine results in increased activity of PLCB3 protein
1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione inhibits the reaction [Norepinephrine results in increased expression of PLCB3 mRNA]; 1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione inhibits the reaction [Norepinephrine results in increased expression of PLCB3 protein]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Norepinephrine results in increased expression of PLCB3 mRNA]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Norepinephrine results in increased expression of PLCB3 protein]; bisindolylmaleimide I inhibits the reaction [Norepinephrine results in increased expression of PLCB3 mRNA]; bisindolylmaleimide I inhibits the reaction [Norepinephrine results in increased expression of PLCB3 protein]; Norepinephrine results in increased expression of and results in increased activity of PLCB3 protein; Prazosin inhibits the reaction [Norepinephrine results in increased expression of and results in increased activity of PLCB3 protein]; Prazosin inhibits the reaction [Norepinephrine results in increased expression of PLCB3 mRNA]; Prazosin inhibits the reaction [Norepinephrine results in increased expression of PLCB3 protein]; pyrazolanthrone inhibits the reaction [Norepinephrine results in increased expression of PLCB3 mRNA]
Norepinephrine results in increased expression of PLCB3 mRNA; Norepinephrine results in increased expression of PLCB3 protein

PMID:16714034 PMID:19225867

NCBI chr 1:204,143,257...204,160,384
Ensembl chr 1:204,144,956...204,160,228

G

phospholipase C, delta 1

increases activity
multiple interactions
increases expression

Norepinephrine results in increased activity of PLCD1 protein
1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione inhibits the reaction [Norepinephrine results in increased expression of PLCD1 mRNA]; 1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione inhibits the reaction [Norepinephrine results in increased expression of PLCD1 protein]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Norepinephrine results in increased expression of PLCD1 mRNA]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Norepinephrine results in increased expression of PLCD1 protein]; bisindolylmaleimide I inhibits the reaction [Norepinephrine results in increased expression of PLCD1 mRNA]; bisindolylmaleimide I inhibits the reaction [Norepinephrine results in increased expression of PLCD1 protein]; Norepinephrine results in increased expression of and results in increased activity of PLCD1 protein; Prazosin inhibits the reaction [Norepinephrine results in increased expression of and results in increased activity of PLCD1 protein]; Prazosin inhibits the reaction [Norepinephrine results in increased expression of PLCD1 mRNA]; Prazosin inhibits the reaction [Norepinephrine results in increased expression of PLCD1 protein]; pyrazolanthrone inhibits the reaction [Norepinephrine results in increased expression of PLCD1 mRNA]
Norepinephrine results in increased expression of PLCD1 mRNA; Norepinephrine results in increased expression of PLCD1 protein

PMID:16714034 PMID:19225867

NCBI chr 8:118,795,196...118,818,186
Ensembl chr 8:118,795,201...118,818,186

G

phospholipase C, gamma 1

increases activity
multiple interactions
increases expression

Norepinephrine results in increased activity of PLCG1 protein
1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione inhibits the reaction [Norepinephrine results in increased expression of PLCG1 mRNA]; 1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione inhibits the reaction [Norepinephrine results in increased expression of PLCG1 protein]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Norepinephrine results in increased expression of PLCG1 mRNA]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Norepinephrine results in increased expression of PLCG1 protein]; bisindolylmaleimide I inhibits the reaction [Norepinephrine results in increased expression of PLCG1 mRNA]; bisindolylmaleimide I inhibits the reaction [Norepinephrine results in increased expression of PLCG1 protein]; Norepinephrine results in increased expression of and results in increased activity of PLCG1 protein; Prazosin inhibits the reaction [Norepinephrine results in increased expression of and results in increased activity of PLCG1 protein]; Prazosin inhibits the reaction [Norepinephrine results in increased expression of PLCG1 mRNA]; Prazosin inhibits the reaction [Norepinephrine results in increased expression of PLCG1 protein]
Norepinephrine results in increased expression of PLCG1 mRNA; Norepinephrine results in increased expression of PLCG1 protein

PMID:16714034 PMID:19225867

NCBI chr 3:149,385,587...149,416,330
Ensembl chr 3:149,385,587...149,416,330

G

peptidase, mitochondrial processing subunit beta

decreases expression

Norepinephrine results in decreased expression of PMPCB mRNA

NCBI chr 4:13,297,583...13,310,363
Ensembl chr 4:13,297,559...13,310,367

G

pancreatic lipase

increases expression

Norepinephrine results in increased expression of PNLIP mRNA

NCBI chr 1:257,774,012...257,811,656
Ensembl chr 1:257,798,581...257,811,654

G

peroxisome proliferator activated receptor alpha

increases expression

Norepinephrine results in increased expression of PPARA mRNA

NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346

G

peroxisome proliferator-activated receptor gamma

increases expression

Norepinephrine results in increased expression of PPARG mRNA

NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468

G

PPARG coactivator 1 alpha

multiple interactions
increases expression

[Propranolol co-treated with Prazosin] inhibits the reaction [Norepinephrine results in increased expression of PPARGC1A mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Norepinephrine results in increased expression of PPARGC1A mRNA]
Norepinephrine inhibits the reaction [Testosterone results in decreased expression of PPARGC1A mRNA]

PMID:16513826 PMID:16954335

NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656

G

protein phosphatase 1, regulatory subunit 12A

increases phosphorylation
multiple interactions

Norepinephrine results in increased phosphorylation of PPP1R12A protein
PRKD1 protein affects the reaction [Norepinephrine results in increased phosphorylation of PPP1R12A protein]
CRT 0066101 inhibits the reaction [Norepinephrine results in increased phosphorylation of PPP1R12A protein]; fasudil inhibits the reaction [Norepinephrine results in increased phosphorylation of PPP1R12A protein]

NCBI chr 7:43,482,808...43,593,689
Ensembl chr 7:43,482,803...43,593,425

G

protein phosphatase 1, regulatory (inhibitor) subunit 14A

increases phosphorylation
multiple interactions

Norepinephrine results in increased phosphorylation of PPP1R14A protein
chelerythrine inhibits the reaction [Norepinephrine results in increased phosphorylation of PPP1R14A protein]

NCBI chr 1:84,583,127...84,590,743
Ensembl chr 1:84,586,627...84,590,671

G

protein kinase D1

multiple interactions
increases phosphorylation

PRKD1 protein affects the reaction [Norepinephrine results in increased phosphorylation of MYL1 protein]; PRKD1 protein affects the reaction [Norepinephrine results in increased phosphorylation of PPP1R12A protein]
CRT 0066101 inhibits the reaction [Norepinephrine results in increased phosphorylation of PRKD1 protein]

NCBI chr 6:67,725,193...68,039,002
Ensembl chr 6:67,725,905...68,039,042

G

phosphatase and tensin homolog

multiple interactions

[Estradiol co-treated with Norepinephrine] results in decreased expression of PTEN mRNA; [Progesterone co-treated with Norepinephrine] results in increased expression of PTEN mRNA; Norepinephrine inhibits the reaction [Testosterone results in decreased expression of PTEN mRNA]

NCBI chr 1:230,630,443...230,697,070
Ensembl chr 1:230,630,338...230,696,838

G

prostaglandin-endoperoxide synthase 2

multiple interactions

[N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in decreased activity of PTGS2 protein] which results in decreased susceptibility to Norepinephrine

NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188

G

glycogen phosphorylase, muscle associated

affects expression

Norepinephrine affects the expression of PYGM mRNA

NCBI chr 1:203,690,550...203,705,369
Ensembl chr 1:203,690,533...203,705,368

G

REL proto-oncogene, NF-kB subunit

multiple interactions
affects localization

Acetylcysteine inhibits the reaction [Norepinephrine affects the localization of REL protein]; Ascorbic Acid inhibits the reaction [Norepinephrine affects the localization of REL protein]; bisindolylmaleimide I inhibits the reaction [Norepinephrine promotes the reaction [REL protein binds to ICAM1 promoter]]; Norepinephrine promotes the reaction [REL protein binds to F3 promoter]; Norepinephrine promotes the reaction [REL protein binds to ICAM1 promoter]; prolinedithiocarbamate inhibits the reaction [Norepinephrine affects the localization of REL protein]; REL mutant form inhibits the reaction [Norepinephrine results in increased expression of F3 mRNA]; REL mutant form inhibits the reaction [Norepinephrine results in increased expression of ICAM1 mRNA]; Vitamin E inhibits the reaction [Norepinephrine affects the localization of REL protein]; wortmannin inhibits the reaction [Norepinephrine affects the localization of REL protein]; wortmannin inhibits the reaction [Norepinephrine promotes the reaction [REL protein binds to ICAM1 promoter]]

NCBI chr14:97,690,105...97,721,194
Ensembl chr14:97,695,161...97,720,892

G

RELA proto-oncogene, NF-kB subunit

multiple interactions
affects localization

4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [Norepinephrine affects the localization of RELA protein]; 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [Norepinephrine promotes the reaction [RELA protein binds to ICAM1 promoter]]; Acetylcysteine inhibits the reaction [Norepinephrine affects the localization of RELA protein]; Ascorbic Acid inhibits the reaction [Norepinephrine affects the localization of RELA protein]; Norepinephrine affects the localization of [NFKB1 protein binds to RELA protein]; Norepinephrine promotes the reaction [[NFKB1 protein binds to RELA protein] which binds to SOD2 promoter]; Norepinephrine promotes the reaction [RELA protein binds to F3 promoter]; Norepinephrine promotes the reaction [RELA protein binds to ICAM1 promoter]; Norepinephrine results in increased activity of [NFKB1 protein binds to RELA protein]; prolinedithiocarbamate inhibits the reaction [Norepinephrine affects the localization of RELA protein]; RELA mutant form inhibits the reaction [Norepinephrine results in increased expression of F3 mRNA]; RELA mutant form inhibits the reaction [Norepinephrine results in increased expression of ICAM1 mRNA]; RELA mutant form inhibits the reaction [Norepinephrine results in increased expression of SOD2 mRNA]; Vitamin E inhibits the reaction [Norepinephrine affects the localization of RELA protein]

PMID:16782692 PMID:23114885

NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484

G

S100 calcium binding protein A8

increases expression

Norepinephrine results in increased expression of S100A8 mRNA; Norepinephrine results in increased expression of S100A8 protein

NCBI chr 2:176,166,517...176,167,645
Ensembl chr 2:176,167,124...176,167,643

G

S100 calcium binding protein A9

increases expression

Norepinephrine results in increased expression of S100A9 mRNA; Norepinephrine results in increased expression of S100A9 protein

NCBI chr 2:176,190,361...176,193,182
Ensembl chr 2:176,190,361...176,193,230

G

S100 calcium binding protein B

increases expression
affects response to substance

Norepinephrine results in increased expression of S100B mRNA; Norepinephrine results in increased expression of S100B protein
S100B protein affects the susceptibility to Norepinephrine

NCBI chr20:12,372,866...12,381,619
Ensembl chr20:12,372,881...12,394,743

G

scaffold attachment factor B

increases expression

Norepinephrine results in increased expression of SAFB mRNA

NCBI chr 9:1,417,449...1,438,408
Ensembl chr 9:1,417,525...1,438,644

G

stearoyl-CoA desaturase

increases expression

Norepinephrine results in increased expression of SCD1 mRNA

NCBI chr 1:243,269,745...243,282,878
Ensembl chr 1:243,269,747...243,282,562

G

serpin family E member 1

increases expression

Norepinephrine results in increased expression of SERPINE1 mRNA

NCBI chr12:19,601,272...19,611,657
Ensembl chr12:19,601,272...19,611,657

G

serpin family H member 1

multiple interactions
increases expression

carvedilol inhibits the reaction [Norepinephrine results in increased expression of SERPINH1 mRNA]; carvedilol inhibits the reaction [Norepinephrine results in increased expression of SERPINH1 protein]
Norepinephrine results in increased expression of SERPINH1 mRNA; Norepinephrine results in increased expression of SERPINH1 protein

NCBI chr 1:153,643,500...153,650,853
Ensembl chr 1:153,643,510...153,650,801

G

SHC adaptor protein 1

multiple interactions
increases phosphorylation

1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt inhibits the reaction [Norepinephrine results in increased phosphorylation of SHC1 protein alternative form]; bisindolylmaleimide I inhibits the reaction [Norepinephrine results in increased phosphorylation of SHC1 protein alternative form]; EGFR protein inhibits the reaction [Norepinephrine results in increased phosphorylation of SHC1 protein alternative form]; Prazosin inhibits the reaction [Norepinephrine results in increased phosphorylation of SHC1 protein alternative form]; RTKI cpd inhibits the reaction [Norepinephrine results in increased phosphorylation of SHC1 protein alternative form]; SHC1 protein affects the reaction [Norepinephrine results in decreased expression of SOD2 protein]; SHC1 protein affects the reaction [Norepinephrine results in increased phosphorylation of FOXO3 protein]; Tetradecanoylphorbol Acetate inhibits the reaction [Norepinephrine results in increased phosphorylation of SHC1 protein alternative form]; U 0126 inhibits the reaction [Norepinephrine results in increased phosphorylation of SHC1 protein alternative form]

NCBI chr 2:174,837,937...174,849,538
Ensembl chr 2:174,837,930...174,849,536

G

solute carrier family 12 member 1

decreases expression

Norepinephrine results in decreased expression of SLC12A1 protein

NCBI chr 3:112,406,140...112,482,913
Ensembl chr 3:112,406,140...112,482,899

G

solute carrier family 14 member 2

decreases expression

Norepinephrine results in decreased expression of SLC14A2 protein

NCBI chr18:71,612,460...72,039,462
Ensembl chr18:71,612,460...71,792,968

G

solute carrier family 18 member A1

multiple interactions

Norepinephrine inhibits the reaction [SLC18A1 protein results in increased uptake of Serotonin]

NCBI chr16:20,653,268...20,687,051
Ensembl chr16:20,653,508...20,687,051

G

solute carrier family 18 member A2

multiple interactions
increases expression
decreases activity
affects binding

Norepinephrine inhibits the reaction [SLC18A2 protein results in increased uptake of Serotonin]
Norepinephrine results in increased expression of SLC18A2 mRNA
Norepinephrine results in decreased activity of SLC18A2 protein
Norepinephrine binds to SLC18A2 protein

PMID:1438304 PMID:7912402 PMID:14618266 PMID:15475732

NCBI chr 1:258,413,748...258,449,143
Ensembl chr 1:258,413,959...258,448,325

G

solute carrier family 22 member 3

increases uptake
multiple interactions

SLC22A3 protein results in increased uptake of Norepinephrine
Norepinephrine affects the reaction [SLC22A3 protein results in increased uptake of Tetraethylammonium]

PMID:9830022 PMID:20858707

NCBI chr 1:48,235,476...48,324,617
Ensembl chr 1:48,235,476...48,324,612

G

solute carrier family 29 member 4

increases uptake

SLC29A4 protein results in increased uptake of Norepinephrine

NCBI chr12:11,853,540...11,884,660
Ensembl chr12:11,853,540...11,874,834

G

solute carrier family 6 member 2

multiple interactions
increases uptake
decreases expression
decreases uptake
decreases activity

N-Methyl-3,4-methylenedioxyamphetamine inhibits the reaction [SLC6A2 protein results in increased uptake of Norepinephrine]; Norepinephrine inhibits the reaction [nisoxetine binds to SLC6A2 protein]; SLC6A2 protein promotes the reaction [Norepinephrine results in increased activity of TAAR1 protein]
[Cullen corylifolium extract results in decreased activity of SLC6A2 protein] which results in decreased uptake of Norepinephrine; Norepinephrine affects the localization of and affects the metabolism of SLC6A2 protein
[Desipramine results in decreased activity of SLC6A2 protein] which results in decreased abundance of Norepinephrine; Bupivacaine inhibits the reaction [[Desipramine results in decreased activity of SLC6A2 protein] which results in decreased abundance of Norepinephrine]; Lidocaine inhibits the reaction [[Desipramine results in decreased activity of SLC6A2 protein] which results in decreased abundance of Norepinephrine]; tricaine inhibits the reaction [[Desipramine results in decreased activity of SLC6A2 protein] which results in decreased abundance of Norepinephrine]
Norepinephrine results in decreased expression of SLC6A2 protein
SLC6A2 mutant form results in decreased uptake of Norepinephrine
Norepinephrine results in decreased activity of SLC6A2 protein

PMID:11082428 PMID:11458707 PMID:16338971 PMID:16725121 PMID:17234900 More...

NCBI chr19:14,010,292...14,055,317
Ensembl chr19:14,010,386...14,050,357

G

solute carrier family 6 member 3

multiple interactions
increases uptake

SLC6A3 protein promotes the reaction [Norepinephrine results in increased activity of TAAR1 protein]
SLC6A3 protein results in increased uptake of Norepinephrine

PMID:17234900 PMID:17250655

NCBI chr 1:29,709,443...29,750,413
Ensembl chr 1:29,709,443...29,750,413

G

solute carrier family 6 member 4

multiple interactions

SLC6A4 protein promotes the reaction [Norepinephrine results in increased activity of TAAR1 protein]

NCBI chr10:61,824,208...61,858,924
Ensembl chr10:61,826,123...61,858,384

G

solute carrier family 8 member A1

increases expression

Norepinephrine results in increased expression of SLC8A1 mRNA; Norepinephrine results in increased expression of SLC8A1 protein

NCBI chr 6:13,194,609...13,547,369
Ensembl chr 6:13,194,662...13,535,628

G

superoxide dismutase 2

decreases expression
increases expression
multiple interactions

Norepinephrine results in decreased expression of SOD2 protein
Norepinephrine results in increased expression of SOD2 mRNA
Acetylcysteine inhibits the reaction [Norepinephrine results in increased expression of SOD2 mRNA]; Ascorbic Acid inhibits the reaction [Norepinephrine results in increased expression of SOD2 mRNA]; NFKB1 mutant form inhibits the reaction [Norepinephrine results in increased expression of SOD2 mRNA]; Norepinephrine promotes the reaction [[NFKB1 protein binds to RELA protein] which binds to SOD2 promoter]; prolinedithiocarbamate inhibits the reaction [Norepinephrine results in increased expression of SOD2 mRNA]; RELA mutant form inhibits the reaction [Norepinephrine results in increased expression of SOD2 mRNA]; Vitamin E inhibits the reaction [Norepinephrine results in increased expression of SOD2 mRNA]
SHC1 protein affects the reaction [Norepinephrine results in decreased expression of SOD2 protein]

PMID:19168439 PMID:23114885

NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189

G

steroidogenic acute regulatory protein

increases expression

Norepinephrine results in increased expression of STAR mRNA

NCBI chr16:66,267,094...66,274,368
Ensembl chr16:66,264,807...66,271,672

G

signal transducer and activator of transcription 3

multiple interactions
increases phosphorylation

[Clorgyline co-treated with Selegiline] inhibits the reaction [Norepinephrine results in increased phosphorylation of STAT3 protein]; Carnosine inhibits the reaction [Norepinephrine results in increased phosphorylation of STAT3 protein]

NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057

G

spleen associated tyrosine kinase

increases expression

Norepinephrine results in increased expression of SYK mRNA

NCBI chr17:12,604,615...12,678,437
Ensembl chr17:12,604,619...12,661,410

G

trace-amine-associated receptor 1

multiple interactions

SLC6A2 protein promotes the reaction [Norepinephrine results in increased activity of TAAR1 protein]; SLC6A3 protein promotes the reaction [Norepinephrine results in increased activity of TAAR1 protein]; SLC6A4 protein promotes the reaction [Norepinephrine results in increased activity of TAAR1 protein]

NCBI chr 1:21,517,742...21,518,740
Ensembl chr 1:21,517,258...21,532,084

G

thromboxane A2 receptor

multiple interactions

[SQ 29548 binds to and results in decreased activity of TBXA2R protein] which results in decreased susceptibility to Norepinephrine

NCBI chr 7:8,383,347...8,390,753
Ensembl chr 7:8,383,378...8,388,176

G

transcription factor A, mitochondrial

multiple interactions

[Estradiol co-treated with Norepinephrine] results in decreased expression of TFAM mRNA; [Progesterone co-treated with Norepinephrine] results in increased expression of TFAM mRNA

NCBI chr20:17,356,243...17,368,293
Ensembl chr20:17,356,197...17,368,292

G

transforming growth factor, beta 1

multiple interactions
increases expression

Prazosin inhibits the reaction [Norepinephrine results in increased expression of TGFB1 mRNA]

PMID:15326086 PMID:19575289

NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847

G

transforming growth factor, beta 2

increases expression
multiple interactions

Norepinephrine results in increased expression of TGFB2 mRNA; Norepinephrine results in increased expression of TGFB2 protein
Prazosin inhibits the reaction [Norepinephrine results in increased expression of TGFB2 mRNA]

NCBI chr13:98,160,075...98,261,771
Ensembl chr13:98,160,087...98,261,405

G

transforming growth factor, beta 3

increases expression
multiple interactions

Norepinephrine results in increased expression of TGFB3 mRNA
Prazosin inhibits the reaction [Norepinephrine results in increased expression of TGFB3 mRNA]

NCBI chr 6:105,704,058...105,726,661
Ensembl chr 6:105,704,236...105,726,564

G

tyrosine hydroxylase

multiple interactions
increases chemical synthesis

[Clonidine results in decreased activity of and results in decreased expression of TH protein] which results in decreased abundance of Norepinephrine; [Clonidine results in increased expression of TH protein] which results in increased abundance of Norepinephrine
TH protein results in increased chemical synthesis of Norepinephrine

PMID:9822156 PMID:19067675

NCBI chr 1:198,071,500...198,078,832
Ensembl chr 1:198,071,503...198,109,767

G

Thy-1 cell surface antigen

decreases expression
multiple interactions

Norepinephrine results in decreased expression of THY1
Propranolol inhibits the reaction [Norepinephrine results in decreased expression of THY1]

NCBI chr 8:44,389,495...44,394,688
Ensembl chr 8:44,389,513...44,394,659

G

translocase of inner mitochondrial membrane 13

increases expression

Norepinephrine results in increased expression of TIMM13 mRNA

NCBI chr 7:8,809,069...8,810,172
Ensembl chr 7:8,809,058...8,809,910

G

TIMP metallopeptidase inhibitor 2

multiple interactions
increases expression

Metoprolol inhibits the reaction [Norepinephrine results in increased expression of TIMP2 mRNA]; Prazosin inhibits the reaction [Norepinephrine results in increased expression of TIMP2 mRNA]

PMID:14577597 PMID:15326086

NCBI chr10:103,541,199...103,590,611
Ensembl chr10:103,531,505...103,590,611

G

tumor necrosis factor

multiple interactions
increases expression
increases secretion

Acetylcysteine inhibits the reaction [Norepinephrine results in increased secretion of TNF protein]; Ascorbic Acid inhibits the reaction [Norepinephrine results in increased secretion of TNF protein]; Norepinephrine inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased secretion of TNF protein]; Norepinephrine promotes the reaction [TNF protein results in increased expression of IL6 protein]
Norepinephrine results in increased expression of TNF mRNA

PMID:8392517 PMID:15081246 PMID:15158148 PMID:25437044

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

tumor protein p53

increases expression

Norepinephrine results in increased expression of TP53 mRNA

NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524

G

uncoupling protein 1

multiple interactions
increases expression

[Rosiglitazone results in increased susceptibility to Norepinephrine] which results in increased expression of UCP1 mRNA; [Rosiglitazone results in increased susceptibility to Norepinephrine] which results in increased expression of UCP1 protein; AG 1879 promotes the reaction [Norepinephrine results in increased expression of UCP1 mRNA]
[AVP protein co-treated with Norepinephrine] inhibits the reaction [Triiodothyronine inhibits the reaction [EGF protein results in decreased expression of UCP1 mRNA]]; [AVP protein co-treated with Norepinephrine] inhibits the reaction [Triiodothyronine promotes the reaction [FGF1 protein results in increased expression of UCP1 mRNA]]; [AVP protein co-treated with Norepinephrine] inhibits the reaction [Triiodothyronine promotes the reaction [FGF2 protein results in increased expression of UCP1 mRNA]]; [AVP protein co-treated with Norepinephrine] inhibits the reaction [Triiodothyronine results in increased expression of UCP1 mRNA]; [EGF protein co-treated with AVP protein co-treated with Norepinephrine co-treated with Triiodothyronine] results in decreased expression of UCP1 mRNA; [FGF1 protein co-treated with AVP protein co-treated with Norepinephrine co-treated with Triiodothyronine] results in decreased expression of UCP1 mRNA; [Triiodothyronine co-treated with Norepinephrine] results in increased expression of UCP1 mRNA

PMID:10465291 PMID:10788502 PMID:11742803 PMID:29910772 PMID:31048375

NCBI chr19:24,808,782...24,816,853
Ensembl chr19:24,808,783...24,816,852

G

uncoupling protein 2

increases expression

Norepinephrine results in increased expression of UCP2 mRNA

PMID:8593794 PMID:12588052

NCBI chr 1:154,839,242...154,845,612
Ensembl chr 1:154,839,209...154,845,611

G

upstream transcription factor 1

multiple interactions

USF1 gene polymorphism promotes the reaction [Norepinephrine results in increased metabolism of Lipids]; USF1 protein affects the reaction [Norepinephrine results in increased metabolism of Lipids]

NCBI chr13:83,845,230...83,854,875
Ensembl chr13:83,822,035...83,854,885

G

vitamin D receptor

increases abundance

VDR protein results in increased abundance of Norepinephrine

NCBI chr 7:128,987,981...129,037,677
Ensembl chr 7:128,987,981...129,037,677

G

vascular endothelial growth factor A

multiple interactions
increases expression

[Cobalt co-treated with Norepinephrine] results in increased expression of VEGFA mRNA; [Cycloheximide co-treated with Norepinephrine] results in increased expression of VEGFA mRNA; [Norepinephrine co-treated with Tetradecanoylphorbol Acetate] results in increased expression of VEGFA mRNA; AG 1879 inhibits the reaction [Norepinephrine results in increased expression of VEGFA mRNA]; Cyclic AMP affects the reaction [Norepinephrine results in increased expression of VEGFA mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Norepinephrine results in increased expression of VEGFA mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Norepinephrine results in increased expression of VEGFA]; Propranolol inhibits the reaction [Norepinephrine results in increased expression of VEGFA mRNA]

NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641

G

X-box binding protein 1

affects localization

Norepinephrine affects the localization of XBP1 protein

NCBI chr14:80,390,629...80,395,713
Ensembl chr14:80,390,643...80,395,693

G

xanthine dehydrogenase

increases expression

Norepinephrine results in increased expression of XDH mRNA

NCBI chr 6:21,530,463...21,592,172
Ensembl chr 6:21,530,113...21,592,268

2-methylserotonin

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

5-hydroxytryptamine receptor 3A

multiple interactions

2-methyl-5-HT binds to and results in increased activity of HTR3A protein

NCBI chr 8:49,242,018...49,254,475
Ensembl chr 8:49,242,020...49,254,389

G

interleukin 1 beta

multiple interactions

2-methyl-5-HT promotes the reaction [Lipopolysaccharides results in increased secretion of IL1B protein]

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 6

multiple interactions

2-methyl-5-HT promotes the reaction [Lipopolysaccharides results in increased secretion of IL6 protein]

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

3-methoxytyramine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

trace-amine-associated receptor 1

increases activity
multiple interactions

3-methoxytyramine results in increased activity of TAAR1 protein
[3-methoxytyramine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP

NCBI chr 1:21,517,742...21,518,740
Ensembl chr 1:21,517,258...21,532,084

G

vitamin D receptor

multiple interactions
increases abundance

Calcitriol promotes the reaction [VDR protein results in increased abundance of 3-methoxytyramine]

NCBI chr 7:128,987,981...129,037,677
Ensembl chr 7:128,987,981...129,037,677

4-methoxytyramine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

trace-amine-associated receptor 1

increases activity
multiple interactions

3-hydroxy-4-methoxyphenethylamine results in increased activity of TAAR1 protein
[3-hydroxy-4-methoxyphenethylamine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP

NCBI chr 1:21,517,742...21,518,740
Ensembl chr 1:21,517,258...21,532,084

5-Hydroxydopamine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

catechol-O-methyltransferase

increases methylation

COMT protein results in increased methylation of 5-hydroxydopamine

NCBI chr11:82,568,052...82,587,642
Ensembl chr11:82,568,025...82,587,642

5-methoxy-N,N-diisopropyltryptamine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

cytochrome P450, family 2, subfamily b, polypeptide 3

decreases activity
multiple interactions

5-methoxy-N,N-diisopropyltryptamine analog results in decreased activity of CYP2B6 protein
[5-methoxy-N,N-diisopropyltryptamine analog results in decreased activity of CYP2B6 protein] which results in decreased metabolism of Bupropion

NCBI chr 1:81,652,762...81,732,153
Ensembl chr 1:81,652,787...81,732,143

G

cytochrome P450, family 2, subfamily C, polypeptide 6

multiple interactions
decreases activity

[5-methoxy-N,N-diisopropyltryptamine analog results in decreased activity of CYP2C19 protein] which results in decreased metabolism of Omeprazole

NCBI chr 1:237,938,521...237,976,238
Ensembl chr 1:237,693,094...238,057,596

G

cytochrome P450, family 2, subfamily d, polypeptide 1

increases metabolic processing

CYP2D1 protein results in increased metabolism of 5-methoxy-N,N-diisopropyltryptamine

NCBI chr 7:113,908,950...113,913,420
Ensembl chr 7:113,908,947...113,922,084

G

cytochrome P450, family 2, subfamily d, polypeptide 2

increases metabolic processing

CYP2D2 protein results in increased metabolism of 5-methoxy-N,N-diisopropyltryptamine

NCBI chr 7:113,935,138...113,939,209
Ensembl chr 7:113,935,138...113,939,209

G

cytochrome P450, family 2, subfamily d, polypeptide 4

multiple interactions
decreases activity

[5-methoxy-N,N-diisopropyltryptamine analog results in decreased activity of CYP2D6 protein] which results in decreased metabolism of Dextromethorphan

NCBI chr 7:113,882,584...113,891,754
Ensembl chr 7:113,881,618...113,891,759

G

cytochrome P450, family 2, subfamily e, polypeptide 1

multiple interactions
decreases activity

[5-methoxy-N,N-diisopropyltryptamine analog results in decreased activity of CYP2E1 protein] which results in decreased metabolism of Chlorzoxazone

NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023

5-methoxytryptamine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

cytochrome P450, family 2, subfamily d, polypeptide 4

multiple interactions

CYP2D6 protein binds to and results in decreased methylation of 5-Methoxytryptamine

NCBI chr 7:113,882,584...113,891,754
Ensembl chr 7:113,881,618...113,891,759

G

5-hydroxytryptamine receptor 7

multiple interactions

[5-Methoxytryptamine binds to and results in increased activity of HTR7 protein] which results in increased abundance of Cyclic AMP

NCBI chr 1:233,636,442...233,761,063
Ensembl chr 1:233,636,452...233,760,626

G

kynurenine 3-monooxygenase

increases expression

5-Methoxytryptamine results in increased expression of KMO mRNA

NCBI chr13:87,557,080...87,589,334
Ensembl chr13:87,557,286...87,588,881

G

protein phosphatase 1, regulatory (inhibitor) subunit 1B

decreases phosphorylation
increases phosphorylation

5-Methoxytryptamine results in decreased phosphorylation of PPP1R1B protein
5-Methoxytryptamine results in increased phosphorylation of PPP1R1B protein

NCBI chr10:83,347,731...83,356,775
Ensembl chr10:83,347,731...83,356,775

G

superoxide dismutase 2

decreases expression

5-Methoxytryptamine results in decreased expression of SOD2 mRNA

NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189

G

trace-amine-associated receptor 1

increases activity
multiple interactions

5-Methoxytryptamine results in increased activity of TAAR1 protein
[5-Methoxytryptamine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP

NCBI chr 1:21,517,742...21,518,740
Ensembl chr 1:21,517,258...21,532,084

G

tryptophan hydroxylase 1

decreases expression

5-Methoxytryptamine results in decreased expression of TPH1 mRNA

NCBI chr 1:97,157,375...97,178,415
Ensembl chr 1:97,157,409...97,178,344

adrenaline

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

serpin family F member 1

multiple interactions

epinephrine promotes the reaction [lipopolysaccharide increases expression of Serpinf1 protein in plasma]

RGD

NCBI chr10:60,250,198...60,262,593
Ensembl chr10:60,249,708...60,262,646

arbutamine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

adrenoceptor beta 1

multiple interactions

arbutamine binds to and results in increased activity of ADRB1 protein

NCBI chr 1:255,771,962...255,774,973
Ensembl chr 1:255,771,597...255,807,259

compound 48/80

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

C-C motif chemokine ligand 2

increases secretion

p-Methoxy-N-methylphenethylamine results in increased secretion of CCL2 protein

NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226

G

glucuronidase, beta

increases secretion

p-Methoxy-N-methylphenethylamine results in increased secretion of GUSB protein

NCBI chr12:26,701,188...26,714,718
Ensembl chr12:26,697,951...26,726,905

G

hexosaminidase subunit alpha

increases secretion
multiple interactions

p-Methoxy-N-methylphenethylamine results in increased secretion of HEXA protein
Apigenin inhibits the reaction [p-Methoxy-N-methylphenethylamine results in increased secretion of HEXA protein]

NCBI chr 8:59,936,526...59,961,654
Ensembl chr 8:59,936,660...59,962,013

G

hexosaminidase subunit beta

increases secretion

p-Methoxy-N-methylphenethylamine results in increased secretion of HEXB protein

NCBI chr 2:28,483,997...28,504,165
Ensembl chr 2:28,484,012...28,504,223

G

5-hydroxytryptamine receptor 1A

increases activity

p-Methoxy-N-methylphenethylamine results in increased activity of HTR1A protein

NCBI chr 2:36,693,462...36,698,026
Ensembl chr 2:36,694,174...36,695,442

G

KIT proto-oncogene receptor tyrosine kinase

affects response to substance

KIT protein affects the susceptibility to p-Methoxy-N-methylphenethylamine

NCBI chr14:32,547,459...32,624,694
Ensembl chr14:32,548,877...32,624,652

G

kininogen 1

decreases activity

p-Methoxy-N-methylphenethylamine results in decreased activity of KNG1 protein

NCBI chr11:77,812,757...77,835,555
Ensembl chr11:77,812,752...77,835,555

G

LCK proto-oncogene, Src family tyrosine kinase

multiple interactions
increases activity

atractylon inhibits the reaction [p-Methoxy-N-methylphenethylamine results in increased activity of LCK protein]; damnacanthal inhibits the reaction [p-Methoxy-N-methylphenethylamine results in increased activity of LCK protein]; pyeongwee-san extract inhibits the reaction [p-Methoxy-N-methylphenethylamine results in increased activity of LCK protein]

NCBI chr 5:141,888,318...141,916,945
Ensembl chr 5:141,888,326...141,903,794

G

mitogen activated protein kinase 1

multiple interactions
increases phosphorylation

epigallocatechin gallate inhibits the reaction [p-Methoxy-N-methylphenethylamine results in increased phosphorylation of MAPK1 protein]

NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616

G

mitogen activated protein kinase 3

multiple interactions
increases phosphorylation

epigallocatechin gallate inhibits the reaction [p-Methoxy-N-methylphenethylamine results in increased phosphorylation of MAPK3 protein]

NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863

G

MAS related GPR family member X2

affects response to substance

MRGPRX2 protein affects the susceptibility to p-Methoxy-N-methylphenethylamine

NCBI chr 1:98,116,192...98,135,534

G

nuclear receptor subfamily 3, group C, member 1

decreases activity

p-Methoxy-N-methylphenethylamine results in decreased activity of NR3C1 protein

NCBI chr18:31,271,681...31,393,320
Ensembl chr18:31,271,681...31,393,375

G

tumor necrosis factor

increases secretion

p-Methoxy-N-methylphenethylamine results in increased secretion of TNF protein

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

tryptase beta 2

increases secretion

p-Methoxy-N-methylphenethylamine results in increased secretion of TPSB2 protein

NCBI chr10:14,381,779...14,383,571
Ensembl chr10:14,382,013...14,383,569

Cysteinyldopa

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

OCA2 melanosomal transmembrane protein

decreases abundance

OCA2 gene mutant form results in decreased abundance of Cysteinyldopa

NCBI chr 1:107,116,278...107,446,093
Ensembl chr 1:107,116,278...107,446,074

dobutamine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily B member 11

decreases activity

Dobutamine results in decreased activity of ABCB11 protein

NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730

G

adenylate cyclase 6

affects response to substance

ADCY6 protein affects the susceptibility to Dobutamine

NCBI chr 7:129,742,827...129,763,922
Ensembl chr 7:129,742,838...129,763,754

G

adrenoceptor alpha 2A

multiple interactions

Dobutamine binds to and results in increased activity of ADRA2A protein

NCBI chr 1:253,061,480...253,064,280
Ensembl chr 1:253,060,218...253,064,365

G

adrenoceptor beta 1

affects response to substance
multiple interactions

ADRB1 gene affects the susceptibility to Dobutamine; ADRB1 gene polymorphism affects the susceptibility to Dobutamine; ADRB1 protein polymorphism affects the susceptibility to Dobutamine
[Dobutamine co-treated with ICI 118551] results in decreased expression of ADRB1 mRNA; [Dobutamine co-treated with ICI 118551] results in decreased expression of ADRB1 protein; Dobutamine binds to and results in increased activity of ADRB1 protein; Dobutamine inhibits the reaction [Iodocyanopindolol binds to ADRB1 protein]; Oxygen deficiency results in increased susceptibility to [Dobutamine binds to and results in increased activity of ADRB1 protein]
ADRB1 gene polymorphism affects the susceptibility to [Dobutamine co-treated with Metoprolol]; AG 1879 inhibits the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; AG 1879 inhibits the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; AG 1879 inhibits the reaction [Dobutamine promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]]; ARRB1 protein promotes the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; ARRB1 protein promotes the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; ARRB2 protein promotes the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; ARRB2 protein promotes the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; Dobutamine binds to and results in increased activity of ADRB1 protein; Dobutamine inhibits the reaction [Iodocyanopindolol binds to ADRB1 protein]; Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]; Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]; Dobutamine promotes the reaction [ADRB1 protein results in increased phosphorylation of and results in increased uptake of EGFR protein]; HBEGF protein inhibits the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; HBEGF protein inhibits the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; HBEGF protein promotes the reaction [Dobutamine promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]]; N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide inhibits the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide inhibits the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide inhibits the reaction [Dobutamine promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]]; Propranolol inhibits the reaction [Dobutamine promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]]; Propranolol inhibits the reaction [Dobutamine promotes the reaction [ADRB1 protein results in increased uptake of EGFR protein]]; RTKI cpd inhibits the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; RTKI cpd inhibits the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; RTKI cpd inhibits the reaction [Dobutamine promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]]

PMID:8096834 PMID:10192281 PMID:11753577 PMID:14502278 PMID:15564877 More...

NCBI chr 1:255,771,962...255,774,973
Ensembl chr 1:255,771,597...255,807,259

G

adrenoceptor beta 2

affects response to substance

ADRB2 gene polymorphism affects the susceptibility to Dobutamine

NCBI chr18:55,642,459...55,644,501
Ensembl chr18:55,502,903...55,644,512

G

adrenoceptor beta 3

multiple interactions

[Dobutamine co-treated with ICI 118551] results in increased expression of ADRB3 mRNA; [Dobutamine co-treated with ICI 118551] results in increased expression of ADRB3 protein

NCBI chr16:64,839,820...64,844,552
Ensembl chr16:64,841,788...64,844,552

G

alpha-2-HS-glycoprotein

affects response to substance

AHSG protein affects the susceptibility to Dobutamine

NCBI chr11:78,121,388...78,127,998
Ensembl chr11:78,117,918...78,145,999

G

AKT serine/threonine kinase 1

affects response to substance
multiple interactions

AKT1 protein affects the susceptibility to Dobutamine
Dobutamine inhibits the reaction [Oxidopamine results in decreased phosphorylation of AKT1 protein]

PMID:16094411 PMID:16339297

NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921

G

AKT serine/threonine kinase 2

multiple interactions

Dobutamine inhibits the reaction [Oxidopamine results in decreased phosphorylation of AKT2 protein]

NCBI chr 1:82,877,228...82,933,828
Ensembl chr 1:82,883,547...82,933,817

G

AKT serine/threonine kinase 3

multiple interactions

Dobutamine inhibits the reaction [Oxidopamine results in decreased phosphorylation of AKT3 protein]

NCBI chr13:88,943,708...89,225,831
Ensembl chr13:88,946,091...89,225,708

G

arrestin, beta 1

multiple interactions

ARRB1 protein promotes the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; ARRB1 protein promotes the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]

NCBI chr 1:153,837,964...153,912,111
Ensembl chr 1:153,838,078...153,904,061

G

arrestin, beta 2

multiple interactions

ARRB2 protein promotes the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; ARRB2 protein promotes the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]

NCBI chr10:55,146,887...55,154,854
Ensembl chr10:55,146,818...55,154,850

G

BCL2 associated X, apoptosis regulator

increases expression

Dobutamine results in increased expression of BAX protein

NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368

G

BCL2, apoptosis regulator

decreases expression

Dobutamine results in decreased expression of BCL2 protein

NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

BCL2 interacting protein 1

increases expression

Dobutamine results in increased expression of BNIP1 protein

NCBI chr10:16,386,876...16,399,124
Ensembl chr10:16,386,841...16,399,157

G

C-C motif chemokine ligand 2

multiple interactions

Dobutamine inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 mRNA]; Dobutamine inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 protein]

NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226

G

C-C motif chemokine ligand 3

multiple interactions

Dobutamine inhibits the reaction [Lipopolysaccharides results in increased expression of CCL3 protein]

NCBI chr10:68,451,388...68,452,938
Ensembl chr10:68,451,388...68,452,938

G

clusterin

increases expression

Dobutamine results in increased expression of CLU protein

NCBI chr15:40,161,068...40,200,315
Ensembl chr15:40,174,617...40,200,315

G

catechol-O-methyltransferase

increases methylation
increases expression

COMT protein results in increased methylation of Dobutamine
Dobutamine results in increased expression of COMT mRNA

PMID:11160877 PMID:12423672

NCBI chr11:82,568,052...82,587,642
Ensembl chr11:82,568,025...82,587,642

G

carnitine palmitoyltransferase 1A

increases expression

Dobutamine results in increased expression of CPT1A mRNA; Dobutamine results in increased expression of CPT1A protein

NCBI chr 1:200,564,634...200,627,059
Ensembl chr 1:200,565,613...200,627,055

G

cAMP responsive element modulator

affects response to substance

CREM protein affects the susceptibility to Dobutamine

NCBI chr17:54,238,889...54,305,989
Ensembl chr17:54,239,030...54,305,989

G

cardiotrophin 1

affects response to substance

CTF1 protein affects the susceptibility to Dobutamine

NCBI chr 1:182,328,035...182,336,346
Ensembl chr 1:182,328,090...182,333,335

G

C-X-C motif chemokine ligand 2

multiple interactions

Dobutamine inhibits the reaction [Lipopolysaccharides results in increased expression of CXCL2 mRNA]

NCBI chr14:17,181,030...17,183,075
Ensembl chr14:17,181,062...17,183,075

G

dopamine beta-hydroxylase

affects response to substance

DBH protein affects the susceptibility to Dobutamine

NCBI chr 3:10,488,260...10,505,245
Ensembl chr 3:10,488,260...10,505,248

G

dystrophin

increases response to substance

DMD gene mutant form results in increased susceptibility to Dobutamine

NCBI chr X:47,272,324...49,504,219
Ensembl chr X:47,272,331...49,504,207

G

epidermal growth factor receptor

decreases response to substance
multiple interactions

EGFR gene mutant form results in decreased susceptibility to Dobutamine
AG 1879 inhibits the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; AG 1879 inhibits the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; AG 1879 inhibits the reaction [Dobutamine promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]]; ARRB1 protein promotes the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; ARRB1 protein promotes the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; ARRB2 protein promotes the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; ARRB2 protein promotes the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]; Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]; Dobutamine promotes the reaction [ADRB1 protein results in increased phosphorylation of and results in increased uptake of EGFR protein]; HBEGF protein inhibits the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; HBEGF protein inhibits the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; HBEGF protein promotes the reaction [Dobutamine promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]]; N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide inhibits the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide inhibits the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide inhibits the reaction [Dobutamine promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]]; Propranolol inhibits the reaction [Dobutamine promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]]; Propranolol inhibits the reaction [Dobutamine promotes the reaction [ADRB1 protein results in increased uptake of EGFR protein]]; RTKI cpd inhibits the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; RTKI cpd inhibits the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; RTKI cpd inhibits the reaction [Dobutamine promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]]

PMID:18599591 PMID:18787115

NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382

G

estrogen receptor 1

multiple interactions

Dobutamine binds to and results in increased activity of ESR1 protein

NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002

G

coagulation factor III, tissue factor

increases expression

Dobutamine results in increased expression of F3 protein

NCBI chr 2:209,827,061...209,838,666
Ensembl chr 2:209,826,959...209,838,668

G

fibroblast growth factor 2

affects response to substance

FGF2 protein affects the susceptibility to Dobutamine

PMID:10491406 PMID:14583313

NCBI chr 2:120,236,328...120,290,673
Ensembl chr 2:120,236,328...120,291,221

G

Fos proto-oncogene, AP-1 transcription factor subunit

multiple interactions

Dobutamine results in increased activity of [JUN protein binds to JUND protein binds to FOS protein]; Metoprolol inhibits the reaction [Dobutamine results in increased activity of [JUN protein binds to JUND protein binds to FOS protein]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Dobutamine results in increased activity of [JUN protein binds to JUND protein binds to FOS protein]]

NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036

G

glucose-6-phosphate dehydrogenase

increases activity

Dobutamine results in increased activity of G6PD protein

NCBI chr X:152,201,081...152,220,863
Ensembl chr X:152,201,098...152,220,801

G

growth hormone 1

multiple interactions

GH1 protein promotes the reaction [Dobutamine results in increased metabolism of Lipids]

NCBI chr10:91,228,102...91,230,079
Ensembl chr10:91,228,103...91,230,078

G

glycerol kinase

increases activity

Dobutamine results in increased activity of GK protein

NCBI chr X:50,162,089...50,238,707
Ensembl chr X:50,163,123...50,238,631

G

GNAS complex locus

increases response to substance

GNAS gene SNP results in increased susceptibility to Dobutamine

NCBI chr 3:163,071,003...163,136,350
Ensembl chr 3:163,071,417...163,127,262
Ensembl chr 3:163,071,417...163,127,262

G

glycogen synthase kinase 3 beta

affects response to substance

GSK3B gene mutant form affects the susceptibility to Dobutamine

NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646

G

heparin-binding EGF-like growth factor

multiple interactions

HBEGF protein inhibits the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; HBEGF protein inhibits the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; HBEGF protein promotes the reaction [Dobutamine promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]]

NCBI chr18:28,106,284...28,116,167
Ensembl chr18:28,105,760...28,116,441

G

heme oxygenase 1

multiple interactions
increases expression

esmolol inhibits the reaction [Dobutamine results in increased expression of HMOX1 protein]; Metoprolol inhibits the reaction [Dobutamine results in increased expression of HMOX1 mRNA]; Metoprolol inhibits the reaction [Dobutamine results in increased expression of HMOX1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Dobutamine results in increased expression of HMOX1 mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Dobutamine results in increased expression of HMOX1 protein]
Dobutamine results in increased expression of HMOX1 mRNA; Dobutamine results in increased expression of HMOX1 protein

PMID:15179140 PMID:16627864

NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079

G

insulin-like growth factor 1

increases response to substance

IGF1 protein results in increased susceptibility to Dobutamine

NCBI chr 7:22,282,895...22,361,972
Ensembl chr 7:22,282,930...22,359,296

G

interleukin 10

multiple interactions

Dobutamine inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of IL10 protein]
Dobutamine inhibits the reaction [Lipopolysaccharides results in increased expression of IL10 protein]

PMID:11605937 PMID:15502056

NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313

G

interleukin 1 beta

increases expression
decreases expression

Dobutamine results in increased expression of IL1B mRNA
Dobutamine results in decreased expression of IL1B mRNA

PMID:9387890 PMID:32816093

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 6

increases expression
decreases expression
multiple interactions

Dobutamine results in increased expression of IL6 protein
Dobutamine results in decreased expression of IL6 mRNA
Dobutamine inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]; Dobutamine inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 protein]

PMID:11605937 PMID:12423672 PMID:16286589

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

integrin subunit beta 1

affects response to substance

ITGB1 protein affects the susceptibility to Dobutamine

NCBI chr19:56,705,123...56,753,199
Ensembl chr19:56,705,171...56,753,195

G

Jun proto-oncogene, AP-1 transcription factor subunit

multiple interactions

Dobutamine results in increased activity of [JUN protein binds to JUND protein binds to FOS protein]; Metoprolol inhibits the reaction [Dobutamine results in increased activity of [JUN protein binds to JUND protein binds to FOS protein]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Dobutamine results in increased activity of [JUN protein binds to JUND protein binds to FOS protein]]

NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656

G

JunD proto-oncogene, AP-1 transcription factor subunit

multiple interactions

Dobutamine results in increased activity of [JUN protein binds to JUND protein binds to FOS protein]; Metoprolol inhibits the reaction [Dobutamine results in increased activity of [JUN protein binds to JUND protein binds to FOS protein]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Dobutamine results in increased activity of [JUN protein binds to JUND protein binds to FOS protein]]

NCBI chr16:18,734,121...18,735,799
Ensembl chr16:18,734,122...18,735,799

G

potassium voltage-gated channel subfamily H member 2

decreases activity

Dobutamine results in decreased activity of KCNH2 protein

NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008

G

potassium inwardly-rectifying channel, subfamily J, member 11

multiple interactions
affects response to substance

KCNJ11 protein affects the reaction [[Manganese co-treated with Dobutamine] results in increased abundance of Calcium]
KCNJ11 protein affects the susceptibility to Dobutamine

NCBI chr 1:96,591,048...96,594,574
Ensembl chr 1:96,591,049...96,594,082

G

kallikrein 1

affects response to substance

KLK1 protein affects the susceptibility to Dobutamine

NCBI chr 1:94,642,644...94,646,760
Ensembl chr 1:94,642,687...94,646,754

G

leptin

decreases secretion
decreases expression

Dobutamine results in decreased secretion of LEP protein
Dobutamine results in decreased expression of LEP mRNA; Dobutamine results in decreased expression of LEP protein

PMID:9002984 PMID:11022189

NCBI chr 4:57,661,127...57,675,262
Ensembl chr 4:57,661,131...57,675,262

G

leptin receptor

affects response to substance

LEPR protein affects the susceptibility to Dobutamine

NCBI chr 5:116,294,409...116,477,904
Ensembl chr 5:116,289,823...116,475,908

G

mitogen activated protein kinase 1

multiple interactions
increases phosphorylation

[Dobutamine co-treated with ICI 118551] results in increased activity of MAPK1 protein
AG 1879 inhibits the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; ARRB1 protein promotes the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; ARRB2 protein promotes the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]; HBEGF protein inhibits the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide inhibits the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; RTKI cpd inhibits the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]
Dobutamine results in increased phosphorylation of MAPK1 protein

PMID:16760913 PMID:18787115 PMID:19719783

NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616

G

mitogen activated protein kinase 3

multiple interactions
increases phosphorylation

[Dobutamine co-treated with ICI 118551] results in increased activity of MAPK3 protein
AG 1879 inhibits the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; ARRB1 protein promotes the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; ARRB2 protein promotes the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]; HBEGF protein inhibits the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide inhibits the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; RTKI cpd inhibits the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]
Dobutamine results in increased phosphorylation of MAPK3 protein

PMID:16760913 PMID:18787115 PMID:19719783

NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863

G

mitogen-activated protein kinase 9

multiple interactions

[Dobutamine co-treated with ICI 118551] results in increased activity of MAPK9 protein

NCBI chr10:34,169,661...34,211,138
Ensembl chr10:34,169,675...34,210,178

G

myoglobin

affects response to substance

MB protein affects the susceptibility to Dobutamine

NCBI chr 7:108,759,903...108,767,134
Ensembl chr 7:108,759,904...108,767,383

G

NFKB inhibitor alpha

multiple interactions

Dobutamine inhibits the reaction [Tetradecanoylphorbol Acetate results in increased degradation of NFKBIA protein]

NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941

G

nitric oxide synthase 1

affects response to substance

NOS1 protein affects the susceptibility to Dobutamine

NCBI chr12:38,615,111...38,795,492
Ensembl chr12:38,626,714...38,710,945

G

nitric oxide synthase 2

affects response to substance

NOS2 protein affects the susceptibility to Dobutamine

PMID:9396439 PMID:11489778

NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210

G

nuclear receptor subfamily 1, group H, member 4

increases activity

Dobutamine results in increased activity of NR1H4 protein

NCBI chr 7:23,846,122...23,942,085
Ensembl chr 7:23,846,122...23,942,047

G

phosphoglycerate dehydrogenase

increases expression

Dobutamine results in increased expression of PHGDH mRNA

NCBI chr 2:185,906,962...185,936,054
Ensembl chr 2:185,906,966...185,935,944

G

phospholamban

affects response to substance

PLN protein affects the susceptibility to Dobutamine

NCBI chr20:32,629,537...32,639,559

G

protein phosphatase 2 catalytic subunit alpha

affects response to substance

PPP2CA protein affects the susceptibility to Dobutamine

NCBI chr10:36,358,110...36,377,864
Ensembl chr10:36,358,101...36,377,862

G

protein kinase cAMP-activated catalytic subunit alpha

multiple interactions

Dobutamine inhibits the reaction [Oxidopamine results in decreased phosphorylation of PRKACA protein]

NCBI chr19:24,155,081...24,178,430
Ensembl chr19:24,155,090...24,178,430

G

protein kinase C, epsilon

affects response to substance

PRKCE protein affects the susceptibility to Dobutamine

NCBI chr 6:7,965,048...8,451,966
Ensembl chr 6:7,965,048...8,451,719

G

PROP paired-like homeobox 1

decreases response to substance

PROP1 gene mutant form results in decreased susceptibility to Dobutamine

NCBI chr10:35,271,959...35,274,434
Ensembl chr10:35,271,973...35,274,434

G

prostaglandin-endoperoxide synthase 2

decreases expression

Dobutamine results in decreased expression of PTGS2 mRNA

NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188

G

renin

multiple interactions
increases expression
increases secretion
increases activity

Cycloheximide inhibits the reaction [Dobutamine results in increased secretion of REN protein]; Dactinomycin inhibits the reaction [Dobutamine results in increased secretion of REN protein]
Dobutamine results in increased expression of REN mRNA
Dobutamine results in increased activity of REN protein

PMID:9203624 PMID:9209250

NCBI chr13:44,796,260...44,807,491
Ensembl chr13:44,796,091...44,807,489

G

S100 calcium binding protein A1

increases response to substance

S100A1 gene mutant form results in increased susceptibility to Dobutamine

NCBI chr 2:175,993,922...175,998,765
Ensembl chr 2:175,993,922...175,999,544

G

sodium channel epithelial 1 subunit gamma

increases expression

Dobutamine results in increased expression of SCNN1G mRNA

NCBI chr 1:176,304,942...176,338,816
Ensembl chr 1:176,304,942...176,338,816

G

sarcoglycan, delta

affects response to substance

SGCD affects the susceptibility to Dobutamine

NCBI chr10:31,346,480...32,328,364
Ensembl chr10:31,280,511...31,724,840

G

spectrin, alpha, non-erythrocytic 1

increases degradation

Dobutamine deficiency results in increased degradation of SPTAN1 protein

NCBI chr 3:13,241,164...13,306,047
Ensembl chr 3:13,241,217...13,306,046

G

tachykinin, precursor 1

multiple interactions

Dobutamine promotes the reaction [TAC1 protein binds to and results in increased activity of TACR1 protein]

NCBI chr 4:35,679,183...35,687,180
Ensembl chr 4:35,679,704...35,687,178

G

tachykinin receptor 1

multiple interactions

Dobutamine promotes the reaction [TAC1 protein binds to and results in increased activity of TACR1 protein]

NCBI chr 4:114,920,844...115,089,733
Ensembl chr 4:114,920,844...115,089,733

G

transforming growth factor, beta 1

increases expression

Dobutamine results in increased expression of TGFB1 mRNA

NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847

G

transforming growth factor, beta 2

increases expression

Dobutamine results in increased expression of TGFB2 mRNA

NCBI chr13:98,160,075...98,261,771
Ensembl chr13:98,160,087...98,261,405

G

tumor necrosis factor

decreases expression
decreases secretion

Dobutamine results in decreased expression of TNF mRNA
Dobutamine results in decreased secretion of TNF protein

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

TNF alpha induced protein 6

decreases expression

Dobutamine results in decreased expression of TNFAIP6 mRNA

NCBI chr 3:36,502,250...36,521,652
Ensembl chr 3:36,502,188...36,521,649

G

upstream transcription factor 1

multiple interactions

USF1 gene polymorphism promotes the reaction [Dobutamine results in increased metabolism of Lipids]; USF1 protein affects the reaction [Dobutamine results in increased metabolism of Lipids]

NCBI chr13:83,845,230...83,854,875
Ensembl chr13:83,822,035...83,854,885

G

vascular endothelial growth factor A

affects response to substance

VEGFA protein affects the susceptibility to Dobutamine

PMID:11599061 PMID:14583313 PMID:19237429

NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641

dopamine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

alpha 1,3-galactosyltransferase 2

increases expression

Dopamine results in increased expression of A3GALT2 mRNA

NCBI chr 5:141,101,329...141,113,760
Ensembl chr 5:141,107,983...141,115,641

G

ABL proto-oncogene 2, non-receptor tyrosine kinase

decreases expression

Dopamine results in decreased expression of ABL2 mRNA

NCBI chr13:68,673,702...68,770,846
Ensembl chr13:68,673,722...68,839,742

G

actin, beta

affects expression

Dopamine affects the expression of ACTB protein

NCBI chr12:11,663,112...11,666,697
Ensembl chr12:11,663,109...11,672,877

G

actin, beta-like 2

decreases expression

Dopamine results in decreased expression of ACTBL2 protein

NCBI chr 2:42,858,020...42,860,767
Ensembl chr 2:42,858,020...42,860,767

G

actin, gamma 1

increases expression

Dopamine results in increased expression of ACTG1 mRNA

NCBI chr10:105,619,738...105,622,587
Ensembl chr10:105,619,737...105,624,232
Ensembl chr 3:105,619,737...105,624,232

G

ADAM metallopeptidase domain 9

increases expression

Dopamine results in increased expression of ADAM9 mRNA

NCBI chr16:67,022,538...67,101,647
Ensembl chr16:67,022,655...67,100,917

G

ADAM metallopeptidase with thrombospondin type 1 motif, 4

increases expression

Dopamine results in increased expression of ADAMTS4 mRNA

NCBI chr13:83,670,556...83,680,045
Ensembl chr13:83,670,183...83,680,065

G

adenosine A1 receptor

multiple interactions

[N(6)-cyclohexyladenosine binds to and results in increased activity of ADORA1 protein] promotes the reaction [Methamphetamine results in increased secretion of Dopamine]

NCBI chr13:45,658,872...45,695,821
Ensembl chr13:45,658,872...45,695,801

G

adrenoceptor alpha 2A

affects binding

Dopamine binds to ADRA2A protein

NCBI chr 1:253,061,480...253,064,280
Ensembl chr 1:253,060,218...253,064,365

G

adrenoceptor alpha 2C

affects binding

Dopamine binds to ADRA2C protein

NCBI chr14:75,470,884...75,472,846
Ensembl chr14:75,471,143...75,472,846

G

adrenoceptor beta 2

multiple interactions

[Terbutaline binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Dopamine; ICI 118551 inhibits the reaction [[Terbutaline binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Dopamine]

NCBI chr18:55,642,459...55,644,501
Ensembl chr18:55,502,903...55,644,512

G

angiotensinogen

multiple interactions

Clozapine inhibits the reaction [Dopamine promotes the reaction [AGT protein results in increased secretion of Aldosterone]]; Clozapine promotes the reaction [Raclopride promotes the reaction [Dopamine promotes the reaction [AGT protein results in increased secretion of Aldosterone]]]; Dopamine promotes the reaction [AGT protein results in increased secretion of Aldosterone]; Raclopride inhibits the reaction [Dopamine promotes the reaction [AGT protein results in increased secretion of Aldosterone]]; Raclopride promotes the reaction [Dopamine promotes the reaction [AGT protein results in increased secretion of Aldosterone]]

NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977

G

aldehyde dehydrogenase 2 family member

multiple interactions

[[CVT-10216 results in decreased activity of ALDH2 protein] which results in increased abundance of Tetrahydropapaveroline] inhibits the reaction [Cocaine results in increased abundance of and results in increased secretion of Dopamine]; ALDH2 protein affects the reaction [Cocaine results in increased abundance of Dopamine]

NCBI chr12:34,949,549...34,982,527
Ensembl chr12:34,901,219...34,982,521

G

aldolase, fructose-bisphosphate A

increases expression

Dopamine results in increased expression of ALDOA protein

NCBI chr 1:181,402,275...181,407,476
Ensembl chr 1:181,402,275...181,406,182

G

annexin A3

increases expression

Dopamine results in increased expression of ANXA3 protein

NCBI chr14:12,727,708...12,781,717
Ensembl chr14:12,719,795...12,781,617

G

arginase 1

decreases expression

Dopamine results in decreased expression of ARG1 mRNA; Dopamine results in decreased expression of ARG1 protein

NCBI chr 1:20,475,878...20,488,422
Ensembl chr 1:20,475,968...20,488,422

G

arrestin, beta 1

multiple interactions

Dopamine promotes the reaction [DRD2 protein affects the localization of ARRB1 protein]; GRK2 protein promotes the reaction [Dopamine promotes the reaction [DRD2 protein affects the localization of ARRB1 protein]]

NCBI chr 1:153,837,964...153,912,111
Ensembl chr 1:153,838,078...153,904,061

G

arrestin, beta 2

multiple interactions

Dopamine promotes the reaction [DRD2 protein affects the localization of ARRB2 protein]; GRK2 protein promotes the reaction [Dopamine promotes the reaction [DRD2 protein affects the localization of ARRB2 protein]]

NCBI chr10:55,146,887...55,154,854
Ensembl chr10:55,146,818...55,154,850

G

ATPase plasma membrane Ca2+ transporting 2

decreases expression

Dopamine results in decreased expression of ATP2B2 mRNA

NCBI chr 4:146,894,602...147,208,060
Ensembl chr 4:146,896,332...147,140,665

G

ATP synthase peripheral stalk subunit d

increases expression

Dopamine results in increased expression of ATP5PD protein

NCBI chr10:100,657,700...100,662,960
Ensembl chr10:100,657,708...100,663,479

G

beta-1,4-galactosyltransferase 1

increases expression

Dopamine results in increased expression of B4GALT1 mRNA

NCBI chr 5:55,935,614...55,982,461
Ensembl chr 5:55,935,615...55,982,461

G

BCL2 associated X, apoptosis regulator

decreases expression

Dopamine results in decreased expression of BAX protein

NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368

G

Bcl-2 binding component 3

increases expression

[Dopamine results in increased expression of HIF1A protein] which results in increased expression of BBC3 mRNA; [Dopamine results in increased expression of HIF1A protein] which results in increased expression of BBC3 protein

NCBI chr 1:77,013,281...77,022,509
Ensembl chr 1:77,014,543...77,022,509

G

BCL2, apoptosis regulator

decreases expression
multiple interactions

Dopamine results in decreased expression of BCL2 protein
polydatin inhibits the reaction [Dopamine results in decreased expression of BCL2 protein]; Resveratrol inhibits the reaction [Dopamine results in decreased expression of BCL2 protein]

PMID:17603292 PMID:28980048

NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

brain-derived neurotrophic factor

increases abundance

BDNF gene mutant form results in increased abundance of Dopamine

NCBI chr 3:96,165,042...96,215,621
Ensembl chr 3:96,165,042...96,215,615

G

BCL2 interacting protein 3

increases expression

[Dopamine results in increased expression of HIF1A protein] which results in increased expression of BNIP3 mRNA; [Dopamine results in increased expression of HIF1A protein] which results in increased expression of BNIP3 protein

NCBI chr 1:193,708,164...193,725,348
Ensembl chr 1:193,708,167...193,725,359

G

complement C1q binding protein

increases expression

Dopamine results in increased expression of C1QBP protein

NCBI chr10:55,699,954...55,704,605
Ensembl chr10:55,699,954...55,704,649

G

calumenin

increases expression

Dopamine results in increased expression of CALU mRNA

NCBI chr 4:57,949,086...57,976,589
Ensembl chr 4:57,948,997...57,976,593

G

calcyon neuron-specific vesicular protein

decreases secretion

CALY protein results in decreased secretion of Dopamine

NCBI chr 1:194,862,671...194,873,861
Ensembl chr 1:194,862,672...194,873,551

G

calcium/calmodulin-dependent protein kinase II alpha

multiple interactions

[Ionomycin co-treated with CAMK2A protein] inhibits the reaction [DRD3 protein promotes the reaction [Dopamine results in increased phosphorylation of MAPK1 protein]]

NCBI chr18:54,378,642...54,441,120
Ensembl chr18:54,378,784...54,438,994

G

caspase 3

multiple interactions
increases activity
increases cleavage

[Dopamine co-treated with Zinc deficiency] results in increased activity of CASP3 protein; Acetylcysteine inhibits the reaction [Dopamine results in increased activity of and results in increased cleavage of CASP3 protein]; Dopamine results in increased activity of and results in increased cleavage of CASP3 protein; Dopamine results in increased cleavage of and results in increased activity of CASP3 protein; PRKN protein inhibits the reaction [Dopamine results in increased cleavage of CASP3 protein]; resveratrol inhibits the reaction [Dopamine results in increased cleavage of and results in increased activity of CASP3 protein]
Dopamine results in increased activity of CASP3 protein
SH-6 compound promotes the reaction [Dopamine results in increased activity of CASP3 protein]; SH-6 compound promotes the reaction [tanespimycin promotes the reaction [Dopamine results in increased activity of CASP3 protein]]; tanespimycin promotes the reaction [Dopamine results in increased activity of CASP3 protein]

PMID:15198987 PMID:17136323 PMID:17603292 PMID:18194434 PMID:19410601 More...

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

caspase 7

multiple interactions
increases activity

Acetylcysteine inhibits the reaction [Dopamine results in increased activity of and results in increased cleavage of CASP7 protein]; Dopamine results in increased activity of and results in increased cleavage of CASP7 protein
Dopamine results in increased activity of CASP7 protein

PMID:17136323 PMID:19410601

NCBI chr 1:255,437,438...255,476,737
Ensembl chr 1:255,437,172...255,476,729

G

catalase

multiple interactions
increases expression

CAT protein inhibits the reaction [N-Methyl-3,4-methylenedioxyamphetamine results in decreased abundance of Dopamine]
Dopamine results in increased expression of CAT mRNA
[Dopamine co-treated with Dicumarol] results in increased expression of CAT mRNA

PMID:11299314 PMID:11435997

NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478

G

chromobox 7

decreases expression

Dopamine results in decreased expression of CBX7 mRNA

NCBI chr 7:111,460,656...111,479,231
Ensembl chr 7:111,460,656...111,477,973

G

C-C motif chemokine ligand 22

decreases expression

Dopamine results in decreased expression of CCL22 mRNA

NCBI chr19:10,257,602...10,264,373
Ensembl chr19:10,257,601...10,264,400

G

CD55 molecule (Cromer blood group)

increases expression

Dopamine results in increased expression of CD55 mRNA

NCBI chr13:41,857,242...41,885,966
Ensembl chr13:41,857,395...41,885,831

G

cofilin 1

increases expression

Dopamine results in increased expression of CFL1 protein

NCBI chr 1:202,796,012...202,801,337
Ensembl chr 1:202,786,627...202,817,587

G

cholinergic receptor, muscarinic 5

decreases secretion
affects secretion

CHRM5 gene mutant form results in decreased secretion of Dopamine
CHRM5 protein affects the secretion of Dopamine

NCBI chr 3:99,284,846...99,337,252
Ensembl chr 3:99,284,846...99,337,252

G

cholinergic receptor nicotinic alpha 3 subunit

increases secretion

CHRNA3 protein results in increased secretion of Dopamine

NCBI chr 8:55,401,668...55,415,165
Ensembl chr 8:55,401,702...55,415,165

G

cholinergic receptor nicotinic alpha 4 subunit

affects binding

dopamine binds to Chrna4 protein in rat brain striatal sections

RGD

NCBI chr 3:168,136,246...168,157,839
Ensembl chr 3:168,136,266...168,156,957

G

cholinergic receptor nicotinic alpha 6 subunit

multiple interactions

[pozanicline binds to and results in increased activity of [CHRNA6 protein binds to CHRNB2 protein]] which results in increased secretion of Dopamine; Nicotine inhibits the reaction [[CHRNA6 protein binds to CHRNB2 protein] which results in increased secretion of Dopamine]

PMID:17227438 PMID:19481067

NCBI chr16:64,697,741...64,704,441
Ensembl chr16:64,697,741...64,704,441

G

cholinergic receptor nicotinic beta 2 subunit

multiple interactions

[pozanicline binds to and results in increased activity of [CHRNA6 protein binds to CHRNB2 protein]] which results in increased secretion of Dopamine; Nicotine inhibits the reaction [[CHRNA6 protein binds to CHRNB2 protein] which results in increased secretion of Dopamine]

PMID:17227438 PMID:19481067

NCBI chr 2:175,181,402...175,189,619
Ensembl chr 2:175,181,402...175,189,619

G

cholinergic receptor nicotinic beta 4 subunit

increases secretion

CHRNB4 protein results in increased secretion of Dopamine

NCBI chr 8:55,417,583...55,437,027
Ensembl chr 8:55,418,313...55,437,027

G

cytoskeleton-associated protein 4

increases expression

Dopamine results in increased expression of CKAP4 mRNA

NCBI chr 7:19,230,814...19,238,914
Ensembl chr 7:19,230,203...19,238,914

G

chloride intracellular channel 1

increases expression

Dopamine results in increased expression of CLIC1 mRNA

NCBI chr20:3,764,867...3,773,711
Ensembl chr20:3,761,461...3,773,712

G

collagen type XII alpha 1 chain

increases expression

Dopamine results in increased expression of COL12A1 mRNA

NCBI chr 8:80,547,592...80,665,665
Ensembl chr 8:80,547,593...80,665,686

G

catechol-O-methyltransferase

increases methylation
increases metabolic processing
multiple interactions

COMT protein results in increased methylation of Dopamine
COMT protein results in increased metabolism of Dopamine
[tolcapone results in decreased activity of COMT protein] promotes the reaction [Clozapine results in increased abundance of Dopamine]; COMT protein affects the reaction [Amphetamine results in increased abundance of Dopamine]
3,4-methylenedioxyethamphetamine inhibits the reaction [COMT protein results in increased methylation of Dopamine]; [entacapone results in decreased activity of COMT protein] which results in increased abundance of Dopamine; [tolcapone results in decreased activity of COMT protein] which results in increased abundance of Dopamine; N-methyl-1-(1,3-benzodioxol-5-yl)-2-butanamine inhibits the reaction [COMT protein results in increased methylation of Dopamine]

PMID:7566641 PMID:11160877 PMID:11248589 PMID:12898346 PMID:14574438 More...

NCBI chr11:82,568,052...82,587,642
Ensembl chr11:82,568,025...82,587,642

G

carnitine palmitoyltransferase 1A

increases expression

Dopamine results in increased expression of CPT1A mRNA; Dopamine results in increased expression of CPT1A protein

NCBI chr 1:200,564,634...200,627,059
Ensembl chr 1:200,565,613...200,627,055

G

cAMP responsive element binding protein 1

multiple interactions

[Dopamine binds to and results in increased activity of DRD1 protein] which results in increased phosphorylation of CREB1 protein; Calcium promotes the reaction [Dopamine results in increased phosphorylation of CREB1 protein]; Dizocilpine Maleate inhibits the reaction [Dopamine results in increased phosphorylation of CREB1 protein]; Dopamine binds to and results in increased activity of CREB1 protein; KN 62 inhibits the reaction [Dopamine results in increased phosphorylation of CREB1 protein]; SCH 23390 inhibits the reaction [[Dopamine binds to and results in increased activity of DRD1 protein] which results in increased phosphorylation of CREB1 protein]

NCBI chr 9:65,903,511...65,972,562
Ensembl chr 9:65,903,547...65,970,816

G

citrate synthase

increases expression

Dopamine results in increased expression of CS protein

NCBI chr 7:758,074...791,421
Ensembl chr 7:758,345...791,421

G

cathepsin D

increases expression

Dopamine results in increased expression of CTSD protein

NCBI chr 1:197,527,467...197,539,343
Ensembl chr 1:197,527,467...197,539,488

G

C-X-C motif chemokine ligand 9

increases expression

Dopamine results in increased expression of CXCL9 mRNA

NCBI chr14:15,722,868...15,727,779
Ensembl chr14:15,722,908...15,728,435

G

cytochrome P450, family 1, subfamily a, polypeptide 1

multiple interactions
decreases activity

Dopamine inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A1 protein]
Dopamine results in decreased activity of CYP1A1 protein

PMID:18420780 PMID:18493746

NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125

G

cytochrome P450, family 1, subfamily a, polypeptide 2

decreases activity

Dopamine results in decreased activity of CYP1A2 protein

NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312

G

cytochrome P450, family 1, subfamily b, polypeptide 1

decreases activity

Dopamine results in decreased activity of CYP1B1 protein

NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917

G

cytochrome P450, family 2, subfamily C, polypeptide 6

decreases activity

Dopamine results in decreased activity of CYP2C29 protein

NCBI chr 1:237,938,521...237,976,238
Ensembl chr 1:237,693,094...238,057,596

G

cytochrome P450, family 2, subfamily d, polypeptide 4

decreases activity
increases abundance
multiple interactions

Dopamine results in decreased activity of CYP2D6 protein
CYP2D6 protein results in increased abundance of Dopamine
[CYP2D6 protein results in increased metabolism of Tyramine] which results in increased abundance of Dopamine

PMID:18420780 PMID:26763401

NCBI chr 7:113,882,584...113,891,754
Ensembl chr 7:113,881,618...113,891,759

G

cytochrome P450, family 2, subfamily e, polypeptide 1

decreases activity

Dopamine results in decreased activity of CYP2E1 protein

NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023

G

cytochrome P450, family 3, subfamily a, polypeptide 2

decreases activity

Dopamine results in decreased activity of CYP3A4 protein

NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008

G

dopamine beta-hydroxylase

affects abundance
multiple interactions

DBH gene polymorphism affects the abundance of Dopamine
DBH protein affects the reaction [Dopamine binds to DRD2 protein]

PMID:15716360 PMID:16163519

NCBI chr 3:10,488,260...10,505,245
Ensembl chr 3:10,488,260...10,505,248

G

DISC1 scaffold protein

multiple interactions

DISC1 protein modified form results in increased uptake of and affects the metabolism of Dopamine

NCBI chr19:53,014,201...53,223,617
Ensembl chr19:53,014,616...53,219,778

G

dopamine receptor D1

multiple interactions
increases activity
affects localization

Dopamine binds to and results in increased activity of DRD1 protein; SCH 23390 inhibits the reaction [Dopamine affects the localization of DRD1 protein]; SCH 23390 inhibits the reaction [Dopamine results in increased activity of DRD1 protein]
[alpha-pyrrolidinovalerophenone results in increased secretion of Dopamine] results in increased activity of [DRD1 protein co-treated with DRD2 protein]
[Dopamine binds to and results in increased activity of DRD1 protein] which results in increased phosphorylation of CREB1 protein; [Dopamine results in increased activity of DRD1 protein] which results in increased phosphorylation of GRIN1 protein; Dopamine deficiency inhibits the reaction [SCH 23390 binds to DRD1 protein]; DRD1 protein promotes the reaction [zonisamide affects the secretion of Dopamine]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[Dopamine results in increased activity of DRD1 protein] which results in increased phosphorylation of GRIN1 protein]; SCH 23390 inhibits the reaction [[Dopamine binds to and results in increased activity of DRD1 protein] which results in increased phosphorylation of CREB1 protein]

PMID:12813475 PMID:14622123 PMID:15985612 PMID:19482038 PMID:22292096 More...

NCBI chr17:10,540,440...10,544,971
Ensembl chr17:10,540,558...10,545,002

G

dopamine receptor D2

multiple interactions
affects response to substance
increases activity
affects binding

[Dopamine co-treated with DRD2 protein alternative form] results in increased activity of RHOA protein; [Dopamine co-treated with Raclopride] promotes the reaction [Dopamine binds to DRD2 protein]; Dopamine promotes the reaction [DRD2 protein affects the localization of ARRB1 protein]; Dopamine promotes the reaction [DRD2 protein affects the localization of ARRB2 protein]; GRK2 protein promotes the reaction [Dopamine promotes the reaction [DRD2 protein affects the localization of ARRB1 protein]]; GRK2 protein promotes the reaction [Dopamine promotes the reaction [DRD2 protein affects the localization of ARRB2 protein]]
[alpha-pyrrolidinovalerophenone results in increased secretion of Dopamine] results in increased activity of [DRD1 protein co-treated with DRD2 protein]
DRD2 protein affects the susceptibility to Dopamine
Dopamine results in increased activity of DRD2 protein
[Quinpirole binds to and results in increased activity of DRD2 protein] which results in increased uptake of Dopamine; [Raclopride binds to and results in decreased activity of DRD2 protein] which results in increased abundance of Dopamine; [Remoxipride results in decreased activity of DRD2 protein] inhibits the reaction [Dopamine results in decreased susceptibility to Pilocarpine]; Clozapine promotes the reaction [Dopamine binds to DRD2 protein]; Cocaine promotes the reaction [[DRD2 protein results in increased phosphorylation of TH protein] which results in increased abundance of Dopamine]; cypermethrin inhibits the reaction [[Quinpirole binds to and results in increased activity of DRD2 protein] which results in increased uptake of Dopamine]; DBH protein affects the reaction [Dopamine binds to DRD2 protein]; decamethrin inhibits the reaction [[Quinpirole binds to and results in increased activity of DRD2 protein] which results in increased uptake of Dopamine]; Dopamine promotes the reaction [Oxidopamine binds to DRD2 protein]; DRD2 mutant form inhibits the reaction [Dopamine results in decreased expression of IL10 protein]; DRD2 mutant form inhibits the reaction [Dopamine results in decreased expression of TGFB1 protein]; DRD2 mutant form inhibits the reaction [Dopamine results in decreased expression of VEGFA protein]; DRD2 mutant form inhibits the reaction [Dopamine results in increased expression of TNF protein]; DRD4 protein affects the reaction [Dopamine binds to DRD2 protein]; estradiol 3-benzoate inhibits the reaction [[Quinpirole binds to and results in increased activity of DRD2 protein] which results in increased uptake of Dopamine]; Ethanol affects the reaction [Dopamine binds to DRD2 protein]; GRK6 protein affects the reaction [Dopamine binds to DRD2 protein]; Haloperidol inhibits the reaction [[Quinpirole binds to and results in increased activity of DRD2 protein] which results in increased uptake of Dopamine]; Haloperidol promotes the reaction [Dopamine binds to DRD2 protein]; Olanzapine promotes the reaction [Dopamine binds to DRD2 protein]; Quetiapine Fumarate promotes the reaction [Dopamine binds to DRD2 protein]; Risperidone promotes the reaction [Dopamine binds to DRD2 protein]; Spiperone inhibits the reaction [Cocaine promotes the reaction [[DRD2 protein results in increased phosphorylation of TH protein] which results in increased abundance of Dopamine]]; tautomycin inhibits the reaction [[Quinpirole binds to and results in increased activity of DRD2 protein] which results in increased uptake of Dopamine]; Tea inhibits the reaction [Dopamine promotes the reaction [Oxidopamine binds to DRD2 protein]]
Dopamine binds to DRD2 protein alternative form

PMID:8103596 PMID:10936494 PMID:12476322 PMID:15140183 PMID:15341276 More...

NCBI chr 8:49,708,927...49,772,876
Ensembl chr 8:49,708,927...49,772,875

G

dopamine receptor D3

increases activity
multiple interactions

Dopamine results in increased activity of DRD3 protein
Butaclamol inhibits the reaction [Dopamine results in increased activity of DRD3 protein]; Dopamine binds to and results in increased activity of DRD3 protein; Endocannabinoids promotes the reaction [Dopamine binds to and results in increased activity of DRD3 protein]
[Ionomycin co-treated with CAMK2A protein] inhibits the reaction [DRD3 protein promotes the reaction [Dopamine results in increased phosphorylation of MAPK1 protein]]; [Raclopride binds to and results in decreased activity of DRD3 protein] which results in increased abundance of Dopamine; DRD3 protein promotes the reaction [Dopamine results in increased phosphorylation of MAPK1 protein]; DRD3 protein promotes the reaction [Dopamine results in increased phosphorylation of MAPK3 protein]; NGB 2904 inhibits the reaction [DRD3 protein promotes the reaction [Dopamine results in increased phosphorylation of MAPK1 protein]]; NGB 2904 inhibits the reaction [DRD3 protein promotes the reaction [Dopamine results in increased phosphorylation of MAPK3 protein]]

PMID:15341276 PMID:19046384 PMID:19217379 PMID:30102254 PMID:31323226

NCBI chr11:56,879,689...56,931,901
Ensembl chr11:56,879,689...56,940,596

G

dopamine receptor D4

multiple interactions
affects binding

DRD4 protein affects the reaction [Dopamine binds to DRD2 protein]
Dopamine binds to Drd4 protein
Clozapine inhibits the reaction [Dopamine results in increased activity of DRD4 protein]; Dopamine binds to and results in increased activity of DRD4 protein; Endocannabinoids inhibits the reaction [Dopamine binds to and results in increased activity of DRD4 protein]

CTD
RGD

PMID:15716360 PMID:30102254 PMID:31323226 PMID:8078498

NCBI chr 1:196,396,366...196,400,824
Ensembl chr 1:196,396,366...196,399,553

G

dopamine receptor D5

increases expression

Dopamine results in increased expression of DRD5 mRNA

NCBI chr14:72,487,950...72,491,050
Ensembl chr14:72,489,347...72,490,774

G

extracellular matrix protein 2

decreases expression

Dopamine results in decreased expression of ECM2 mRNA

NCBI chr17:15,120,194...15,152,536
Ensembl chr17:15,120,196...15,152,516

G

eukaryotic translation elongation factor 1 alpha 1

increases expression

Dopamine results in increased expression of EEF1A1 protein

NCBI chr 8:79,341,554...79,344,784
Ensembl chr 8:79,341,557...79,344,839

G

EF-hand domain family, member D2

multiple interactions
decreases secretion

[EFHD2 gene mutant form affects the susceptibility to Ethanol] which results in increased secretion of Dopamine
EFHD2 gene mutant form results in decreased secretion of Dopamine

NCBI chr 5:154,160,945...154,176,980
Ensembl chr 5:154,160,946...154,176,980

G

engrailed homeobox 1

multiple interactions

[EN1 protein co-treated with EN2 protein] inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased abundance of Dopamine]; [EN1 protein co-treated with EN2 protein] results in increased abundance of Dopamine; NDUFS1 mutant form inhibits the reaction [[EN1 protein co-treated with EN2 protein] inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased abundance of Dopamine]]

NCBI chr13:31,750,892...31,756,477
Ensembl chr13:31,751,545...31,755,943

G

engrailed homeobox 2

multiple interactions

[EN1 protein co-treated with EN2 protein] inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased abundance of Dopamine]; [EN1 protein co-treated with EN2 protein] results in increased abundance of Dopamine; NDUFS1 mutant form inhibits the reaction [[EN1 protein co-treated with EN2 protein] inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased abundance of Dopamine]]

NCBI chr 4:7,221,096...7,226,943
Ensembl chr 4:7,221,096...7,226,943

G

endoglin

decreases expression

Dopamine results in decreased expression of ENG mRNA

NCBI chr 3:15,934,566...15,972,618
Ensembl chr 3:15,934,518...15,973,230

G

ectonucleotide pyrophosphatase/phosphodiesterase 3

increases expression

Dopamine results in increased expression of ENPP3 mRNA

NCBI chr 1:20,563,700...20,635,044
Ensembl chr 1:20,563,697...20,635,041

G

endoplasmic reticulum protein 29

increases expression

Dopamine results in increased expression of ERP29 mRNA

NCBI chr12:35,089,698...35,095,952
Ensembl chr12:35,089,707...35,096,376

G

coagulation factor III, tissue factor

multiple interactions

Dopamine promotes the reaction [TNF protein results in increased expression of F3 mRNA]

NCBI chr 2:209,827,061...209,838,666
Ensembl chr 2:209,826,959...209,838,668

G

fibronectin 1

increases expression

Dopamine results in increased expression of FN1 mRNA

NCBI chr 9:73,196,044...73,264,695
Ensembl chr 9:73,196,044...73,264,678

G

Fos proto-oncogene, AP-1 transcription factor subunit

multiple interactions
increases expression

6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid inhibits the reaction [[Dopamine co-treated with SLC6A3 protein] results in increased expression of FOS protein]; [Dopamine co-treated with SLC6A3 protein] results in increased expression of FOS mRNA; [Dopamine co-treated with SLC6A3 protein] results in increased expression of FOS protein; bisindolylmaleimide I inhibits the reaction [[Dopamine co-treated with SLC6A3 protein] results in increased expression of FOS protein]; Bupropion inhibits the reaction [[Dopamine co-treated with SLC6A3 protein] results in increased expression of FOS mRNA]; Bupropion inhibits the reaction [[Dopamine co-treated with SLC6A3 protein] results in increased expression of FOS protein]; Cocaine inhibits the reaction [[Dopamine co-treated with SLC6A3 protein] results in increased expression of FOS mRNA]; Cocaine inhibits the reaction [[Dopamine co-treated with SLC6A3 protein] results in increased expression of FOS protein]; Methylphenidate inhibits the reaction [[Dopamine co-treated with SLC6A3 protein] results in increased expression of FOS mRNA]; Methylphenidate inhibits the reaction [[Dopamine co-treated with SLC6A3 protein] results in increased expression of FOS protein]
Dopamine results in increased expression of FOS mRNA; Dopamine results in increased expression of FOS protein

PMID:10700011 PMID:12112414 PMID:19217379

NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036

G

glucose-6-phosphate dehydrogenase

increases activity
decreases activity
multiple interactions

Dopamine results in increased activity of G6PD protein
Dopamine results in decreased activity of G6PD protein
Atenolol inhibits the reaction [Dopamine results in increased activity of G6PD protein]

PMID:1978808 PMID:26820767

NCBI chr X:152,201,081...152,220,863
Ensembl chr X:152,201,098...152,220,801

G

glyceraldehyde-3-phosphate dehydrogenase

increases expression

Dopamine results in increased expression of GAPDH protein

NCBI chr 4:157,962,312...157,967,158
Ensembl chr 4:157,962,343...157,966,235

G

GTP cyclohydrolase 1

increases abundance

GCH1 protein results in increased abundance of Dopamine

NCBI chr15:20,404,267...20,437,727
Ensembl chr15:20,402,527...20,437,698

G

glutamate-cysteine ligase, catalytic subunit

multiple interactions

Dopamine promotes the reaction [Zinc deficiency results in increased cleavage of GCLC protein]

NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544

G

glutamate cysteine ligase, modifier subunit

multiple interactions

[GCLM gene mutant form results in increased susceptibility to Paraquat] which results in decreased abundance of Dopamine

NCBI chr 2:210,347,482...210,367,537
Ensembl chr 2:210,347,482...210,367,535

G

glial cell derived neurotrophic factor

multiple interactions
increases metabolic processing

GDNF protein inhibits the reaction [Oxidopamine results in decreased secretion of Dopamine]
GDNF protein results in increased metabolism of Dopamine

PMID:12213621 PMID:15269253

NCBI chr 2:56,894,022...56,919,935
Ensembl chr 2:56,895,010...56,917,209

G

ghrelin and obestatin prepropeptide

decreases export

GHRL protein results in decreased export of Dopamine

NCBI chr 4:146,865,712...146,869,621
Ensembl chr 4:146,865,712...146,869,621

G

gonadotropin releasing hormone 1

multiple interactions

Dopamine affects the reaction [manganese chloride results in increased secretion of GNRH1 protein]

NCBI chr15:41,972,482...41,976,690
Ensembl chr15:41,972,905...41,973,581
Ensembl chr15:41,972,905...41,973,581

G

glutamate ionotropic receptor AMPA type subunit 1

increases localization
increases expression

Dopamine results in increased localization of GRIA1 protein
dopamine increases expression of Gria1 protein in nucleus accumbens cultured cells

CTD
RGD

PMID:19674091 PMID:19674091

NCBI chr10:41,210,713...41,527,283
Ensembl chr10:41,210,713...41,527,283

G

glutamate ionotropic receptor AMPA type subunit 2

increases localization
increases expression

Dopamine results in increased localization of GRIA2 protein
dopamine increases expression of Gria2 protein in nucleus accumbens cultured cells

CTD
RGD

PMID:19674091 PMID:19674091

NCBI chr 2:165,949,379...166,069,510
Ensembl chr 2:165,947,521...166,069,510

G

glutamate ionotropic receptor NMDA type subunit 1

multiple interactions

[Dopamine results in increased activity of DRD1 protein] which results in increased phosphorylation of GRIN1 protein; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[Dopamine results in increased activity of DRD1 protein] which results in increased phosphorylation of GRIN1 protein]

NCBI chr 3:8,103,680...8,130,603
Ensembl chr 3:8,103,680...8,130,603

G

G protein-coupled receptor kinase 2

multiple interactions

GRK2 protein promotes the reaction [Dopamine promotes the reaction [DRD2 protein affects the localization of ARRB1 protein]]; GRK2 protein promotes the reaction [Dopamine promotes the reaction [DRD2 protein affects the localization of ARRB2 protein]]

NCBI chr 1:201,580,823...201,601,580
Ensembl chr 1:201,581,480...201,601,582

G

G protein-coupled receptor kinase 6

multiple interactions

GRK6 protein affects the reaction [Dopamine binds to DRD2 protein]

NCBI chr17:9,177,018...9,192,813
Ensembl chr17:9,177,019...9,192,644

G

glutamate metabotropic receptor 5

multiple interactions

[6-methyl-2-(phenylethynyl)pyridine binds to and results in decreased activity of GRM5 protein] inhibits the reaction [Methamphetamine results in decreased abundance of Dopamine]; [6-methyl-2-(phenylethynyl)pyridine binds to and results in decreased activity of GRM5 protein] inhibits the reaction [Methamphetamine results in increased secretion of Dopamine]; [6-methyl-2-(phenylethynyl)pyridine binds to and results in decreased activity of GRM5 protein] inhibits the reaction [Veratridine results in increased secretion of Dopamine]; [6-methyl-2-(phenylethynyl)pyridine binds to and results in decreased activity of GRM5 protein] which results in decreased secretion of Dopamine

NCBI chr 1:141,310,069...141,884,980
Ensembl chr 1:141,312,368...141,882,274

G

glutathione-disulfide reductase

decreases activity

Dopamine results in decreased activity of GSR protein

NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661

G

glutathione S-transferase alpha 1

decreases activity

Dopamine analog results in decreased activity of GSTA1 protein

NCBI chr 9:23,703,476...23,720,121
Ensembl chr 9:23,703,477...23,720,121

G

glutathione S-transferase mu 1

decreases activity

Dopamine analog results in decreased activity of GSTM1 protein

NCBI chr 2:195,649,845...195,655,402
Ensembl chr 2:195,649,845...195,655,411

G

glutathione S-transferase pi 1

decreases activity

Dopamine analog results in decreased activity of GSTP1 protein

NCBI chr 1:201,337,762...201,340,230
Ensembl chr 1:201,321,672...201,340,226

G

H1.5 linker histone, cluster member

increases expression

Dopamine results in increased expression of H1-5 protein

NCBI chr17:42,726,132...42,727,162
Ensembl chr17:42,726,127...42,769,160

G

hypocretin receptor 1

multiple interactions

[1-(2-methylbenzoxazol-6-yl)-3-(1,5)naphthyridin-4-yl urea binds to and results in decreased activity of HCRTR1 protein] inhibits the reaction [Amphetamine results in increased secretion of Dopamine]

NCBI chr 5:142,477,214...142,486,674
Ensembl chr 5:142,477,214...142,486,674

G

hypoxia inducible factor 1 subunit alpha

increases expression
multiple interactions
decreases expression

[Dopamine results in increased expression of HIF1A protein] which results in increased expression of BBC3 mRNA; [Dopamine results in increased expression of HIF1A protein] which results in increased expression of BBC3 protein; [Dopamine results in increased expression of HIF1A protein] which results in increased expression of BNIP3 mRNA; [Dopamine results in increased expression of HIF1A protein] which results in increased expression of BNIP3 protein; [Dopamine results in increased expression of HIF1A protein] which results in increased expression of TP53 protein; Dopamine results in increased expression of HIF1A protein
Clodronic Acid inhibits the reaction [Dopamine results in decreased expression of HIF1A protein]; eticlopride inhibits the reaction [Dopamine results in decreased expression of HIF1A protein]; zoledronic acid inhibits the reaction [Dopamine results in decreased expression of HIF1A protein]
[Dopamine results in increased expression of HIF1A protein] which results in increased expression of and results in increased phosphorylation of TP53 protein; Acetylcysteine inhibits the reaction [Dopamine results in increased expression of HIF1A protein]

PMID:19410601 PMID:25818600

NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261

G

3-hydroxy-3-methylglutaryl-CoA synthase 2

decreases expression

Dopamine results in decreased expression of HMGCS2 mRNA

NCBI chr 2:185,875,609...185,903,505
Ensembl chr 2:185,875,616...185,902,130

G

heme oxygenase 1

increases expression
multiple interactions

[Dopamine results in increased expression of HMOX1 mRNA] which results in increased expression of SOD2 mRNA; Dopamine results in increased expression of HMOX1 mRNA
[SNCA protein co-treated with Dopamine] results in increased expression of HMOX1 protein; [SNCA protein co-treated with Paraquat co-treated with Dopamine] results in increased expression of HMOX1 protein; HMOX1 protein inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased abundance of Dopamine]

PMID:10942521 PMID:18799798 PMID:21735318

NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079

G

histamine receptor H 1

multiple interactions

[1-phenyl-3-dimethylamino-1,2,3,4-tetrahydronaphthalene analog binds to and results in increased activity of HRH1 protein] promotes the reaction [TH protein results in increased chemical synthesis of Dopamine]

NCBI chr 4:147,564,963...147,649,353
Ensembl chr 4:147,645,995...147,647,455

G

heat shock protein 90 alpha family class B member 1

increases expression

Dopamine results in increased expression of HSP90AB1 protein

NCBI chr 9:15,432,986...15,438,358
Ensembl chr 9:15,433,691...15,438,488

G

heat shock protein 90 beta family member 1

increases expression

Dopamine results in increased expression of HSP90B1 protein

NCBI chr 7:21,110,431...21,124,762
Ensembl chr 7:21,110,457...21,124,788

G

heat shock protein family A (Hsp70) member 5

increases expression

Dopamine results in increased expression of HSPA5 protein

NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891

G

heat shock protein family A (Hsp70) member 6 like, pseudogene 1

increases expression

Dopamine results in increased expression of HSPA6 protein

NCBI chr13:83,273,176...83,274,317

G

heat shock protein family A (Hsp70) member 9

increases expression

Dopamine results in increased expression of HSPA9 protein

NCBI chr18:26,536,131...26,554,294
Ensembl chr18:26,535,798...26,554,292

G

5-hydroxytryptamine receptor 2A

multiple interactions

[4-iodo-2,5-dimethoxyphenylisopropylamine binds to and results in increased activity of HTR2A protein] which results in increased secretion of and results in increased abundance of Dopamine; Cocaine promotes the reaction [[4-iodo-2,5-dimethoxyphenylisopropylamine binds to and results in increased activity of HTR2A protein] which results in increased secretion of and results in increased abundance of Dopamine]; Ketanserin inhibits the reaction [[4-iodo-2,5-dimethoxyphenylisopropylamine binds to and results in increased activity of HTR2A protein] which results in increased secretion of and results in increased abundance of Dopamine]; Ketanserin inhibits the reaction [Cocaine promotes the reaction [[4-iodo-2,5-dimethoxyphenylisopropylamine binds to and results in increased activity of HTR2A protein] which results in increased secretion of and results in increased abundance of Dopamine]]

NCBI chr15:49,950,035...50,022,188
Ensembl chr15:49,950,804...50,020,928

G

5-hydroxytryptamine receptor 2C

multiple interactions

HTR2C protein affects the reaction [Cocaine results in increased abundance of Dopamine]

NCBI chr X:110,640,777...110,870,288
Ensembl chr X:110,641,153...110,870,287

G

5-hydroxytryptamine receptor 3A

multiple interactions

Dopamine binds to and results in increased activity of [HTR3A protein binds to HTR3A protein]; Dopamine binds to and results in increased activity of [HTR3A protein binds to HTR3B protein]

NCBI chr 8:49,242,018...49,254,475
Ensembl chr 8:49,242,020...49,254,389

G

5-hydroxytryptamine receptor 3B

multiple interactions

Dopamine binds to and results in increased activity of [HTR3A protein binds to HTR3B protein]

NCBI chr 8:49,279,291...49,308,444
Ensembl chr 8:49,279,173...49,308,444

G

interleukin 10

decreases expression
multiple interactions

Dopamine results in decreased expression of IL10 mRNA; Dopamine results in decreased expression of IL10 protein
DRD2 mutant form inhibits the reaction [Dopamine results in decreased expression of IL10 protein]; eticlopride inhibits the reaction [Dopamine results in decreased expression of IL10 protein]

NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313

G

insulin 2

multiple interactions
increases secretion
increases expression

Dopamine promotes the reaction [Metoclopramide results in increased expression of INS protein]
Dopamine results in increased secretion of INS protein
Dopamine results in increased expression of INS protein

NCBI chr 1:197,843,277...197,992,522
Ensembl chr 1:197,843,281...197,864,775

G

Jun proto-oncogene, AP-1 transcription factor subunit

increases phosphorylation
multiple interactions

Dopamine results in increased phosphorylation of JUN protein
PRKN protein inhibits the reaction [Dopamine results in increased phosphorylation of JUN protein]

NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656

G

potassium voltage-gated channel subfamily A member 1

multiple interactions

KCNA1 protein affects the reaction [Amphetamine results in increased secretion of Dopamine]

NCBI chr 4:159,464,223...159,472,905
Ensembl chr 4:159,464,188...159,472,682

G

potassium inwardly-rectifying channel, subfamily J, member 6

decreases abundance

KCNJ6 gene mutant form results in decreased abundance of Dopamine

NCBI chr11:34,061,702...34,308,758
Ensembl chr11:34,061,708...34,308,758

G

KDEL endoplasmic reticulum protein retention receptor 3

increases expression

Dopamine results in increased expression of KDELR3 mRNA

NCBI chr 7:111,079,236...111,089,463
Ensembl chr 7:111,079,218...111,101,600

G

karyopherin subunit alpha 2

increases expression

Dopamine results in increased expression of KPNA2 mRNA

NCBI chr10:91,933,951...91,946,115
Ensembl chr10:91,933,951...91,946,150

G

legumain

increases expression

Dopamine results in increased expression of LGMN mRNA

NCBI chr 6:121,544,048...121,582,495
Ensembl chr 6:121,544,053...121,582,480

G

lipopolysaccharide-induced TNF factor

increases expression

Dopamine results in increased expression of LITAF mRNA

NCBI chr10:4,656,308...4,692,981
Ensembl chr10:4,625,552...4,692,763

G

lamin A/C

increases expression

Dopamine results in increased expression of LMNA protein

NCBI chr 2:173,939,751...173,960,423
Ensembl chr 2:173,939,751...173,960,423

G

lysyl oxidase-like 2

increases expression

Dopamine results in increased expression of LOXL2 mRNA

NCBI chr15:44,683,449...44,773,067
Ensembl chr15:44,683,880...44,773,067

G

lecithin retinol acyltransferase

increases expression

Dopamine results in increased expression of LRAT mRNA

NCBI chr 2:168,264,093...168,273,155
Ensembl chr 2:168,266,877...168,273,619

G

leucine-rich repeat kinase 2

multiple interactions

LRRK2 mutant form results in increased susceptibility to [Dopamine co-treated with SLC6A3 protein]

NCBI chr 7:122,826,696...122,987,711
Ensembl chr 7:122,826,696...122,987,703

G

monoamine oxidase A

increases abundance
decreases amination
multiple interactions

MAOA mutant form results in increased abundance of Dopamine
MAOA protein results in decreased amination of Dopamine
3,4-Methylenedioxyamphetamine inhibits the reaction [MAOA protein results in decreased amination of Dopamine]; N-Methyl-3,4-methylenedioxyamphetamine inhibits the reaction [MAOA protein results in decreased amination of Dopamine]

PMID:11834493 PMID:26721607

NCBI chr X:6,032,172...6,098,308
Ensembl chr X:6,030,795...6,099,593

G

monoamine oxidase B

multiple interactions
increases degradation
decreases amination

[Ro 16-6491 results in decreased activity of MAOB protein] which results in decreased susceptibility to Dopamine; [Selegiline results in decreased activity of MAOB protein] which results in increased abundance of Dopamine
MAOB protein results in increased degradation of Dopamine
1-(8-bromobenzo(1,2-b;4,5-b')difuran-4-yl)-2-aminopropane inhibits the reaction [MAOB protein results in increased degradation of Dopamine]; N-Methyl-3,4-methylenedioxyamphetamine inhibits the reaction [MAOB protein results in decreased amination of Dopamine]; Selegiline inhibits the reaction [MAOB protein results in decreased amination of Dopamine]; Selegiline inhibits the reaction [MAOB protein results in increased degradation of Dopamine]

PMID:16012872 PMID:20875051 PMID:26721607 PMID:30036687

NCBI chr X:5,907,327...6,010,996
Ensembl chr X:5,907,266...6,011,003

G

mitogen activated protein kinase 1

multiple interactions
increases phosphorylation

Dopamine results in increased phosphorylation of and results in increased activity of MAPK1 protein; RGS3 protein affects the reaction [Dopamine results in increased phosphorylation of and results in increased activity of MAPK1 protein]
[Ionomycin co-treated with CAMK2A protein] inhibits the reaction [DRD3 protein promotes the reaction [Dopamine results in increased phosphorylation of MAPK1 protein]]; DRD3 protein promotes the reaction [Dopamine results in increased phosphorylation of MAPK1 protein]; NGB 2904 inhibits the reaction [DRD3 protein promotes the reaction [Dopamine results in increased phosphorylation of MAPK1 protein]]

PMID:16760913 PMID:18977218 PMID:19217379

NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616

G

mitogen activated protein kinase 3

multiple interactions
increases phosphorylation

Dopamine results in increased phosphorylation of and results in increased activity of MAPK3 protein; RGS3 protein affects the reaction [Dopamine results in increased phosphorylation of and results in increased activity of MAPK3 protein]
DRD3 protein promotes the reaction [Dopamine results in increased phosphorylation of MAPK3 protein]; NGB 2904 inhibits the reaction [DRD3 protein promotes the reaction [Dopamine results in increased phosphorylation of MAPK3 protein]]

PMID:16760913 PMID:18977218 PMID:19217379

NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863

G

mitogen-activated protein kinase 8

multiple interactions
increases phosphorylation

Acetylcysteine inhibits the reaction [Dopamine results in increased phosphorylation of MAPK8 protein]; Glutathione inhibits the reaction [Dopamine results in increased phosphorylation of MAPK8 protein]

NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981

G

microtubule-associated protein tau

multiple interactions

Dopamine metabolite promotes the reaction [MAPT protein binds to MAPT protein]; Dopamine promotes the reaction [MAPT protein binds to MAPT protein]

NCBI chr10:89,138,644...89,236,137
Ensembl chr10:89,138,627...89,236,129

G

myristoylated alanine rich protein kinase C substrate

increases expression

Dopamine results in increased expression of MARCKS protein

NCBI chr20:40,685,315...40,691,012
Ensembl chr20:40,685,315...40,691,012

G

mannose receptor, C type 1

decreases expression

Dopamine results in decreased expression of MRC1 mRNA; Dopamine results in decreased expression of MRC1 protein

NCBI chr17:77,249,187...77,330,857
Ensembl chr17:77,249,187...77,330,857

G

metallothionein 1

multiple interactions

[MT1 co-treated with Dopamine] results in decreased abundance of semiquinone radicals; [MT1 gene mutant form co-treated with MT2 gene mutant form co-treated with Mercuric Chloride] results in decreased abundance of Dopamine

PMID:17910954 PMID:18226494

NCBI chr19:10,826,032...10,827,048
Ensembl chr19:10,826,032...10,827,049
Ensembl chr17:10,826,032...10,827,049
Ensembl chr X:10,826,032...10,827,049

G

metallothionein 2A

multiple interactions

[MT1 gene mutant form co-treated with MT2 gene mutant form co-treated with Mercuric Chloride] results in decreased abundance of Dopamine

NCBI chr19:10,832,009...10,832,783
Ensembl chr19:10,832,002...10,832,784

G

mechanistic target of rapamycin kinase

decreases phosphorylation

Dopamine results in decreased phosphorylation of MTOR protein

NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311

G

5-methyltetrahydrofolate-homocysteine methyltransferase

multiple interactions
increases activity

2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Dopamine results in increased activity of MTR protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Dopamine results in increased activity of MTR protein]; Ethanol promotes the reaction [Dopamine results in increased activity of MTR protein]; wortmannin inhibits the reaction [Dopamine results in increased activity of MTR protein]

NCBI chr17:58,219,998...58,308,560
Ensembl chr17:58,220,071...58,304,822

G

myc target 1

decreases expression

Dopamine results in decreased expression of MYCT1 mRNA

NCBI chr 1:42,018,137...42,029,410
Ensembl chr 1:42,018,137...42,029,410

G

nucleolin

increases expression

Dopamine results in increased expression of NCL protein

NCBI chr 9:86,999,588...87,008,112
Ensembl chr 9:86,998,019...87,008,136

G

NADH:ubiquinone oxidoreductase core subunit S1

multiple interactions

NDUFS1 mutant form inhibits the reaction [[EN1 protein co-treated with EN2 protein] inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased abundance of Dopamine]]

NCBI chr 9:64,546,430...64,579,751
Ensembl chr 9:64,546,225...64,579,893

G

NADH:ubiquinone oxidoreductase subunit S4

multiple interactions

NDUFS4 protein affects the reaction [Rotenone results in increased abundance of Dopamine]; Paclitaxel inhibits the reaction [NDUFS4 protein affects the reaction [Rotenone results in increased abundance of Dopamine]]

NCBI chr 2:45,951,327...46,061,829
Ensembl chr 2:45,951,313...46,061,846

G

NFKB inhibitor zeta

increases expression

Dopamine results in increased expression of NFKBIZ mRNA

NCBI chr11:44,782,676...44,810,722
Ensembl chr11:44,782,676...44,810,723

G

nitric oxide synthase 1

multiple interactions

NOS1 protein affects the reaction [Methamphetamine results in decreased abundance of Dopamine]

PMID:11085313 PMID:20575850

NCBI chr12:38,615,111...38,795,492
Ensembl chr12:38,626,714...38,710,945

G

nitric oxide synthase 2

multiple interactions
increases expression

Atenolol inhibits the reaction [Dopamine inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased abundance of Nitrites]]; Atenolol inhibits the reaction [Dopamine inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]]; carvedilol inhibits the reaction [Dopamine inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased abundance of Nitrites]]; carvedilol inhibits the reaction [Dopamine inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]]; Dopamine inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased abundance of Nitrites]; Dopamine inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]; Prazosin inhibits the reaction [Dopamine inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased abundance of Nitrites]]; Prazosin inhibits the reaction [Dopamine inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]]
Dopamine results in increased expression of NOS2 mRNA; Dopamine results in increased expression of NOS2 protein

PMID:19439816 PMID:25818600

NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210

G

natriuretic peptide C

multiple interactions

NPPC protein inhibits the reaction [Cocaine results in increased abundance of Dopamine]

NCBI chr 9:87,320,051...87,324,251
Ensembl chr 9:87,320,051...87,324,251

G

nuclear receptor subfamily 3, group C, member 1

increases abundance
multiple interactions

NR3C1 protein results in increased abundance of Dopamine
[RU 43044 binds to and results in decreased activity of NR3C1 protein] inhibits the reaction [Methamphetamine results in increased secretion of Dopamine]

PMID:11226678 PMID:18925659

NCBI chr18:31,271,681...31,393,320
Ensembl chr18:31,271,681...31,393,375

G

nuclear receptor interacting protein 3

increases expression

Dopamine results in increased expression of NRIP3 mRNA

NCBI chr 1:163,789,738...163,815,036
Ensembl chr 1:163,789,738...163,815,600

G

neurotrophin 3

increases expression

Dopamine results in increased expression of NTF3 mRNA; Dopamine results in increased expression of NTF3 protein

NCBI chr 4:158,914,984...158,984,453
Ensembl chr 4:158,914,957...158,984,596

G

osteomodulin

decreases expression

Dopamine results in decreased expression of OMD mRNA

NCBI chr17:15,060,217...15,068,441
Ensembl chr17:15,060,217...15,068,441

G

opioid receptor, kappa 1

multiple interactions

[U 69593 binds to and results in increased activity of OPRK1 protein] inhibits the reaction [Cocaine affects the abundance of Dopamine]

NCBI chr 5:13,860,016...13,877,823
Ensembl chr 5:13,860,021...13,877,823

G

poly (ADP-ribose) polymerase 1

multiple interactions
increases cleavage

Dopamine promotes the reaction [Zinc deficiency results in increased cleavage of PARP1 protein]; PRKN protein inhibits the reaction [Dopamine results in increased cleavage of PARP1 protein]; resveratrol inhibits the reaction [Dopamine results in increased cleavage of PARP1 protein]; Zinc deficiency promotes the reaction [Dopamine results in increased cleavage of PARP1 protein]
[PARP1 protein results in increased susceptibility to 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] which results in increased abundance of Dopamine

PMID:10318960 PMID:15198987 PMID:17603292 PMID:19410601 PMID:22987761 More...

NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404

G

protein-L-isoaspartate (D-aspartate) O-methyltransferase 1

multiple interactions
decreases expression

1,3-dimethylthiourea inhibits the reaction [Dopamine results in decreased expression of PCMT1 mRNA]; Acetylcysteine inhibits the reaction [Dopamine results in decreased expression of PCMT1 mRNA]; Acetylcysteine inhibits the reaction [Dopamine results in decreased expression of PCMT1 protein]
Dopamine results in decreased expression of PCMT1 mRNA; Dopamine results in decreased expression of PCMT1 protein

NCBI chr 1:2,111,756...2,160,354
Ensembl chr 1:2,111,763...2,159,201

G

protein disulfide isomerase family A, member 3

decreases expression

Dopamine results in decreased expression of PDIA3 protein

NCBI chr 3:108,388,189...108,412,013
Ensembl chr 3:108,388,245...108,413,236

G

protein disulfide isomerase family A, member 6

increases expression

Dopamine results in increased expression of PDIA6 mRNA

NCBI chr 6:40,062,980...40,080,223
Ensembl chr 6:40,062,926...40,080,613

G

phosphogluconate dehydrogenase

decreases activity

Dopamine results in decreased activity of PGD protein

NCBI chr 5:159,582,746...159,598,945
Ensembl chr 5:159,561,271...159,742,778

G

phosphoglycerate kinase 1

decreases expression

Dopamine results in decreased expression of PGK1 mRNA

NCBI chr X:71,271,454...71,287,429
Ensembl chr X:71,271,440...71,287,418

G

prohibitin 1

increases expression

Dopamine results in increased expression of PHB1 protein

NCBI chr10:80,605,268...80,618,043
Ensembl chr10:80,605,251...80,618,042

G

PTEN induced kinase 1

multiple interactions
affects abundance

[PINK1 mutant form results in increased susceptibility to Paraquat] which results in decreased abundance of Dopamine; Paraquat affects the reaction [PINK1 protein affects the abundance of Dopamine]

NCBI chr 5:150,530,523...150,542,635
Ensembl chr 5:150,530,523...150,542,635

G

pyruvate kinase M1/2

increases expression

Dopamine results in increased expression of PKM protein

NCBI chr 8:60,057,629...60,079,600
Ensembl chr 8:60,057,402...60,079,599

G

phospholipase D family, member 3

affects expression

Dopamine affects the expression of PLD3 protein

NCBI chr 1:82,821,863...82,844,280
Ensembl chr 1:82,821,875...82,844,072

G

proteolipid protein 2

increases expression

Dopamine results in increased expression of PLP2 mRNA

NCBI chr X:14,834,249...14,837,648
Ensembl chr X:14,834,231...14,838,514

G

proopiomelanocortin

multiple interactions

POMC protein affects the reaction [Nicotine results in increased abundance of Dopamine]

NCBI chr 6:26,939,844...26,945,666
Ensembl chr 6:26,939,837...26,945,664

G

POTE ankyrin domain family, member F

increases expression

Dopamine results in increased expression of POTEF protein

NCBI chr18:23,626,518...23,629,132
Ensembl chr 3:72,977,767...72,979,694

G

peroxiredoxin 3

increases expression

Dopamine results in increased expression of PRDX3 protein

NCBI chr 1:260,001,642...260,014,064
Ensembl chr 1:260,001,637...260,014,111

G

protein kinase C, delta

multiple interactions

[rottlerin results in decreased activity of PRKCD protein] inhibits the reaction [Methamphetamine results in increased metabolism of Dopamine]; PRKCD protein affects the reaction [Methamphetamine results in increased metabolism of Dopamine]

NCBI chr16:5,769,217...5,799,380
Ensembl chr16:5,769,215...5,799,352

G

parkin RBR E3 ubiquitin protein ligase

multiple interactions
increases expression

PRKN protein inhibits the reaction [Dopamine results in increased abundance of Reactive Oxygen Species]; PRKN protein inhibits the reaction [Dopamine results in increased cleavage of CASP3 protein]; PRKN protein inhibits the reaction [Dopamine results in increased cleavage of PARP1 protein]; PRKN protein inhibits the reaction [Dopamine results in increased phosphorylation of JUN protein]
PRKN mutant form results in increased abundance of and results in increased metabolism of Dopamine; PRKN protein affects the abundance of and affects the metabolism of Dopamine; PRKN protein promotes the reaction [Amphetamine results in increased abundance of Dopamine]
Dopamine results in increased expression of PRKN mRNA

PMID:12915482 PMID:15198987 PMID:15993444 PMID:16987221

NCBI chr 1:48,688,651...49,882,520
Ensembl chr 1:48,690,556...49,882,555

G

prolactin

multiple interactions
decreases secretion
decreases expression

[Raloxifene Hydrochloride co-treated with Dopamine] results in decreased expression of PRL protein; Domperidone inhibits the reaction [Dopamine results in decreased expression of PRL protein]
Haloperidol inhibits the reaction [Dopamine results in decreased secretion of PRL protein]; Risperidone inhibits the reaction [Dopamine results in decreased secretion of PRL protein]

PMID:1380082 PMID:8532072 PMID:30865525

NCBI chr17:37,859,999...37,870,062
Ensembl chr17:37,860,007...37,870,062

G

protein S

increases expression

Dopamine results in increased expression of PROS1 mRNA

NCBI chr11:230,597...311,288
Ensembl chr11:230,696...311,286

G

peptidyl-tRNA hydrolase 1 homolog

increases expression

Dopamine results in increased expression of PTRH1 mRNA

NCBI chr 3:16,064,867...16,071,098
Ensembl chr 3:16,064,880...16,070,648

G

receptor for activated C kinase 1

increases expression

Dopamine results in increased expression of RACK1 protein

NCBI chr10:33,169,415...33,174,896
Ensembl chr10:33,169,169...33,174,975

G

RAN, member RAS oncogene family

increases expression

Dopamine results in increased expression of RAN mRNA

NCBI chr12:27,674,049...27,678,598
Ensembl chr12:27,674,050...27,678,276

G

RAN GTPase activating protein 1

increases expression

Dopamine results in increased expression of RANGAP1 mRNA

NCBI chr 7:113,224,695...113,250,441
Ensembl chr 7:113,224,703...113,250,438

G

regulator of G-protein signaling 3

multiple interactions

RGS3 protein affects the reaction [Dopamine results in increased phosphorylation of and results in increased activity of MAPK1 protein]; RGS3 protein affects the reaction [Dopamine results in increased phosphorylation of and results in increased activity of MAPK3 protein]

NCBI chr 5:76,022,038...76,161,895
Ensembl chr 5:76,022,001...76,161,894

G

ras homolog family member A

multiple interactions

[Dopamine co-treated with DRD2 protein alternative form] results in increased activity of RHOA protein

NCBI chr 8:108,991,926...109,025,746
Ensembl chr 8:108,991,954...109,025,746

G

ribosomal protein S6 kinase B1

decreases phosphorylation

Dopamine results in decreased phosphorylation of RPS6KB1 protein

NCBI chr10:71,323,777...71,367,908
Ensembl chr10:71,323,777...71,367,908

G

ribosomal protein SA

increases expression

Dopamine results in increased expression of RPSA protein

NCBI chr 8:119,851,225...119,855,103
Ensembl chr 8:119,851,225...119,855,247

G

RuvB-like AAA ATPase 1

increases expression

Dopamine results in increased expression of RUVBL1 protein

NCBI chr 4:120,932,486...120,967,400
Ensembl chr 4:120,932,417...121,029,384

G

S100 calcium binding protein A11

increases expression

Dopamine results in increased expression of S100A11 mRNA

NCBI chr 2:179,191,688...179,197,098
Ensembl chr 2:179,191,715...179,197,044

G

S100 calcium-binding protein A4

increases expression

Dopamine results in increased expression of S100A4 mRNA

NCBI chr 2:176,090,951...176,093,258
Ensembl chr 2:176,091,804...176,093,254

G

secretin

increases metabolic processing

SCT protein results in increased metabolism of Dopamine

NCBI chr 1:196,382,857...196,383,668
Ensembl chr 1:196,382,856...196,383,658

G

septin 9

decreases expression

Dopamine results in decreased expression of SEPTIN9 protein

NCBI chr10:102,409,798...102,579,056
Ensembl chr10:102,409,711...102,579,055

G

serine hydroxymethyltransferase 2

increases expression

Dopamine results in increased expression of SHMT2 protein

NCBI chr 7:63,358,961...63,364,293
Ensembl chr 7:63,358,961...63,364,236

G

solute carrier family 18 member A1

multiple interactions

Dopamine inhibits the reaction [SLC18A1 protein results in increased uptake of Serotonin]

NCBI chr16:20,653,268...20,687,051
Ensembl chr16:20,653,508...20,687,051

G

solute carrier family 18 member A2

multiple interactions
increases uptake
decreases activity
affects binding
decreases abundance

Heptachlor Epoxide inhibits the reaction [SLC18A2 protein results in increased uptake of Dopamine]; N-Methyl-3,4-methylenedioxyamphetamine inhibits the reaction [SLC18A2 protein results in increased uptake of Dopamine]; para-methyl-4-methylaminorex inhibits the reaction [SLC18A2 protein results in increased uptake of Dopamine]; Reserpine inhibits the reaction [SLC18A2 protein results in increased uptake of Dopamine]
DDT inhibits the reaction [SLC18A2 protein results in increased uptake of Dopamine]; Dichlorodiphenyldichloroethane inhibits the reaction [SLC18A2 protein results in increased uptake of Dopamine]; SLC18A2 protein affects the transport of and affects the abundance of Dopamine
Dopamine inhibits the reaction [SLC18A2 protein results in increased uptake of Serotonin]
Dopamine results in decreased activity of SLC18A2 protein
Dopamine binds to SLC18A2 protein
SLC18A2 results in decreased abundance of Dopamine

PMID:1438304 PMID:7912402 PMID:10499361 PMID:15475732 PMID:18533268 More...

NCBI chr 1:258,413,748...258,449,143
Ensembl chr 1:258,413,959...258,448,325

G

solute carrier family 22 member 1

multiple interactions

Dopamine affects the reaction [SLC22A1 protein results in increased uptake of Tetraethylammonium]

NCBI chr 1:48,076,657...48,103,679
Ensembl chr 1:48,076,666...48,103,678

G

solute carrier family 22 member 16

multiple interactions

Dopamine inhibits the reaction [SLC22A16 protein results in increased uptake of Tetraethylammonium]

NCBI chr20:43,972,808...44,068,447
Ensembl chr20:43,972,836...44,065,019

G

solute carrier family 22 member 2

multiple interactions

Dopamine affects the reaction [SLC22A2 protein results in increased uptake of Tetraethylammonium]

NCBI chr 1:48,121,061...48,163,268
Ensembl chr 1:48,121,061...48,163,268

G

solute carrier family 22 member 3

increases uptake
multiple interactions

SLC22A3 protein results in increased uptake of Dopamine
Dopamine affects the reaction [SLC22A3 protein results in increased uptake of Tetraethylammonium]; Dopamine inhibits the reaction [SLC22A3 protein results in increased uptake of 1-Methyl-4-phenylpyridinium]; Dopamine inhibits the reaction [SLC22A3 protein results in increased uptake of Dopamine]

PMID:9830022 PMID:20858707

NCBI chr 1:48,235,476...48,324,617
Ensembl chr 1:48,235,476...48,324,612

G